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Zusammenfassung 
 
Rab5 ist eine kleine GTPase, die maßgeblich an der Regulierung des Membrantransportes zu- 
und -an frühen Endosomen beteiligt ist. GTPasen sind molekulare Schalter, die durch 
Guaninnukleotid Austauschfaktoren (GEFs) aktiviert und durch die Hydrolyse von GTP mit 
Hilfe katalytischer GTPase aktivierender Proteinen (GAPs) inaktiviert werden. GEFs 
vermitteln den Austausch von GTPase-gebundenem GDP gegen freies GTP. Einer von 
mindestens neun bisher beschriebenen Rab5 GEFs ist Rin1. Die genauen Unterschiede in 
Funktion und Wirkungsweise der verschiedenen Rab5 GEFs sind derzeit noch nicht im 
Gesamten entschlüsselt. Rin1 ist ein Multidomänenprotein mit verschiedenen Funktionen in 
der intrazellulären Signaltransduktion. Neben der Aktivierung von Rab5 spielt Rin1 ebenfalls 
eine Rolle in ABL Kinasen Signalwegen. Hier verstärkt es die Aktivierung der ABL Kinasen.  
Rab5 Überaktivierung wurde mit verschiedenen Krebsarten in Zusammenhang gebracht. In 
den meisten Fällen kann diese Überaktivierung auf Rin1 Überexpression zurückgeführt 
werden. Rin1 verfügt jedoch auch über eine krebsunterdrückende Funktion, die im 
Zusammenhang mit seiner Interaktion mit ABL Kinasen steht. 
Diese Arbeit zielt auf die Identifikation eines niedermolekularen Inhibitors der Rin1-
vermittelten Rab5 Aktivierung ab. Der Inhibitor könnte helfen, die komplexen 
Signalkaskaden, an denen Rab5 beteiligt ist, aufzuschlüsseln. Idealerweise wäre er spezifisch 
für Rin1 gegenüber anderen GEFs. Außerdem sollte er die Interaktion zwischen Rin1 und den 
ABL Kinasen nicht beeinflussen.  
Hierfür wurde ein in vitro Hochdurchsatzscreening mit über 20 000 potentiellen 
niedermolekularen Inhibitoren durchgeführt. Das Screeningexperiment überwachte den 
Rin1-vermittelten Austausch von GDP gegen das Fluoreszenzmarkierte GTP Analogon 
Bodipy-TR-GTP an Rab5. So wurde unter Anderem der niedermolekulare Inhibitor CG3 05 
A02 identifiziert. Während Spezifitäts- und Aggregationsstudien stellte sich dieser als der 
vielversprechendste Kandidat heraus.  
Seine Charakterisierung ergab Spezifität für Rin1 und Rabex-5 an der GTPase Rab5a im 
Bodipy-TR-GTP Nukleotidaustauschexperiment. Verschiedene andere GEF/GTPase Paare 
wurden nicht beeinflusst, obwohl deren Austauschmechanismus dem von Rin1 und Rabex-5 
an Rab5 ähnelt. Die IC50 Werte, die in den Austauschexperimenten mit Rin1 und Rabex-5 
ermittelt wurden, liegen beide im niedrigen micromolaren Bereich. Beide GEFs verfügen 
über eine homologe katalytische Vps9 Domäne. Es kann derzeit nicht ausgeschlossen 
werden, dass CG3 05 A02 auch weitere Vps9 Domänen GEFs inhibiert. Der Inhibitor führte 
keine Aggregation von Rin1 oder Rab5 herbei und hatte auch keinen unspezifischen Effekt in 
einem unverwandten Insulinrezeptor Autophosphorylierungsexperiment. Außerdem 
beeinflusste er die Interaktion zwischen Rin1 und ABL1 nicht, was gegen eine 
intramolekulare, domänenunspezifische Inhibition sprach.  
Bedauerlicherweise zeigte ein weiteres Kontrollexperiment keine Inhibition des Rin1-
vermittelten Nukleotidaustausches, wenn radioaktiv markiertes GTP verwendet wurde. 
Dieses Ergebnis sprach für eine Bodipy-TR-GTP-Abhängigkeit der Inhibition. Diese stammt 
wahrscheinlich nicht von einer Interaktion zwischen dem Inhibitor und dem GTP Analog her, 
denn in diesem Fall wäre die Inhibition in allen Bodipy-TR-GTP 
Nukleotidaustauschexperimenten aufgetreten, auch wenn andere GEFs und GTPasen 
getestet wurden. Aufgrund dieser Markierungsabhängigkeit ist der Inhibitor für die zelluläre 
und die in vivo Anwendung ungeeignet. 
An welches Protein CG3 05 A02 bindet konnte nicht final aufgeklärt werden. Das Beladen 
von Rab5a mit Bodipy-TR-GTP in Abwesenheit eines GEFs wurde von CG3 05 A02 nicht 
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beeinflusst, was gegen einen GTP-kompetitiven Mechanismus der Inhibition spricht. Der 
Inhibitor bindet entweder an die Vps9 Domänen von Rin1 und Rabex-5, in der Nähe von 
diesen, oder an den Komplex zwischen den GEFs und Rab5. Aufgrund der Datenlage wurde 
ein auf sterischer Hinderung basierender Inhibitionsmechanismus vermutet, bei dem der 
Bodipy-TR-Rest und der an den Proteinkomplex gebundene Inhibitor sich behindern, sodass 
das Nukleotid nicht in die Bindungstasche gelangen kann. Das deutlich kleinere, radioaktiv 
markierte GTP ist von dieser Hinderung nicht betroffen.  
Kristallisation der Proteine im Komplex mit CG3 05 A02 könnte zur Identifizierung einer 
Bindestelle führen, die als Ausgangspunkt für zukünftige in silico Screenings dienen könnte. 
Aus einem derartigen Screening könnte dann eine zweite Generation von Inhibitoren der 
Rin1-vermittelten Rab5 Aktivierung hervorgehen.  
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Abstract 
 
The small GTPase Rab5 is a key regulator of early endosomal trafficking. It functions as a 
molecular switch that can be activated by guanine nucleotide exchange factors (GEFs) and 
inactivated via hydrolysis of GTP with the help of catalytic GTPase activating proteins (GAPs). 
GEFs mediate the exchange of GTPase-bound GDP for GTP. One of at least nine Rab5 GEFs, 
that have been identified until today, is Rin1. However, the differences in the exact roles of 
these GEFs are not completely understood. Rin1 is a multi-domain protein that has multiple 
signalling functions alongside the Rab5 activation. It is for example also involved in ABL 
kinase signalling, where it increases ABL activation. Rab5 over-activation has been reported 
to be involved in the genesis and progression of many different types of cancer and it could 
often be traced back to Rin1 over-expression. On the other hand Rin1 has been found to 
have a tumour repressive effect, mediated by its ABL kinase signalling function.  
This study aimed on the identification of a small molecule inhibitor of the Rin1-mediated 
Rab5 activation. Such a small molecule inhibitor could be used as a tool to unravel parts of 
the complex signalling networks around Rab5. Ideally the inhibitor should be specific for Rin1 
over other GEFs and moreover not influence its ABL kinase signalling function.  
A high-throughput in vitro screening of more than 20 000 small molecules has been 
performed. The screening assay monitored the Rin1-catalyzed nucleotide exchange on 
Rab5a by the use of the fluorescently labelled GTP analogue Bodipy-TR-GTP. Amongst other 
primary hits the compound CG3 05 A02 was identified. During specificity and aggregation 
studies it turned out to be the most promising candidate.  
Characterization of CG3 05 A02 revealed that its inhibitory effect in the Bodipy-TR-GTP 
nucleotide exchange assay is specific for Rin1 and Rabex-5 on Rab5a over several other 
GEF/GTPase pairs. The IC50 values were in both cases found to be in the low micromolar 
range. Rin1 and Rabex-5 share the homologous catalytic Vps9 domain and the compound 
might also be able to inhibit other Vps9 domain-containing GEFs. The compound did not 
induce aggregation of Rin1 or Rab5a and had no unspecific off-target effects in an unrelated 
insulin receptor auto-phosphorylation assay. It moreover did not influence the interaction 
between Rin1 and ABL1, indicating no intramolecular domain-unspecific inhibition. 
Unfortunately a control experiment with radioactively labelled GTP showed no inhibitory 
effect of the comound. The inhibition therefore depends on the use of Bodipy-TR-GTP but 
unlikely originates from CG3 05 A02 binding to the GTP analogue. In this case it would have 
inhibited the Bodipy-TR-GTP nucleotide exchange assay when GEFs/GTPases other than 
Rin1/Rabex-5 and Rab5 were used. This label-dependence classifies the compound 
unsuitable for cellular or in vivo application. 
The actual target of CG3 05 A02 could not be finally addressed but Bodipy-TR-GTP binding to 
Rab5a in absence of a GEF was not influenced by the compound. This argues against GTP-
competitive binding as the mechanism of inhibition. The compound potentially targets either 
directly the Vps9 domains of Rin1 and Rabex-5, areas adjacent to these, or the complex 
between the GEFs and Rab5. A mechanism based on steric hindrance involving the 
compound and the Bodipy-TR moiety of the GTP analogue was proposed as the mode of 
action. 
Identification of a binding site for CG3 05 A02 in ongoing crystallization approaches could 
provide a starting point for in silico screenings that can result in a second generation of 
inhibitors of the Rin1-mediated Rab5 activation.  
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1 Introduction 
 
1.1 Inter- and intracellular signalling: communication in living organisms 
 
All organisms on this planet are built from cells. There are unicellular organisms including 
archea and most bacteria as well as multi-cellular organisms like plants, fungi and animals. 
Organisms are facing constant changes in their environmental conditions that they have to 
adapt to in order to survive. Survival depends on the ability to detect and react to changes in 
the extracellular space. Cells are separated from this extracellular environment by a plasma 
membrane that consists of a lipid bilayer1. The plasma membrane is equipped with a 
multitude of different proteins that can act as receptors for stimuli like ligand binding, 
changes in temperature or osmolarity, mechanical forces and light2–5. Moreover there are 
proteins capable of performing transport of molecules over the membrane6. After detection 
of a stimulus, the cell transmits the signal in a series of molecular events leading to the 
coordination of a response. These signalling pathways or -cascades are tightly regulated as 
they are the basic mechanisms controlling cell proliferation, growth and metabolism. An 
imbalance in signalling, often caused by a mutation, can lead to pathological conditions 
including unregulated proliferation or cell growth like it is the case in cancer7,8.  
Eukaryotic cells are subdivided into different compartments executing special functions. 
They generate energy from nutrients, degrade substances, process genetic information and 
coordinate cargo transport. This cargo transport also takes place extensively between the 
compartments to secure provision with- and exchange of -molecules like proteins, ions, 
nutrients and nucleic acids. The cargo transport is mostly conducted in membrane enclosed 
particles called vesicles. Upon vesicle budding and fusion, the compartments also exchange 
parts of their membranes and the incorporated proteins9. 
Membrane-bound receptors often get internalized in vesicles after activation. This 
internalization either terminates their signalling, transmits the signal to another cellular 
compartment or changes the signal quality10,11. Signals can be amplified during the 
transduction process since the binding of one ligand molecule can generate a response 
involving multiple molecules. 
Small GTPases are a protein family involved in modulation of signalling pathways and 
integration of signals. They are also known to regulate vesicle transport. GTPases usually get 
activated by interaction with guanine nucleotide exchange factors (GEFs) that exchange 
GTPase-bound guanosine diphosphate (GDP) for guanosine triphosphate (GTP). Inactivation 
occurs via GTP hydrolysis with the help of GTPase activating proteins (GAPs)12. Defective 
regulation of small GTPases can lead to pathological conditions13,14, therefore those proteins 
can be interesting targets for therapeutics15. Small molecule inhibitors and activators are 
widely used as therapeutics in general. Those modulators can often also be used as tools to 
study signalling pathways in greater detail. Some small molecule modulators of GTPases, 
GEFs and GAPs are already known. However, there are many interesting proteins that still 
remain to be targeted. This work aims at the identification of a small molecule inhibitor of 
the Ras interaction/interference protein 1 (Rin1) mediated Ras-related brain protein (Rab5) 
activation. 
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1.2 The role of small GTPases in cellular signalling 
 
As previously mentioned in section 1.1 the activity of small GTPases depends on their 
nucleotide state16. In the inactive state GDP is bound. Upon activation a GEF exchanges GDP 
for GTP12. The intrinsic GTPase activity of small GTPases is often low, therefore GAPs are 
recruited to trigger hydrolysis and transform the GTPase back to its inactive state17. For that 
activation mechanism small GTPases are often referred to as molecular switches18. Small 
GTPases in their active state can interact with multiple effector proteins to trigger cellular 
responses via various signalling cascades19 (figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Activation and inactivation of small GTPases. The GTPase is inactive when GDP is bound and 
becomes activated upon GTP binding. The two nucleotide states are tightly regulated by GEFs and GAPs. GEFs 
exchange bound GDP for GTP while GAPs stimulate GTP hydrolysis. Active GTPases can bind multiple effector 
proteins to trigger cellular responses. 
 
Rat sarcoma (Ras) was the first small GTPase to be discovered in 197920, giving its name to 
the Ras superfamily of small GTPases that by now covers over 150 members21. The 
superfamily is subdivided into five families: the Ras, ADP ribosylation factor (Arf), Ras 
homolog (Rho), Ras-related nuclear protein (Ran) and Rab family. Ras GTPases are engaged 
in cytoplasmic signalling cascades leading to changes in the expression of genes in relation 
with cell differentiation, proliferation and survival22. Arf and Rab GTPases are involved in 
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protein trafficking, vesicular transport and regulation of endocytosis23,24. Modulation of the 
actin cytoskeleton and regulation of transcription factor activity is guided by Rho GTPases25. 
The Ran family comprises only one member. Ran controls nuclear pore transport and 
organization of the mitotic spindle26. 
 
1.3 Activation of small GTPases 
 
GTPases mostly become activated in close proximity to membranes27–30. A magnesium-ion is 
required as co-factor to stabilize nucleotide binding inside the binding pocket. GEFs 
destabilize magnesium and nucleotide binding. The exchange is therefore not directed 
towards GDP for GTP but the about ten times higher abundance of GTP in the cell favours 
GTP binding over GDP re-binding31. Figure 2 shows an overview of the three-dimensional 
structure of H-Ras in complex with the non-hydrolyzable GTP analogue GppNHp32. The 
structure of Ras superfamily GTPases is highly conserved. They all contain the switch regions 
I and II as well as a phosphate binding loop (P-loop) that are involved in magnesium-ion and 
nucleotide binding18,32.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Overview over the 3D structure of H-Ras in complex with the non-cleavable GTP analogue GppNHp. 
Rab, Arf and Rho GTPases have the same basic secondary structure elements and G1-G5 regions. […] Reprinted 
from Itzen and Goody, 201132 with permission from Elsevier (4017670396307). The switch regions I (purple) 
and II (green) as well as the P-loop (blue) are involved in magnesium-ion (green ball) and nucleotide (ball and 
stick representation) binding. 
 
The conformation of GTPases often differs depending on their nucleotide state (GDP-bound, 
GTP-bound or nucleotide free)33,34. Effector proteins can bind to active GTPases leading to 
downstream signal transmission. The switch I, switch II and interswitch regions change most 
and often expose a hydrophobic patch upon GTP binding, accordingly many effectors are 
found to bind to those regions32. However, there are additional areas for effector binding in 
Rab GTPases. Some Rab effectors can recognize a combination of nucleotide-dependent and 
–independent areas35,36. Since the different GTPases are highly similar, the complexity and 
versatility of GTPase-involving signalling pathways originates largely from the diversity of 
GTPase effectors and alterations in GTPase localization, making GTPases important 
modulators of many cellular processes. 
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1.4 The Rab family of small GTPases 
 
The Rab family of small GTPases is the largest family within the Ras superfamily. It is 
encoded by more than 60 genes in the human genome34,35. The family can be subdivided 
into several subfamilies: Rab1, Rab3, Rab4, Rab5, Rab6, Rab8, Rab11, Rab 14, Rab22, Rab27, 
Rab39 and Rab40. However, not all of the identified Rab proteins can be grouped into any of 
those subfamilies37,38. The structure of Rab GTPases consists of a six-stranded β-sheet 
surrounded by five α-helices. This represents the common composition amongst GTPases of 
the Ras superfamily (cp. figure 2)34. The C-terminus, involved in subcellular targeting, differs 
most between the Rab GTPases, whereas the nucleotide-binding switch regions I and II and 
the P-loop are highly conserved39. Alternative splicing variants are also known40. Some Rabs 
are expressed ubiquitously in human tissue but many are tissue specific. They are localized 
on the cytosolic face of cellular membranes. The distinct localization depends partly on post-
translational modifications, mostly prenylations, on a cysteine motif in the C-terminus41,42. 
Based on those prenylations Rab GTPases can cycle between membrane-bound and cytosolic 
states, depending on their activational state. GTPases can undergo several activation cycles 
before being released from the membrane36. Rab membrane-binding is additionally 
regulated by interaction with GDP dissociation inhibitors (GDIs) and GDI displacement 
factors (GDFs). The GDIs prevent GTPases from interacting with the membrane by masking 
the prenyl modifications22. Rab GDIs stabilize the GDP-bound state and shuttle the GTPase 
back to its compartment of origin36,43. A GDF for endosomal Rab GTPases (Rab5, Rab7 and 
Rab9) can release the GDI44,45. However, the importance of GDIs and GDFs for the specific 
organelle-membrane localization has been challenged, suggesting GEFs and effector proteins 
to be crucially involved in this process instead46,47. Possibly the specific localization is 
controlled by diverse mechanisms28. 
 
1.4.1 Rab GTPases as key regulators of vesicular transport 
 
Rab GTPases control vesicular transport along cellular compartments including endosomes, 
lysosomes, endoplasmic reticulum (ER) and golgi apparatus48. They regulate different stages 
of transport: vesicle formation, vesicle and organelle motility and vesicle docking49.  
The specific roles of Rab GTPases in vesicle formation are as yet emerging. Rabs seem to play 
a crucial role in endosomal cargo sorting mediated by retromer and sorting nexins50–52. Also 
the cargo recruitment is mediated by direct or indirect interaction with Rab GTPases53,54. It is 
speculated that Rab-mediated cargo selection and vesicle formation could involve specific 
lipids being recruited to the affected membrane areas55. 
Vesicle and organelle motility depends on microtubules. Rabs and their effector proteins 
regulate intracellular motility via recruitment of kinesin and dynein-dynactin motors to 
control cytoskeletal translocation56–62. The endocytic compartments including endosomes, 
lysosomes and phagosomes can also move in an actin/myosin-dependent manner over 
shorter distances. Here Rab GTPases can recruit myosin to the organelle membranes to 
regulate motility63,64. 
Vesicle docking and fusion has to be highly specific in order to preserve organelle identity 
and to ensure the desired cargo distribution inside the cell23. The regulatory mechanisms 
require Rabs to bind effector proteins that can then interact with proteins of the SNARE 
(soluble NSF attachment protein receptor, NSF stands for N-ethyl-maleimide-sensitive fusion 
protein) machinery. Cognate SNAREs interact with each other between two lipid bilayers and 
ensure precise tethering and membrane fusion65,66. Certain SNAREs are enriched in the 
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different cellular compartments to limit unspecific fusion events. Parts of the membranes 
and the incorporated proteins, including SNAREs, inevitably spread through many organelles 
during vesicular trafficking. Therefore regulatory mechanisms, like those involving Rab 
effectors, are needed to allow fusion only at the appropriate time and place65. Rab effectors 
are, unlike Rabs and SNAREs, not structurally conserved. The structural heterogeneity of Rab 
effectors implies that they are highly specialized for their functions. However, there are 
common motifs among Rab effectors like zinc-fingers and coiled-coil regions23. Rab effectors 
can also be shared between different Rabs to functionally couple them in a signalling 
cascade24,67.  
 
1.4.2 The role of Rab GTPases in endocytosis 
 
Lysosomes, phagosomes and endosomes are the cellular compartments of the endocytic 
pathway. Endosomes can be grouped into early endosomes, late endosomes and recycling 
endosomes68. They are involved in the vesicular internalization of extracellular molecules 
and membrane-bound proteins. This process is called endocytosis and leads inevitably to 
changes in the plasma membrane composition. It controls signalling pathways via receptor 
up- or downregulation68–70. The internalized molecules can become degraded, shuttled to 
other compartments or recycled back to the plasma membrane70. There are several types of 
endocytosis driven by different vesicle types and diverse mechanisms71. The best-described 
mechanism is clathrin-mediated endocytosis (CME), where Rab GTPases play a major role72–
74. However, there are many other clathrin-independent mechanisms including the 
CLIC/GEEC endocytic pathway, flotillin-dependent endocytosis, arf6-dependent endocytosis, 
circular doral ruffles, phagocytosis, trans-endocytosis and macropinocytosis71. Many 
receptors and their ligands become, however, internalized via CME75. Coupling proteins like 
the adaptor protein 2 (AP2) regulate cargo assembly and packing into clathrin-coated 
vesicles (CCVs)76,77. Cargo and adaptor proteins are diverse, reflecting a complexity of the 
process that originates from adaptations to the various materials that are being packed. 
CCVs are budding from the plasma membrane as well as from various intracellular 
compartments71. In the beginning, clathrin nucleation is coordinated by adaptor and 
accessory proteins at the membrane sites that are destined to be internalized77. This 
nucleation leads to clathrin polymerization into curved lattices78. At this point membrane 
curvature occurs, affected by small GTPases of the Arf, Rab and Rho families71. The 
membrane scission protein dynamin then forms a helical polymer around the vesicles neck 
and detaches it from the membrane. Finally Auxilin and Hsc70 release the clathrin coat from 
the vesicle79.  
Rab GTPases can directly affect and recognize positive membrane curvature71,80. The Rab 
GTPases are compartment-specific and enriched in rab microdomains81. They can therefore 
also be used as markers to identify the different organelles71. Other compartment-specific 
proteins are recruited by Rab GTPases that altogether define organelle identity67,81. The 
compartment-specific Rab microdomains are visualized in figure 3. Rab GTPases all fulfil 
certain roles on their specific compartments, often aditionally acting via effector proteins. 
Rab4 for example is essential for the recycling of receptors from the early endosome back to 
the plasma membrane43. Rab GTPases regulate the endocytic pathway on various 
compartments by controlling vesicle formation as well as tethering and fusion (cp. section 
1.4.1) 
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Figure 3: Rab GTPases in the endocytic pathway. Endocytosis describes the vesicular uptake of extracellular 
molecules and membrane-bound proteins. In clathrin-mediated endocytosis (CME), clathrin coated vesicles 
(CCVs, depicted with grey clathrin coat) are formed in membrane proximity. The vesicles get released from the 
membrane with help of the scission protein dynamin depicted in blue. Clathrin un-coating takes place in the 
cytoplasm followed by Rab- and SNARE-mediated tethering (as described in section 1.4.1) and fusion with early 
endosomes. From there, the cargo is transported to the late endosomes, the golgi apparatus for further 
sorting, packing and distribution, the lysosomes for degradation or recycled back to the plasma membrane via 
the recycling endosomes. Rab GTPases are depicted as purple microdomains on the compartment membranes. 
Rab5 is localized on the plasma membrane and on vesicles as well as on early endosomes, where also Rab4, 
Rab15, Rab22 and Rab21 microdomains can be found. Rab4 mediates recycling, Rab 22 controls transport from 
and to the golgi apparatus and Rab15 is involved in trafficking to the recycling endosomes. On the recycling 
endosomes Rab11 and Rab35 regulate the recycling. Rab2, Rab6, Rab8, Rab33 and Rab40 are localized on the 
golgi apparatus and contribute to cargo sorting, packing and further distribution. Rab7 and Rab9 can be found 
on the membranes of late endosomes where they control the transport to the lysosomes and the golgi, 
respectively. 
The figure is partially adapted from Stenmark, 200943 and inspired by figure 3 from Wosnitza, 201382. 
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1.5 Rab5 – regulator of the early steps in CME 
 
Rab5 is localized on the plasma membrane, on vesicles and on the membrane of early 
endosomes. Rab5 controls the formation of CCVs by affecting membrane curvature and 
recruiting adaptor proteins. Tethering and fusion of vesicles on the early endosomes is also 
mediated by Rab5 and its effectors.  
The Rab5 subfamily consists of seven members: Rab5a, Rab5b, Rab5c, Rab17, Rab21, Rab22a 
and Rab22b83. The Rab5 isoforms a-c are highly conserved in terms of sequence, function 
and localization. However, there are certain functions described only for particular isoforms. 
Rab5a can, for example, enhance endocytosis of the epidermal growth factor receptor 
(EGFR)84 and Rab5b is involved in neuroprotection against N-methyl-D-aspartate85. Rab21 
and Rab22 are, like Rab5, localized on early endosomes but also control trafficking at the 
golgi apparatus. Rab17 can be found on recycling endosomes and has recently been 
discovered to play a role in autophagy86. 
 
1.5.1 Diversity in structure and function: Rab5 interaction partners 
 
The many different Rab5 interaction partners are functionally and structurally diverse. Their 
functions include adaptors, GDIs, GDFs, GAPs and GEFs but the specific signalling functions 
of many Rab interaction partners are still to be explored23,32. Effectors are by definition 
proteins, that only interact with active, GTP-bound GTPases, so not all of the interacting 
proteins can be addressed as such32. The proteins mentioned in this section are a small 
selection to exemplify the different types of Rab5 interaction partners and there are many 
more proteins known for most of these types. 
The early endosomal autoantigen 1 (EEA1) is an adaptor protein, acting as a Rab5 effector on 
early endosomes. It is essential for endosome fusion and can bind to the endosomes via a C-
terminal interaction domain87. EEA1 co-localizes with Rab5 on early endosomes due to direct 
interaction between the two proteins. An N-terminal zinc finger on EEA1 specifically 
recognizes the switch I, switch II and interswitch regions of active Rab588. The interaction 
epitope on Rab5 is similar to the epitopes observed in complexes between Rab5 and the 
effectors Rabaptin-5 and Rabenosyn-589,90. Rabaptin-5 can also interact with the Rab5-GEF 
Rabex-5, bringing GEF and GTPase in close proximity. This leads to locally increased Rab5 
activation91. Adaptor proteins like these can mediate the formation of Rab microdomains on 
the organelles of the endocytic pathway67. 
As already mentioned in section 1.4, Rab GTPases cycle between a membrane-bound and a 
cytosolic state. In the cytosolic state they are bound to guanine nucleotide dissociation 
inhibitors (GDIs)80. There are two isoforms known in humans: GDIα, which is predominantly 
expressed in brain tissue and GDIβ, which is expressed ubiquitously92. GDIs can specifically 
target membranes of subcellular compartments and deliver GDI-bound Rab529,30,93.  
Pra1 is one of only two GDI displacement factors (GDFs) that have been discovered. It can 
dissociate endosomal Rab5 from the GDIs to allow nucleotide exchange44,45.  
Adaptors, GDIs and GDFs contribute to the regulation of Rab5 localization on the specific 
membranes80. They modulate the Rab5 distribution inside the cell. Besides, there are also 
proteins that modulate the activity of Rab5. GTPase activating proteins (GAPs) trigger the 
GTP hydrolysis activity of GTPases. 
The intrinsic GTPase activity of Rab5 may be higher compared to, for example Arf194–96, but 
is in general not sufficient to ensure coordinated switching off of the signal transmitted by 
the active GTPase32,96. Rab5 GAPs stimulate the GTPase activity via a conserved 
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Tre2/Bub2/Cdc16 (TBC) domain containing a catalytic arginine residue96–98. There are around 
50 TBC domain-containing proteins in humans but most of them have not been 
characterized yet35. A well-described one is TBC-2 that acts as a Rab5 GAP in C. elegans99.  
 
1.5.2 Rab5 GEFs contain a catalytic Vps9 domain 
 
GEFs are Rab5 interaction partners that exchange Rab5-bound GDP for free GTP, leading to 
Rab5 activation. Rab5 activation is among other things required to complete vesicle 
targeting and fusion100. Accordingly expression of a dominant-negative Rab5 mutant (S34N) 
inhibits endocytic fusion events and expression of a constitutively active mutant (Q79L) 
enhances them95. The intrinsic nucleotide dissociation of GDP from Rab5 is very slow101, 
therefore little nucleotide exchange can take place, even when excess GTP is present. To 
switch between the inactive GDP-bound and the active GTP-bound state, GEFs are 
unconditionally required100. There are at least nine GEFs described for Rab5, but their 
precise role in the regulation of the diverse Rab5 functions is yet not completely 
understood100. All of them contain a homologous catalytic Vps9 domain102–112. A list of the 
known Rab5 GEFs is provided in table 1. The Vps9 domain-containing GEFs are multi-domain 
proteins that additionally possess other signalling domains. They might serve to link Rab5 
activation with different signal transduction cascades100 and are involved in controlling Rab5 
localization46,47.  
 
Table 1: Vps9 domain-containing Rab5 GEFs. 
Name Abbreviation Alternative names Rabs 
Amyotrophic lateral 
sclerosis 2 protein 
Als2 Alsin Rab5 
Als2 C-terminal-like protein Als2CL  Rab5 
Rab5 GDP/GTP exchange 
factor 
Rabex-5 RabGEF1, Rap1 Rab5, Rab21, 
Rab22 
Rab5-activating protein 6 Rap6 GAPVD1, RME-6, GAPex-5 Rab5 
Ras and Rab interactor 1 Rin1 Ras interaction/interference 
protein 1 
Rab5 
Ras and Rab interactor 2 Rin2 Ras interaction/interference 
protein 2 
Rab5 
Ras and Rab interactor 3 Rin3 Ras interaction/interference 
protein 3 
Rab5, Rab31 
Ras and Rab interactor-like 
protein 
Rin-like  Rab5, Rab22 
Ankyrin repeat domain-
containing protein 27 
Ankrd27 Varp Rab5, Rab21, 
Rab32, Rab38,  
Vps9p guanine nucleotide 
exchange factor 
Vps9p  Rab5, Vps21p 
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1.6 Rin1: multiple domains, multiple functions 
 
The Ras and Rab interactor 1 (Rin1) is a soluble multi-domain protein localized at the plasma 
membrane and in the cytosol113. A schematic overview over the domain structure of Rin1 is 
provided in figure 4. The N-terminal Src homology 2 (SH2) domain can interact with receptor 
tyrosine kinases (RTKs) and increase their internalization and degradation114–116. Rin1 
moreover contains a proline-rich region (PR) that acts as Abelson tyrosine-protein kinase 
(ABL) interaction site. Upon interaction with ABL, Rin1 becomes phosphorylated at 
Tyr36113,117. The central Vps9 domain catalyses the exchange of GDP for GTP on Rab5118. This 
activation enables Rab5 to interact with its effectors and mediate the effects described in 
section 1.5.1. The C-terminal Ras interaction site (RA) can directly bind to active Ras (Ras-
GTP), competing with the RAF proto-oncogene serine/threonine-protein kinase 1 (Raf1). In 
this context Rin1 can inhibit cellular transformation induced by activated mutant Ras 
species. Many other Ras effectors have been described to enhance cellular transformation 
instead113. Rin1 contains several phosphorylation sites. Two of them, the best-described 
ones, are Tyr36 and Ser351, which get phosphorylated by ABL and the serine/threonine-
protein kinase D1 (PRKD1), respectively113,119. Phosphorylation of Ser351 enables Rin1 to 
interact with 14-3-3 proteins120. This interaction controls the correct localization of Rin1 as 
well as its ability to compete with Raf1 and is controlled by PRKD1113. The diversity of Rin1 
functions, caused by its multi-domain structure, results in complex signalling capabilities117. 
An imbalance in the regulation of Rin1 functions can lead to severe diseases like chronic 
myelogenous leukaemia (CML)121,122 and other types of cancer123–126. 
 
 
 
 
Figure 4: Domain structure of Rin1. Rin1 possesses an N-terminal Src homology 2 (SH2) domain that can bind 
receptor tyrosine kinases (RTKs) followed by a proline-rich region (PR) that represents the binding site for ABL. 
The central Vps9 domain catalyzes the nucleotide exchange on Rab5. Ras-interaction occurs via the C-terminas 
Ras association domain (RA). Rin1 contains several phosphorylation sites, the two labelled in this figure are the 
best-described ones: Tyr36 and Ser351, which get phosphorylated by ABL and the serine/threonine-protein 
kinase D1 (PRKD1), respectively. The phosphorylation of Ser351 induces interaction with 14-3-3 proteins.  
 
1.6.1 The nucleotide exchange mechanism of Vps9 domain-containing GEFs 
 
The Vps9 domain of Rin1 catalyzes the exchange of Rab5-bound GDP for free GTP. This 
exchange is not directed towards GTP, but the about ten times higher abundance of GTP 
inside the cell favours GTP binding instead of GDP re-binding31,127. There is no structural data 
available for the Vps9 domain of Rin1 yet, but there is a crystal structure published for the 
homologous Rabex-5 Vps9 domain and helical bundle tandem in complex with nucleotide-
free Rab21. The domain consists of six α-helices of which two form a hydrophobic groove 
that represents the binding site for Rab21128. The P-loop, switch I, switch II and interswitch 
regions of Rab21 constitute the recognition site for the Vps9 domain32,128. An aspartate 
residue from the hydrophobic groove of the Vps9 domain interacts with an invariant lysine in 
the P-loop of Rab21. This lysine originally contacts the β and γ phosphates of bound 
nucleotides and this contact gets disrupted by the interaction128. Additionally, there is also 
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an aspartate in the interswitch region of Rab21 that directly interacts with the Mg2+ ion in 
absence of GEFs. Upon GEF binding, this aspartate loses contact with the ion and interacts 
with the conserved P-loop lysine instead, leading to further destabilization of the nucleotide 
binding32. The GEF/GTPase complex gets disrupted by allosteric competitive binding of 
excess GTP129. This mechanism resembles the one described for Sec7 domain-containing 
GEFs on GTPases of the Arf family. The Sec7 domain contains a catalytic glutamate residue 
instead of the aspartate130,131. It can be assumed, that the exchange mechanism of Rin1 on 
Rab5 is similar to the one described for Rabex-5 on Rab21, since both GEFs contain the 
homologous catalytic Vps9 domain. 
 
1.6.2 Rin1 enhances EGFR internalization, degradation and down-regulation 
 
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that can be found 
inside the plasma membrane and the membranes of endosomes, golgi apparatus, nucleus 
and endoplasmic reticulum (ER), anchored with a single transmembrane region114,132,133. It 
consists of three major parts: an extracellular domain where ligand binding takes place, a 
transmembrane region and an intracellular kinase domain flanked by a juxtamembrane 
segment and a C-terminal tail134,135. The intracellular domain contains several tyrosine 
residues that can become phosphorylated during receptor dimerization114. Upon ligand 
binding, the receptor usually dimerizes and one intracellular domain phosphorylates the 
other102. However, ligand-free dimers have also been described136. Phosphotyrosines 
provide binding sites for adaptor proteins that can recruit Ras activators137. There are at 
least seven EGFR ligands known: epidermal growth factor (EGF), transforming growth factor 
α (TGFα), heparin-binding EGF-like growth factor (HBEGF), betacellulin (BTC), amphiregulin 
(AREG), epiregulin (EREG) and epigen (EPGN). EGF, TGFα, HBEGF and BTC have a higher 
affinity to the EGFR than the other three ligands138. Upon EGF binding the receptor becomes 
activated and gets internalized mainly via CME139. As previously described in sections 1.4.2 
and 1.5 active Rab5 is required for CME and Rin1 can activate Rab5 via its GEF function as 
explicated in section 1.6.1. Therefore, Rin1 can indirectly enhance EGFR internalization via 
Rab5 activation84. Additionally Rin1 can directly interact with activated EGFR through its SH2 
domain and with active H-Ras via its RA domain100,113–115,140,141. Binding active H-Ras 
increases the GEF activity of Rin1102 and may also contribute to its membrane 
recruitment100. Eventually, after endocytosis, the EGFR follows one of two possible paths: 
either it gets recycled back to the plasma membrane via the recycling endosomes142 or it is 
transported to the lysosomes for degradation143. Rin1 has been found to interact with the 
signal-transducing adaptor molecule (STAM) leading to fortified RTK degradation116. EGFR 
down-regulation and degradation after EGF stimulation are promoted by the Rin1 mediated 
Rab5 activation114. 
 
1.6.3 The role of Rin1 in ABL kinase signalling 
 
Abelson tyrosine-protein kinases (ABL1 and ABL2) are non-receptor tyrosine kinases that 
regulate actin remodelling through direct binding to filamentous actin (F-actin) and 
phosphorylation of actin related proteins144. The kinase activity of ABL is regulated on 
multiple levels. An N-terminal myristoylation supports an inactive kinase domain 
conformation145. Additionally, the ABL SH2 and SH3 domains stabilize a low activity 
conformation of the kinase domain146. Finally, there are tyrosine residues in the kinase 
domain that increase kinase activity upon (auto)phosphorylation147,148. Rin1 can bind to the 
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ABL SH3 domain with its proline rich region (PR). This binding leads to phosphorylation of 
Rin1 at Tyr36, which thereby gets enabled to interact with the SH2 domain of ABL. The 
divalent interaction increases ABL kinase activation117,119 by releasing ABL SH2- and SH3-
imposed auto-inhibition149.  
 
1.6.4 Two sides of the coin – Rin1 in cancer 
 
On one hand, Rin1 up-regulation has been implicated in the development of different types 
of cancer including squamous cell carcinoma123, colorectal cancer124, melanoma150 and non-
small cell lung cancer125. These studies suggest that Rin1 may play a role in enhancing cell 
proliferation. On the other hand a tumour suppressor function of Rin1 has been described in 
breast cancer, where it negatively regulates tumour invasive growth and inhibits the 
progression of tumourigenesis126.  
In oral squamous cell carcinoma (OSCC), an intra-chromosomal gene amplification of 
chromosome 11q13 encoding Rin1, amongst other proteins, has been found. This 
amplification may lead to a high Rin1 expression level123.  
52 of 101 colorectal cancer specimens have been found to over-express Rin1. Rin1 is, in 
those tumour cells, mainly bound to 14-3-3 proteins and localized in the cytoplasm. A lack of 
the ability to compete with Raf1 for binding of active Ras, due to a lack of plasma membrane 
localization, has been suggested. This may lead to enhanced Ras/Raf1 interaction compared 
to non-tumour cells, resulting in an increase of cell proliferation124. 
An over-expression of Rin1 could also be detected in melanoma samples and its 
accumulation could be associated with poor prognosis. Knock-down of Rin1 in A375 cells, a 
malignant melanoma cell line, suppresses cell proliferation and induces apoptosis150. 
Rin1 is expressed at high levels in many non-small cell lung adenocarcinoma cell lines 
including A549 cells. Depletion of Rin1 from A549 cells leads to a decrease in EGFR signalling 
and a correlating decrease in cell proliferation125,151. This effect supposedly originates from 
the requirement of Rab5-GTP for effective EGFR signalling, which is provided by high levels 
of Rin184,125. As previously described in section 1.6.2, Rin1 can also directly interact with the 
EGFR through its SH2 domain and positively influence EGFR internalization115.  
The RIN1-gene is silenced in several breast cancer cell lines, leading to reduced levels of Rin1 
protein. Rin1 re-expression can inhibit the initiation and progression of tumourigenesis in a 
breast cancer mouse model. Moreover, tumour invasive growth has been shown to be 
negatively regulated by the ABL kinase signalling function of Rin1126. 
Rin1 also plays a role in chronic myelogenous leukaemia since it can activate the oncogenic 
BCR-ABL tyrosine kinase fusion protein. This activation strongly accelerates BCR-ABL induced 
leukaemia (CML) in mice121,122. Alterations in the Rin1 expression level have not yet been 
reported in the context of CML. 
Together these studies suggest that Rin1 can play controversial roles in cancer. At least in 
lung cancer, the oncogenic effects of Rin1 could be traced back to its Rab5-GEF function. The 
effects of Rin1 over-expression in OSCC and melanoma are not completely understood but 
may also arise from enhanced RTK signalling, promoted by an increase of Rab5 activation. 
The tumour suppressor function of Rin1 in breast cancer could be addressed to its ABL 
kinase signalling function. Conclusively Rin1 is a multi-domain protein with domain-specific 
effects in cancer development. 
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1.7 Small molecules as tools to modify single domains in multi-domain 
proteins 
 
Since the discovery of penicillin by Alexander Fleming in 1929 at the latest, drug discovery 
became a huge field in pharmacology, medicine and chemistry152. Combinatory libraries of 
small molecules can be screened in high throughput approaches since the middle of the 20th 
century152,153. Small molecules are not only suitable as therapeutics but also as tools to study 
signalling cascades by modification of the activity of one or more of the proteins involved154. 
With small molecules it is moreover possible to target specific domains and thereby specific 
functions of multi-domain proteins without inevitably affecting their other functions or their 
expression level155,156.  
In contrast, knock-out or knock-down methods usually operate on the level of DNA or RNA 
instead and generally result in the loss of whole proteins and all their functions. Therefore 
the effects of small molecule inhibitors can, in some cases, be more accurate than methods 
like RNA interference (RNAi)156. Knock-outs and knock-downs often have lethal effects on 
the organism, as described for a Rab5 knock-down in C. elegans157, complicating in vivo 
research154. Small molecules are normally easily synthesizable, relatively stable, often cell 
permeable and their effects are also reversible, since they usually can be 
metabolized154,156,158. Multiple small molecules can be combined and applied in variable 
doses to allow a fine-tuning of the desired effects158. Small molecule modifiers of specific 
protein functions are usually discovered in robot-assisted high throughput screening (HTS) 
approaches. For that, a suitable assay that meets certain criteria has to be developed. After 
identification of hit compounds in the HTS, the molecules can be characterized and 
optimized according to structure activity relationship studies. This often also helps to 
address the mechanism behind small molecule effects153,159.  
 
1.7.1 Ras superfamily GTPases as targets for small molecule inhibitors 
 
Various members of the Ras superfamily of small GTPases have been reported to become 
over-activated during cancer development in many different types of cancer, as previously 
described for Rab5 in section 1.6.4. However, small GTPases are elusive drug targets due to 
their flat and flexible topology and their multiplicity of interaction partners21,160. In principle, 
locking GTPases in any of the stages occurring during the canonical GTPase cycle (cp. figure 
1) could lead to inhibition. This comprises anything from targeting the nucleotide binding 
pocket to stabilizing an inactive conformation (GDP-bound, GAP-bound or state I GTP-
bound) and blocking GEF/effector binding sites either reversibly or covalently21. Finding a 
selective GDP- or GTP-competitive GTPase inhibitor is difficult. Due to the high affinity for 
GDP/GTP and conservation of the residues surrounding the nucleotide binding pocket, the 
risk of undesirable cross-inhibition throughout other GTPases is high. Such a nucleotide 
competitive pan-GTPase inhibitor has been described and appears to be long-term 
cytotoxic161. 
The most effort has been directed towards inhibition of Ras, because mutant hyperactive 
Ras subfamily members are implicated in over 20 % of all cancers162–165. The Rab subfamily is 
widely unexplored as target for small molecules with only a few novel binders discovered to 
date. To develop small molecules against other members of the Ras superfamily of GTPases, 
more data on structure and dynamics of Arf, Ran and Rho GTPases is required21.  
Recent strides towards directly targeting Ras superfamily GTPases have refuted the 
‘undruggability’ of these proteins and generated a strong interest in targeting them165. 
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1.7.2 GEFs as targets for small molecule inhibitors  
 
Hyper-activation of GTPases can not only be caused by mutations of the GTPases 
themselves, as it is the case for Ras in many tumours, but also by GTPase over-expression, 
loss of GAP-mediated inactivation and up-regulation of the corresponding GEFs166. Therefore 
it is not surprising that over-expression of GEFs can be found in different cancers167–175, as 
already described also in section 1.6.4 for Rin1. One GTPase can be activated by a large 
variety of different GEFs100. Therefore targeting a single GEF can more specifically influence a 
certain signalling cascade compared to targeting the GTPase itself. GEFs are not classically 
considered ‘druggable’ targets because they often lack grooves and pockets for small 
molecule interactions. They are covered with large contact surfaces for protein-protein 
interactions instead176. Since GEFs are not as conserved in structure and catalytic domains as 
GTPases, the risk for off-target effects is lower and thus the chances to find a specific 
inhibitor are higher166. GEF inhibition can be achieved by either targeting the catalytic GEF 
domain or by locking the GEF/GTPase complex in a way that prevents nucleotide exchange. 
As for Ras GTPases themselves, the strongest efforts have been directed towards finding 
inhibitors of Ras GEFs177–180. However, there are also several inhibitors described for GEFs 
activating other Ras superfamily GTPases181–185. 
Those examples illustrate that targeting GEFs, either directly at their catalytic domains or by 
targeting the GEF/GTPase complex, is possible and worth further trials in the future. 
 
1.7.3 Overview: Inhibitors of Ras superfamily small GTPases and their GEFs 
 
1.7.3.1 Inhibitors of Ras superfamily GTPases 
 
Several inhibitors of small GTPases of the Ras superfamily have been described so far. Not all 
of them are small molecules, some peptide inhibitors have also been found. An overview 
over the inhibitors described below is given in table 2. 
 
Inhibitors of Ras GTPases: 
 
CID1067700 is a nucleotide-competitive pan-GTPase inhibitor discovered in a flow cytometry 
bead-based high-throughput screening (HTS). Inhibition could be shown for representative 
GTPases from the Ras, Rho and Rab subfamilies in biochemical, cellular protein-protein 
interaction and cellular functional assays161.  
The small molecule Kobe0065 has been found in an in silico HTS approach and proved to 
prevent the interaction between H-Ras-GTP and c-Raf1 both, in vitro and in vivo186.  
SML-10-70-1 is a covalent GDP analogue created by rational design. It is selective for mutant 
K-RasG12C over wild-type (wt) Ras and it renders the protein in an inactive state. SML-10-70-1 
is a ‘caged’ analogue of SML-8-73-1, which is thereby made cell permeable and showed anti-
proliferative effects in A549, H23 and H358 cells187. 
An about 4-fold decrease in GTP affinity of K-RasG12C could be obtained with Acrylamide 12 
(AA12) by allosteric binding. It abolishes activation of the mutant Ras by the GEF Son of 
sevenless (Sos) and promotes apoptosis of K-RasG12C expressing cell lines188. 
SCH-53239 targets GEF-Ras-GDP ternary complexes and could reduce cell growth. The 
definite mode of action remains elusive for this compound and its derivatives189. 
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The hydrogen-bond surrogate 3 (HBS3) is a synthetic α-helix designed based on the wt Sos 
αH (929–944). It competes with Sos-binding. It could moreover reduce the Ras-GTP level and 
downstream Erk-activation in serum-starved, EGF stimulated HeLa cells190. 
Another synthetic α-helix designed based on the structure of Sos1 is SAH-SOS1, a stapled 
peptide inhibitor that interferes with wt Ras- and K-Ras-Sos1 interaction. It binds Ras-GDP 
and Ras-GTP with similar affinity and impairs viability of K-Ras dependent cell lines with an 
IC50 of 5 – 15 µM
191. 
Andrographolide (AGP) is a natural product isolated from Andrographis paniculata. It was 
shown to interact with wt Ras and K-Ras and supposedly binds to a Ras-GEF interaction site. 
Intracellular levels of wt Ras-GTP as well as Erk-phosphorylation could be reduced by AGP in 
different cell lines with IC50 values between 4.5 and 9.7 µM
192. 
The Sos-catalyzed nucleotide exchange and release on K-Ras could be impaired by DCAI in 
vitro. It binds to a hydrophobic pocket between switch I and II of K-Ras and inhibits the 
nucleotide exchange with an IC50 of 342 µM and the nucleotide release with an IC50 of 155 
µM193. 
Zn2+- and Cu2+-cyclen stabilize H-Ras in state I GTP-bound conformation, which is a weak 
state for effector binding194,195.  
In a yeast two-hybrid screening approach the small molecule inhibitor MCP110 could be 
identified. It can disrupt the interaction between H-Ras and Raf1 in vitro and in cells and had 
an anti-proliferative effect in cells expressing constitutively active Ras196. 
BQU57 binds to RalB-GDP and supposedly locks this inactive state. It was identified in a 
structure-based virtual screening and binds adjacent to the switch II region of RalB. BQU57 
can effectively reduce RalB-GTP in cells and inhibits colony formation in lung cancer cell 
lines197. 
 
Inhibitors of Rho GTPases: 
 
Mitoxantrone (MTX) is a Rho-GTPase pan-inhibitor identified in an AlphaScreen® approach. 
It impairs GTP loading in vitro and has been shown to slow down cell migration in wound-
healing assays198. 
The allosteric Cdc42 inhibitor CID29950007 locks the GTPase in an inactive conformation and 
induces nucleotide release. It can inhibit Cdc42-mediated cellular functions like filopodia 
formation199. 
EHT 1864 is an allosteric Rac1 inhibitor with an IC50 of 40 nM. It has been shown to reduce 
Aβ peptide levels in Alzheimers disease models200. 
In a virtual screening approach the RhoA/RhoB/RhoC inhibitor Rhosin was identified. Rhosin 
blocks the interaction between Rho and its GEF LARG. Moreover it was shown that Rhosin 
can block Rho-specific downstream signalling and inhibits growth of MCF-7 cells in a dose-
dependent manner201. 
The small molecule ZCL278 was found in an in silico HTS. It interferes with the interaction 
between Cdc42 and its GEF Intersectin and decreases the cellular level of Cdc42-GTP202. 
NSC23766 selectively inhibits the interaction of Rac1 with its GEFs Tiam1 and TrioN with an 
IC50 of about 50 µM in vitro. An anti-proliferative and anti-invasive effect could be shown in 
prostate cancer cells203.  
The small molecule EHop-016 has been designed based on the structure of NSC23766 and 
inhibits Rac activity with an IC50 of 1.1 µM in cells. It significantly reduces tumour growth, 
metastasis and angiogenesis in breast cancer mouse models204. 
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1A-116 interferes with the interaction between Rac1 and its GEF P-Rex1 and could be shown 
to reduce the level of Rac1-GTP in breast cancer cells205.  
Secramine A supposedly stabilizes the interaction between Cdc42 and RhoGDI, preventing 
membrane association and effector binding of Cdc42. It does not affect nucleotide binding 
and exchange206. 
 
Inhibitors of Arf GTPases: 
 
AMF-26 is a small molecule inhibitor that has been identified in an in silico approach based 
on the cellular effects of Brefeldin A (BFA). A logarithm has been used to compare the effects 
of BFA with those of 4000 compounds on a total of 39 cell lines. Reduction of ARF1 
activation by AMF-26 could be shown in a pull down assay207. 
Other inhibitors of proteins from the Arf subfamily of small GTPases are Brefeldin A and LM-
11. These small molecules stabilize the complex between Arf1 and a GEF. They are listed in 
Section 1.7.3.2 (Inhibitors of GEF proteins). 
 
Inhibitors of Rab GTPases: 
 
The stapled peptide StRIP3 has been designed based on the structure of the Rab6-interacting 
protein 1 and locks Rab8a in its GDP-bound state. StRIP3 also interferes with the interaction 
of Rab8a and its effector OCRL1208,209. 
Nexinhib20 is a small molecule inhibitor that disrupts the interaction between Rab27a and 
its effector JFC1 that plays an important tethering role in neutrophil exocytosis210.  
 
Inhibitors of the Ran GTPase: 
 
There is no inhibitor known for the small GTPase Ran to this day. 
 
Table 2: Inhibitors of Ras superfamily GTPases. 
Name Type Target Mechanism Screening IC50 Ref. 
CID1067700 Small 
molecule 
pan-
GTPases 
Nucleotide 
competitive 
Flow 
cytometry 
bead-based 
Different 
for each 
GTPase 
161,21
1 
Kobe0065 Small 
molecule 
H-Ras-
GTP 
Inhibits effector 
interaction 
In silico HTS 46 ± 13 
µM 
186 
SML-10-70-1 Small 
molecule 
K-RasG12C Covalent, GDP 
analogue  
Rational 
design 
26.6 – 
47.6 µM 
(in cells) 
187 
AA12 Small 
molecule 
K-RasG12C Allosteric, 
decreases affinity 
for GTP 
Disulfide 
fragment-
based 
tethering 
0.32 µM 
(in cells) 
188 
SCH53239 Small 
molecule 
Ras-GDP unknown Rational 
design 
0.5 µM 189 
HBS3 Synthetic 
α-helix 
Nucleoti
de-free 
Ras 
Sos competitive, 
inhibits 
interaction 
 
Rational 
design 
28 ± 4.8 
µM 
190 
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SAH-SOS1 Stapled 
peptide 
K-Ras 
and wt 
Ras 
Sos-competitive Rational 
design 
60 – 140 
nM 
191 
AGP Small 
molecule 
K-Ras 
and wt 
Ras 
May inhibit K-
Ras-GEF 
interaction 
None (natural 
product) 
4.5 – 9.7 
µM (in 
cells) 
192 
DCAI Small 
molecule 
K-Ras Inhibits Ras-Sos 
interaction 
NMR-based 
fragment 
screen 
342 µM 193 
Cu2+/Zn2+-
cyclen 
Small 
molecule 
H-Ras Locks Ras-GTP in 
state I  
NMR 
spectroscopy 
Millimola
r  
194,19
5 
MCP110 Small 
molecule 
H-Ras Inhibits Ras-Raf 
interaction 
Yeast two-
hybrid screen 
2 – 25 
µM 
196,21
2 
BQU57 Small 
molecule 
RalB-
GDP 
May lock GDP-
bound state 
In silico HTS ~ 2 µM 
(in cells) 
197 
CID29950007 Small 
molecule 
Cdc42 Allosteric, locks 
inactive 
conformation and 
induces 
nucleotide 
release 
In vitro GTP 
competitive 
HTS 
2 – 3 µM 199 
EHT1864 Small 
molecule 
Rac1 Allosteric, 
induces 
nucleotide 
release 
unknown 40 nM 200,21
3 
MTX Small 
molecule 
pan-Rho 
GTPases 
Inhibits GTP 
loading 
AlphaScreen® Different 
for each 
GTPase 
198 
Rhosin Small 
molecule 
RhoA, 
RhoB, 
RhoC 
Inhibits Rho-LARG 
interaction  
In silico HTS Submicr
omolar 
201 
ZCL278 Small 
molecule 
Cdc42 Inhibits CdC42-
intersectin 
interaction 
In silico HTS Low 
micromo
lar 
202 
NSC23766 Small 
molecule 
Rac1 Inhibits Rac1-
Tiam1/TrioN 
interaction 
In silico HTS 50 µM 203 
EHop-016 Small 
molecule 
Rac1, 
Rac3 
May inhibit Rac1-
Vav2 interaction 
Rational 
design 
1.1 µM 
(in cells) 
204 
1A-116 Small 
molecule 
Rac1 Inhibits Rac1-P-
Rex1 interaction 
In silico HTS 4 µM 205 
Secramine A Small 
molecule 
Cdc42 May stabilize 
Cdc42-RhoGDI 
interaction 
Phenotypic 
HTS 
1 µM (in 
cells) 
206 
AMF-26 Small 
molecule 
Arf1 May inhibit Arf1-
ArfGEF 
interaction 
Drug 
sensitivity data 
base (in silico) 
4.9 µM 
(in cells) 
207 
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StRIP3 Stapled 
peptide 
Rab8a Locks Rab8a-GDP, 
inhibits Rab8a-
OCRL1 interaction 
Rational 
design 
22 µM 165,20
8,209 
Nexinhib20 Small 
molecule 
Rab27a Inhibits Rab27a-
JFC1 interaction 
In vitro FRET-
based HTS 
2.6 µM 210 
 
1.7.3.2 Inhibitors of GEF proteins 
 
Some inhibitors of GEF proteins for GTPases of the Ras superfamily have been identified. 
There are small molecule inhibitors of GEF proteins, but also aptamers and stapled peptides 
have been found. Inhibitors that act by stabilization of GEF/GTPase complexes will be listed 
here, although they by definition also act on the GTPases. An overview over the inhibitors 
described below is given in table 3. 
 
Inhibitors of Ras GEFs: 
 
UC-773587 and UC-857993 are small molecule inhibitors of the Ras GEF Sos1. They have 
been identified in an in silico structural HTS approach followed by an in vitro HTS. The 
binding site could be mapped to the catalytic pocket of Sos1, preventing the interaction 
between Sos1 and Ras214. 
Another small molecule compound that interferes with the Sos1-Ras interaction is NSC-
658497. It binds to the catalytic site of Sos1 and dose-dependently inhibits Sos1-mediated 
Ras activation in vitro as well as cell proliferation of prostate cancer cells215. 
 
Inhibitors of Rho GEFs: 
 
The RNA aptamers K91 and K11 have been identified in a Systematic evolution of ligands by 
exponential enrichment (SELEX) approach. They inhibit the Tiam1-mediated activation of 
Rac1 and Rac2. The aptamer binding motif overlaps with the GTPase binding site of Tiam1 
and involves the helix α9216.  
Y16 is a small molecule inhibitor that dose-dependently blocks the activation of RhoA by its 
GEF LARG. It interacts with the DHPH domain of LARG and could be shown to specifically 
inhibit RhoA activation in fibroblasts as well as growth, migration and invasion of breast 
cancer cells182. 
Tripα is a peptide aptamer identified in a yeast-two-hybrid genetic screen that inhibits the C-
terminal GEF domain of Trio (TrioC). Trio contains two different GEF domains: TrioC and 
TrioN that activate RhoA and RhoG/Rac1, respectively. Tripα could inhibit TrioC activity in 
COS cells183,217. 
TrioN can also be targeted by the small molecule NPPD that has been found in a medium-
throughput screening (MTS) using a yeast exchange assay. It dose-dependently reduces the 
GEF activity of TrioN on RhoG in vitro but turned out to be cytotoxic in mammalian cells218. 
ITX3 was identified in the same yeast exchange assay screening as NPPD and could be shown 
to inhibit the TrioN-mediated nucleotide exchange on RhoG and Rac1. It could inhibit Rac1 
activation in mammalian cells without showing cytotoxic effects184.  
In another yeast exchange assay setup C21 could be discovered. C21 is a small molecule 
inhibitor of the Rac1-GEF Dock5 that does not affect Rac1 activation by TrioN219. 
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Inhibitors of Arf GEFs: 
 
Brefeldin A (BFA) is the first GEF inhibitor that has ever been found, discovered in the 1950s. 
It is a natural product, isolated from the fungus Eupenicillium brefeldianum, which blocks the 
GEF activity of a subgroup of Sec7 domain-containing Arf1 nucleotide exchange factors as 
Gea1 in yeast or Big1 in higher eukaryotes. BFA acts by stabilizing the Arf1-GDP-Sec7 
complex166,185. This mode of action is known as ‘interfacial inhibition’ and suggests a 
promising strategy for targeting GEF/GTPase complexes220.  
Another interfacial inhibitor called LM-11 stabilizes the complex between Arf1-GDP and the 
Sec7 domain of its GEF ARNO. LM-11 has been shown to block the ARNO-mediated 
migration of MDCK cells185. 
M69 is an RNA aptamer that binds to the catalytic Sec7 domain of Cytohesin1, ARNO 
(Cytohesin2) and Cytohesin3 and inhibits the nucleotide exchange on Arf1 and Arf6 with an 
IC50 in the low micromolar range.  
An aptamer displacement screen using the fluorescently-labelled M69 aptamer in a 
fluorescence polarization assay identified the small molecule SecinH3. It inhibits the 
Cytohesin-mediated nucleotide exchange on Arf1 and Arf6 in a concentration-dependent 
manner. Using SecinH3 it could be shown that cytohesins are involved in hepatic insulin 
signalling221. 
A virtual screening approach based on the structure of SecinH3 identified Secin16, that could 
inhibit the ARNO-mediated nucleotide exchange on Arf1 and reduce Cytohesin-dependent 
cell adhesion of human leukocytes222. 
 
Inhibitors of Rab GEFs: 
 
The only inhibitor of a Rab GEF that has been discovered to this day is JH5. JH5 inhibits the 
Rabex-5-mediated nucleotide exchange on Rab5 in vitro, without affecting the Rin1-
mediated nucleotide exchange. The small molecule contains a thiol group that has been 
shown to be important for the inhibitory effect, yet makes this compound sensitive to 
reducing conditions. A cellular effect of JH5 could not be shown82. 
 
Inhibitors of Ran GEFs: 
 
There is no inhibitor known for GEFs of the small GTPase Ran to this day. 
 
Table 3: Inhibitors of GEF proteins. 
Name  Type Target Mechanism Screening IC50 Ref. 
UC-
773587 
Small 
molecule 
Sos1 Inhibits Sos1-Ras 
interaction 
In silico 
followed by 
in vitro HTS 
< 50 µM 214 
UC-
857993 
Small 
molecule 
Sos1 Inhibits Sos1-Ras 
interaction 
In silico 
followed by 
in vitro HTS 
< 50 µM 214 
NSC-
658497 
Small 
molecule 
Sos1 Inhibits Sos1-Ras 
interaction 
In silico 
followed by 
in vitro HTS 
micromola
r 
215 
K91 & 
K11 
RNA 
aptamers 
Tiam1 Inhibit Tiam1-Rac1 
– 2 interaction 
SELEX nanomola
r 
216 
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Y16 Small 
molecule 
LARG Binds to catalytic 
DHPH domain 
In silico HTS Low 
micromola
r 
182 
Tripα Peptide 
aptamer 
TrioC May inhibit TrioC-
RhoA interaction 
Yeast-two-
hybrid 
genetic 
screen 
4 µM 183,21
7 
NPPD Small 
molecule 
TrioN May inhibit TrioN-
RhoG/Rac1 
interaction 
Yeast 
exchange 
assay MTS 
116 µM 218 
ITX3 Small 
molecule 
TrioN May stabilize 
GTPase/TrioN 
complex 
Yeast 
exchange 
assay MTS 
76 µM 184 
C21 Small 
molecule 
Dock5 unknown Yeast 
exchange 
assay MTS 
Micromol
ar range 
 
BFA Small 
molecule 
Arf1-GDP-
Gea1 Sec7 
complex 
Stabilizes Arf1-
GDP-Gea1 Sec7 
complex 
None 
(natural 
product) 
15 µM 166,18
5 
LM-11 Small 
molecule 
Arf1-GDP-
ARNO-
Sec7 
complex 
Stabilizes Arf1-
GDP-ARNO-Sec7 
complex 
In silico HTS 150 – 200 
µM 
185 
M69 RNA 
aptamer 
Cytohesin
1-3 
Binds to catalytic 
Sec7 domain 
SELEX Low 
micromola
r range 
223 
SecinH3 Small 
molecule 
Cytohesin
1-3 
Binds to catalytic 
Sec7 domain 
Aptamer 
displaceme
nt screen 
2.4 – 5.6 
µM 
221 
Secin16 Small 
molecule 
Cytohesin
1-3 
unknown In silico HTS 3.1 µM 222 
JH5 Small 
molecule 
Rabex-5 May bind to 
catalytic Vps9 
domain 
In vitro HTS 0.3 µM 82 
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2 Aim of the Project 
 
The small GTPase Rab5 is involved in early endosomal trafficking and vesicular transport. Its 
activity is regulated by various GEFs and, once activated, it can interact with a multitude of 
different effector proteins. Yet the specific contribution of single GEFs to the diverse Rab5 
functions and interactions is far from being understood and also depends largely on Rab5 
localization. Moreover an up-regulation of Rab5 or Rab5-GEFs can lead to pathological 
conditions like many different types of cancer.  
GEFs are usually multi-domain proteins with specific functions besides GTPase activation. 
The Rab5-GEF Rin1 is of particular interest. It is on the one hand up-regulated in non-small 
cell lung adenocarcinoma and other cancer cell lines, contributing to their proliferative 
nature via excessive Rab5 activation, and on the other hand acts as a tumour suppressor in 
breast cancer cells via its ABL kinase signalling function.  
Rin1 also increases EGFR internalization, degradation and down-regulation and can interact 
with active Ras to enhance Ras-dependent signalling. It has several phosphorylation sites 
and upon phosphorylation can interact with 14-3-3 proteins. The impact of Rin1 domain-
specific functions on downstream signalling cascades can hardly be studied by knock-out or 
knock-down methods, because they usually affect rather the whole protein than certain 
subdomains. To dissect the complex network of protein-protein interactions involving Rin1 
and Rab5, domain-specific small molecule inhibitors could be a useful tool. With such 
inhibitors it could be possible to investigate the influence of, for example, only the GEF 
function of Rin1 by selective inhibition of the Vps9 domain, without affecting its other 
domains. This approach would help elucidating the complex roles of Rin1 and subsequently 
Rab5 and might even contribute to a deeper understanding of other Rab5-GEFs and their 
ability to counteract Rin1 GEF-deficiency.  
To this day there is no small molecule modulator of Rin1 or Rab5 available. The only small 
molecule modulator described for a Rab5-GEF is the Rabex-5GEF inhibitor JH5. A cellular 
effect of JH5 could not be shown, possibly due to its sensitivity to reducing conditions. 
The aim of this project is to identify a small molecule inhibitor of the Rin1-mediated Rab5 
activation. Therefore it is necessary to establish and apply an in vitro nucleotide exchange 
assay suitable for high-throughput screening. This requires the purification of active 
recombinant Rin1- and Rab5 constructs first, followed by assay design and conversion to a 
robot-assisted format. After screening of a small molecule library with more than 20 000 
compounds, the resulting hits should be evaluated and characterized in vitro in terms of 
their biochemical properties, structure-activity relationship and specificity over other GEF 
and GTPase pairs.  
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3 Results 
 
3.1 Protein expression and purification 
 
Several GTPases and GEFs have been expressed and purified during this project. First of all, 
active Rab5a and Rin1C had to be purified to establish the screening assay and perform the 
screening. To test for specificity of the hit compounds, other GEF/GTPase pairs have been 
purified: Rabex-5GEF/ Rab5a, DrrA/Rab1, Tiam1DHPH/Rac2 and Vav1/Rac1. Strep-tagged full 
length Rin1 (Rin1-TS) has been purified to study the effects of the hit compound on the 
Rin1/ABL1 interaction. 
 
3.1.1 Rab5a 
 
Human Rab5a was expressed as an aa17-184 construct, lacking the hypervariable C-terminal 
region that contains the prenylation sites required for membrane anchorage and a short N-
terminal part that is involved in endocytosis and fusion events36,39,224,225. These parts are 
nonessential for nucleotide and GEF binding and a similar construct for Rab5c has been 
described to be active in vitro226. It was heterologously expressed in a pET15b vector with an 
N-terminal 10 x Histidine tag in E. coli BL21-CodonPlus®(DE3)-RIL cells. The protein 
expression before and after Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction was 
monitored via SDS-PAGE as depicted in figure 5a. An increased abundance of a band at 
around 21 kDa was observed after induction, which correlates with the expected mass for 
the Rab5a construct, indicating successful protein expression. The analysis of the purification 
during every step is shown in figure 5b. The 21 kDa protein could be retrieved from the 
fractions 22 – 26 (figure 5b, lane 11) during a size exclusion chromatography. A yield of 83.6 
mg Rab5a in a concentration of 198 µM could be obtained from 2 L of E. coli culture. The 
protein was mainly pure with only a few traces of impurities and could be largely enriched. 
During the Ni-NTA affinity chromatography some amount of the target protein could be 
found in the flow-through and the washing fraction. This might have been avoidable by using 
more of the Ni-NTA resin to avoid saturation. 
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Figure 5: Expression and purification of Rab5a. 15 % SDS-PAGE gels stained with coomassie brilliant blue. A 
pre-stained molecular weight marker is loaded in lane 1 of each gel. a: Analysis of the protein expression 
before (lane 2) and after (lane 3) IPTG induction. b: Step-by-step analysis of the Rab5a purification. The E. coli 
lysate has been loaded in lane 1, followed by the insoluble cell debris in lane 2. Lane 3 shows the flow-through 
fraction after incubation with Ni-NTA beads. In lane 4 the wash fraction from the Ni-NTA chromatography has 
been loaded. The lanes 6 and 7 show the eluate fraction of the Ni-affinity chromatography before (6) and after 
(7) centrifugation to remove possible precipitate. In the lanes 8 – 14 the fractions (pooled by peaks) collected 
during size exclusion chromatography have been loaded. Lane 8: Fractions 1 + 2, lane 9: Fractions 5 – 7, lane 
10: Fractions 18 – 20, lane 11: Fractions 22 – 26, lane 12: Fractions 27 – 29, lane 13: Fractions 33 – 35 and lane 
14: Fractions 38 – 42. Lane 15 has been left empty. 
 
3.1.2 Rin1C 
 
Rin1C is an aa293 – 783 construct of human Rin1 that has been expressed in Sf9 insect cells 
previously and was found to be active in in vitro assays after purification102. It lacks the N-
terminal SH2 domain as well as the proline rich region required for ABL kinase interaction. It 
is built of the Vps9 domain that bares the Rab5-GEF activity as well as the C-terminal Ras 
interaction site and contains a 6 x histidine tag followed by a TEV cleavage site at the N-
terminus. The Bac-to-Bac system has been used to generate the virus required for 
expression of the construct. The purification was analysed at every step on the SDS-PAGE 
gels that are depicted in figure 6. The 55 kDa protein could be collected from fractions 14 – 
22 (figure 6b, lane 14 and c, lanes 2 – 9) during the size exclusion chromatography. A yield of 
15.3 mg Rin1C in a concentration of 113 µM could be obtained from 5 L of Sf9 cell culture. 
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Figure 6: Purification of Rin1C. 10 % SDS-PAGE gels stained with coomassie brilliant blue. A pre-stained 
molecular weight marker is loaded in lane 1 of each gel. a: Analysis of the Ni-NTA affinity chromatography. The 
Sf9 cell lysate is loaded in lane 2, followed by the insoluble cell debris in lane 3. The lysate was split into two 
tubes before incubation with the Ni-NTA beads (for volume reasons). Lanes 4 and 6 show the wash fractions of 
each split and lanes 5 and 7 the corresponding flow-through fractions. Lanes 8, 9 and 10 show the pooled 
eluate of the Ni-NTA beads: before concentration (8), after concentration (9) and after centrifugation to 
remove possible precipitate (10). b: Analysis of the size exclusion chromatography. Lane 2 – 14 are numbered 
after the fractions they contain (fractions 2 – 14). c: Continuation of the fractions from the size exclusion 
chromatography. Lanes 2 – 15 show the fractions 15 – 28, respectively. 
Results 
 
42 
 
3.1.3 Rin1-TS 
 
Strep-tagged full length Rin1 has been expressed in Sf9 insect cells. The construct comprises 
the aa 1-783 of human Rin1. It contains the N-terminal SH2 domain as well as the proline 
rich region required for ABL kinase interaction, the Vps9 domain that bares the GEF activity 
and the C-terminal Ras interaction site. A TEV protease cleavage site followed by a 
streptavidin-binding peptide227 have been attached at the C-terminus. The Bac-to-Bac 
system has been used to generate the virus required for expression of the construct. The 
purification via Streptavidin affinity chromatography followed by buffer exchange and 
sample concentration was analysed at every step on the SDS-PAGE gel depicted in figure 7. 
The protein of interest could be enriched (figure 7, lane 8). A yield of 24.1 µg Rin1-TS in a 
concentration of 2.7 µM could be obtained from 10 mL of Sf9 cell culture. 
 
 
 
Figure 7: Purification of Rin1-TS. 10 % SDS-PAGE gel stained with coomassie brilliant blue. A pre-stained 
molecular weight marker has been loaded in lane 1. The gel shows the analysis of the Streptavidin affinity 
chromatography purification. The Sf9 cell lysate is loaded in lane 2. Lane 3 shows the insoluble cell debris after 
clearance of the lysate. The flow-through, which contains unbound material after incubation with the 
Streptavidin beads, is depicted in lane 4, followed by the washing fraction in lane 5. The eluate has been loaded 
in lane 6. After buffer exchange and concentration, the flow-through from the spin concentrator and the final 
sample have been loaded in lanes 7 and 8, respectively.  
 
3.1.4 Rabex-5GEF 
 
The construct Rabex-5GEF contains only the Vps9 domain that holds the Rab5 GEF function as 
well as a helical bundle required for stabilization. This construct has been purified for in vitro 
assays before and was found to be highly active131. Furthermore it has been found that full-
length Rabex-5 requires the effector Rabaptin-5 for full activity228. The construct comprises 
the aa132-391 of human Rabex-5. It has been expressed in E. coli BL21-CodonPlus®(DE3)-RIL 
cells with an N-terminal 6 x Histidine tag using a pDL2 vectoras described by C. Wosnitza82 
using a modified version of the protocol described by Delprato et al.131. The expression 
before and after IPTG induction was monitored on an SDS-PAGE gel prior to protein 
purification. This gel is depicted in figure 8a. An increase in band intensity for a band approx. 
at the expected mass of 31 kDa could be found, indicating inducible Rabex-5GEF expression. 
The purification via Ni-NTA affinity chromatography and gel filtration has been analysed at 
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every step on the SDS-PAGE gel shown in figure 8b. During the size exclusion 
chromatography the target protein eluted in fractions 22 – 27 (figure 8b, lane 8). A yield of 
27.1 mg Rabex-5GEF in a concentration of 75 µM could be obtained from 2 L of E. coli culture. 
The 31 kDa protein was found to be pure after gel filtration. Due to over-loading of the SDS-
PAGE gel a statement about possible protein loss during the Ni-NTA chromatography could 
not be made.  
 
 
 
Figure 8: Expression and purification of Rabex-5GEF. 15 % SDS-PAGE gels stained with coomassie brilliant blue. 
a: Analysis of the Rabex-5GEF expression in E. coli lysates before (lanes 2 (3 µL lysate) and 3 (7 µL lysate)) and 
after (lanes 4 (3 µL lysate) and 5 (7 µL lysate)) IPTG induction. A pre-stained molecular weight marker has been 
loaded in lane 1. b: Step-by-step analysis of the purification of Rabex-5GEF by Ni-NTA affinity chromatography 
and gel filtration. Lane 1 shows the E. coli lysate, followed by the insoluble cell debris in lane 2. In lane 3 the 
unbound material (flow-through) after Ni-NTA bead-binding has been loaded. The wash fraction is shown in 
lane 4. The lanes 5 and 6 contain the eluate from the Ni-NTA beads before (lane 5) and after (lane 6) 
centrifugation to remove possible precipitate. The lanes 7 – 12 show the different fractions from the size 
exclusion chromatography, pooled by peaks. Lane 7: Fractions 3 – 5, lane 8: Fractions 22 – 27, lane 9: Fractions 
37 – 40, lane 10: Fractions 43 – 47, lane 11: Fractions 49 – 52 and lane 12: Fractions 61 – 62. In lane 13 a pre-
stained molecular weight marker has been loaded. 
 
3.1.5 Rab1 
 
The GTPase Rab1 has been heterologously expressed in E. coli as an MBP fusion protein with 
an N-terminal 6 x Histidine tag using a pMAL vector. The tags could be cleaved by the TEV 
protease due to a cleavage site after the MBP sequence. The construct comprises the aa1 – 
205 of human Rab1. An SDS-PAGE gel to analyse the protein expression before and after 
IPTG induction is depicted in figure 9a. After induction a strong band is visible at about 65 
kDa, corresponding to the expected mass of the MBP-Rab1 fusion protein. This indicates that 
inducible expression occurred. MBP-Rab1 was then purified by Ni-NTA affinity 
chromatography followed by tag cleavage using the TEV protease. After the cleavage, the 6 x 
His tag remained on the N-terminus of MBP so it could be re-bound to Ni-NTA beads to 
separate it from Rab1. A step-by-step analysis of this affinity purification is depicted in figure 
9b. The TEV cleavage could have been optimized by using a larger amount of TEV protease or 
a prolonged cleavage time. Due to incomplete cleavage a huge amount of un-cleaved 
protein was present in the sample applied to the reverse affinity chromatography. The 
incomplete separation during this second Ni-NTA binding step might have been avoidable by 
using a larger amount of resin to circumvent saturation. Finally, a gel filtration was 
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performed to increase the purity of Rab1 and an SDS-PAGE gel of the fractions is shown in 
figure 9c. The 22 kDa target protein eluted in the fractions 48 – 55 (figure 9c, lane 7) during 
the size exclusion chromatography. The protein of interest could be separated from the un-
cleaved fusion protein. However, the final sample still contained traces of His6-MBP. A yield 
of 4.5 mg Rab1 in a concentration of 51 µM could be obtained from 2 L of E. coli culture. 
Since the Rab1 final protein sample turned out to be active (cp. section 3.2) the sample 
quality was sufficient to perform the desired nucleotide exchange assays.  
 
 
 
Figure 9: Expression and purification of Rab1. 12.5 % SDS-PAGE gels stained with coomassie brilliant blue. A 
pre-stained molecular weight marker has been loaded in lane 1 of each gel. a: Analysis of the MBP-Rab1 
expression before (lane 2) and after (lane 3) IPTG induction. b: Step-by-step analysis of the Ni-NTA affinity 
chromatography, tag cleavage and reverse Ni-NTA affinity chromatography. Lane 2 shows the E. coli lysate 
followed by the insoluble cell debris in lane 3. In lane 4 the unbound cellular proteins (flow-through) were 
loaded. The washing fraction is shown in lane 5 and the eluate containing the MBP-Rab1 fusion protein is 
shown in lane 6. The sample after TEV cleavage has been loaded before (lane 7) and after (lane 8) 
centrifugation to remove possible precipitate. The flow-through fraction from the reverse affinity 
chromatography that contained the un-tagged Rab1 protein is loaded in lane 9, followed by the wash fraction 
in lane 10. The eluate retrieved during the reverse Ni-NTA binding is shown in lane 11. c: Size exclusion 
chromatography of the Rab1 sample. In lane 2 the starting material (flow-through from the reverse affinity 
chromatography) is shown. The fractions, pooled by peak, from the size exclusion chromatography have been 
loaded in the lanes 3 – 8. Lane 3: Fractions 4 – 9, lane 4: Fractions 32 – 36, lane 5: Fractions 37 – 43, lane 6: 
Fractions 44 – 47, lane 7: Fractions 48 – 55 and lane 8: Fractions 73 – 77. 
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3.1.6 DrrA 
 
The Rab1-GEF DrrA has been expressed in E. coli using a modified pET19 vector. The 
construct contained a TEV-cleavable N-terminal 6 x Histidine tag and comprises the aa40 – 
533 of human DrrA. The protein expression before and after IPTG induction was monitored 
on the SDS-PAGE gel shown in figure 10a. There was no definite increase in band intensity 
visible at the expected mass of approx. 24 kDa, but the basal expression level could have 
been high, so it was proceeded to purify the protein. First it was bound to Ni-NTA beads, 
followed by TEV cleavage of the Histidine tag and reverse Ni-affinity chromatography. The 
step-by-step analysis of this purification is depicted in figure 10b. The 24 kDa target protein 
could be retrieved from the flow-through fraction during reverse affinity chromatography 
(figure 10b, lane 9). A yield of 1.9 mg DrrA in a concentration of 44 µM could be obtained 
from 2 L of E. coli culture. 
 
 
 
Figure 10: Expression and purification of DrrA. 12.5 % SDS-PAGE gels stained with coomassie brilliant blue. A 
pre-stained molecular weight marker has been loaded in lane 1 on both gels. a: Analysis of the DrrA expression 
before (lane 2) and after (lane 3) IPTG induction. b: Ni-NTA affinity chromatography, TEV cleavage and reverse 
Ni-NTA chromatography. In lane 2 the E. coli lysate has been loaded, followed by the insoluble cell debris in 
lane 3. Lane 4 contains the unbound protein mix after Ni-NTA affinity binding. The washing fraction is shown in 
lane 5. In lane 6 the eluate from the Ni-NTA beads is shown, containing HT-DrrA. The lanes 7 and 8 contain the 
cleaved sample before (lane 7) and after (lane 8) centrifugation to remove possible precipitate. The flow-
through after reverse Ni-NTA chromatography is shown in lane 9 and contains the cut DrrA target protein. In 
lane 10 and 11 the washing fraction and the eluate from the reverse Ni-NTA chromatography have been 
loaded, respectively.  
 
3.1.7 Rac2 
 
The GTPase Rac2 has been expressed in E. coli using a pET SUMO vector. The construct 
comprises the aa1-192 of human Rac2 and contains N-terminal 6 x His- and SUMO tags. The 
IPTG inducible protein expression was monitored on the SDS-PAGE gel depicted in figure 
11a. A strong band for a protein with a mass of approx. 35 kDa can be seen after induction. 
Rac2 was then purified via Ni-NTA affinity binding and size exclusion chromatography. The 
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purification has been analysed at every step on the SDS-PAGE gel shown in figure 11b. Large 
amounts of the protein of interest could be found in the cell debris fraction, indicating 
protein insolubility or incomplete cell lysis. Insoluble protein can result from folding 
problems during the expression and can sometimes be prevented by expression at lower 
temperatures over a longer period of time. Thereby the expression is slower and that results 
in some cases in larger amouts of solube protein. Some amount of His6-SUMO-Rac2 did not 
bind to the Ni-NTA resin during the affinity chromatography or got washed away in the 
following washing step. This might have been avoidable by using a larger amount of Ni-NTA 
resin to circumvent saturation. The 34.8 kDa protein Rac2 could be enriched and eluted in 
the fractions 23 – 29 (figure 11b, lane 11) during the gel filtration. A yield of 58 mg His6-
SUMO-Rac2 in a concentration of 119 µM could be obtained from 2 L of E. coli culture. The 
final sample was mainly pure with only a few traces of impurities left. Aside from that the 
yield was utterly sufficient to perform the desired nucleotide exchange experiments.  
 
 
 
Figure 11: Expression and purification of Rac2. 12.5 % SDS-PAGE gels stained with coomassie brilliant blue. A 
pre-stained molecular weight marker has been loaded in lane 1 on both gels. a: Analysis of the Rac2 expression 
before (lane 2) and after (lane 3) IPTG induction. b: Purification of Rac2 by Ni-NTA affinity binding and size 
exclusion chromatography. The E. coli lysate has been loaded in lane 2 followed by the insoluble cell debris in 
lane 3. Lane 4 shows unbound material after the Ni-NTA affinity binding (flow-through) and lane 5 the wash 
fraction. The eluate is depicted in lanes 6 – 8: Lane 6: directly after elution, lane 7: after over-night storage at 4 
°C and lane 8: after centrifugation to remove possible precipitate. The lanes 9 – 13 show the fractions collected 
during size exclusion chromatography, pooled by peak. Lane 9: Fractions 4 – 7, lane 10: Fractions 18 – 21, lane 
11: Fractions 23 – 29, lane 12: Fractions 30 – 33 and lane 13: Fractions 59 – 63. 
 
3.1.8 Tiam1DHPH 
 
Murine Tiam1 has been expressed in E. coli with an N-terminal Strep-tag and a C-terminal, 
Thrombin-cleavable 6 x Histidine tag using a pET52b(+) vector. The aa1033 – 1406 construct 
comprises the Dbl homology (DH) domain and the pleckstrin homology (PH) domain of 
Tiam1. It has been shown that the DH domain carries the GEF activity but fails to activate 
Rac GTPases in absence of the PH domain229. Analysis of the protein expression was 
performed on the SDS-PAGE gel depicted in figure 12a. A strong increase in band intensity 
after IPTG induction was visible for a band of the expected mass (approx. 48 kDa), indicating 
Results 
 
47 
 
inducible protein expression. The purification was performed via Ni-NTA affinity binding 
followed by thrombin cleavage of the Histidine tag. The target protein was then collected by 
Strep-Tactin affinity chromatography. This purification was analysed step-by-step on the 
SDS-PAGE gel shown in figure 12b. A large amount of Strep-Tiam1DHPH was lost during 
Strep-Tactin affinity chromatography, likely due to incomplete elution. This might have been 
avoided by using a higher concentration of desthiobiotin in the elution buffer or a longer 
incubation of the Strep-Tactin resin with the elution buffer. Since the final sample as shown 
in figure 12b, lane 11 appeared blurry, it was concentrated and afterwards repeatedly 
analysed on an SDS-PAGE gel, which is shown in figure 12c. The target protein could be 
retrieved and used in further applications. A yield of 1.4 mg Tiam1DHPH in a concentration 
of 29 µM could be obtained from 2 L of E. coli culture. The final sample showed four 
additional bands in the SDS-PAGE analysis, indicating traces of impurities but the main band 
corresponded to the 48 kDa protein of interest. The yield was sufficient to perform the 
desired nucleotide exchange experiments.  
 
 
 
Figure 12: Expression and purification of Tiam1DHPH. A pre-stained molecular weight marker has been loaded 
in lane 1 on each gel. a: 12.5 % SDS-PAGE gel stained with coomassie brilliant blue. Analysis of the Tiam1DHPH 
expression before (lane 2) and after (lane 3) IPTG induction. b: 12.5 % SDS-PAGE gel stained with coomassie 
brilliant blue. Ni-NTA affinity chromatography followed by His-tag cleavage using thrombin and subsequent 
strep-Tactin affinity binding. The E. coli lysate has been loaded in lane 2, followed by the insoluble cell debris in 
lane 3. Unbound material after Ni-NTA affinity binding is shown in lane 4. Lane 5 shows the washing fraction 
from the Ni-NTA chromatography. The eluate is shown in lane 6 before over-night thrombin digestion and in 
lane 7 afterwards. Lane 8 shows the digested eluate after centrifugation to remove possible precipitate. The 
strep-Tactin affinity chromatography is shown in the lanes 9 – 11. Lane 9: Flow-through containing unbound 
material, lane 10: washing fraction and lane 11: eluate containing strep-Tiam1DHPH. c: 15% SDS-PAGE gel 
stained with coomassie brilliant blue. Comparison of the concentrated final sample (lane 2) and the sample 
collected during strep-Tactin affinity chromatography (lane 3). 
 
3.1.9 Rac1 
 
Human Rac1 (aa 1 – 184) has been expressed with a Thrombin-cleavable N-terminal GST tag. 
A pGEX2T vector was used for heterologous expression in E. coli BL21-CodonPlus®(DE3)-RIL 
cells. The protein expression before and after IPTG induction has been monitored on the 
SDS-PAGE gel shown in figure 13a. Inducible expression could be seen by an increase in band 
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intensity after induction for a band with the expected mass of approx. 48 kDa for GST-Rac1. 
GST-Rac1 was purified by Glutathione (GSH) affinity chromatography, Thrombin digestion 
and reverse GSH affinity chromatography. This purification was analysed at every step on the 
SDS-PAGE gel depicted in figure 13b. Un-tagged Rac1 (∼ 22 kDa) could be retrieved from the 
flow-through during reverse affinity binding (figure 13b, lane 9). A yield of 3.7 mg Rac1 in a 
concentration of 34 µM could be obtained from 2 L of E. coli culture. The sample was mainly 
pure with only one impurity band showing at the height of the 70 kDa marker band. The 
yield was also sufficient for the desired experiments.  
 
 
 
Figure 13: Expression and purification of Rac1. 12.5 % SDS-PAGE gels stained with coomassie brilliant blue. A 
pre-stained molecular weight marker has been loaded in lane 1 of each gel. a: Analysis of the GST-Rac1 
expression before (lane 2) and after (lane 3) induction with IPTG. b: Analysis of the GSH affinity binding, 
Thrombin cleavage and reverse GSH affinity chromatography. The E. coli lysate has been loaded in lane 2, 
followed by the insoluble cell debris in lane 3. In lane 4 the unbound material (flow-through) after GSH affinity 
binding is shown. Lane 5 shows the washing fraction. The eluate containing GST-Rac1 is shown in lane 6. In 
lanes 7 and 8 the digested sample has been loaded before (lane 7) and after (lane 8) centrifugation to remove 
possible precipitate. The lower band of the duplet represents Rac1 while the upper one corresponds to GST. 
Lane 9 shows the flow-through of the reverse GSH affinity binding and contains the un-tagged Rac1. The lanes 
10 and 11 show the washing fraction and the eluate from the reverse GSH chromatography, respectively. 
 
3.1.10 Vav1 
 
The aa189 – 575 construct of human Vav1 has been expressed in E. coli as a GST fusion 
protein with a TEV cleavage site to remove the GST tag. It contained the mutation M351T 
that has previously been described to increase the amount of soluble Vav1230. A pGEX2T 
vector has been used and the GST-Vav1 expression has been monitored on an SDS-PAGE gel 
before and after IPTG induction (figure 14a). A strong increase in band intensity for a band 
corresponding to a protein with a mass of about 72 kDa could be seen after induction. This 
indicated the inducible expression of GST-Vav1. The protein was then purified by GSH 
affinity chromatography, followed by TEV cleavage and reverse GSH affinity binding. Every 
step was analysed on the SDS-PAGE gel shown in figure 14b. During the E. coli cell lysis a 
large amount of GST-Vav1 could be found in the insoluble cell debris fraction (figure 14b, 
lane 3). This could either have been caused by folding problems during the protein 
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expression or by incomplete cell lysis (cp. section 3.1.7). There was no shift visible when 
comparing the undigested eluate (lane 6) with the digested sample (lane 7). Therefore the 
TEV protease-mediated tag cleavage appeared to be unsuccessful. Possible explainations 
could have been an inactive TEV protease sample or an inaccessible cleavage site caused by 
the folding properties of this fusion protein. Thus GST-Vav1 bound again to the GSH resin 
during the reverse affinity chromatography and was again found in the eluate (figure 14b, 
lane 11). Although the GST-tag could not be cleaved off, the fusion protein was active in the 
nucleotide exchange assay (cp. section 3.2) and it was used for the compound specificity 
testing experiments without further optimization of the purification protocol. A yield of 1 mg 
GST-Vav1 in a concentration of 29 µM could be obtained from 2 L of E. coli culture. 
 
 
 
Figure 14: Expression and purification of Vav1. A pre-stained molecular weight marker has been loaded in lane 
1 on both gels. a: 12.5 % SDS-PAGE gel stained with coomassie brilliant blue showing E. coli lysates before (lane 
2) and after (lane 3) IPTG induction. b: 8 % SDS-PAGE gel stained with coomassie brilliant blue showing a step-
by-step analysis of the purification by GSH affinity binding, GST-tag cleavage using the TEV protease and 
reverse GSH affinity chromatography. In lane 2 the E. coli lysate is shown, followed by the insoluble cell debris 
in lane 3. The unbound material after GSH affinity binding is depicted in lane 4. In lane 5 the washing fraction 
has been loaded. Lines 6, 7 and 8 contain the eluate, the eluate after over-night TEV digestion and the digested 
sample after centrifugation, respectively. In lane 9 the unbound material after reverse GSH affinity binding has 
been loaded, followed by the washing fraction in lane 10. Lane 11 shows the eluate from the reverse GSH 
affinity chromatography that contains undigested GST-Vav1.  
 
3.1.11 NΔ17 Arf1, ARNO-Sec7 and IR-ICD 
 
The proteins NΔ17 Arf1 and ARNO-Sec7 were kind gifts of Benjamin Weiche from the 
Famulok group. The insulin receptor intracellular domain (IR-ICD) was a kind gift of Christian 
Sieg, also from the Famulok group. Detailed information on the constructs can be found in 
section 7.1.5 
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3.2 Nucleotide exchange activity of the recombinant proteins 
 
The fluorescently labelled GTP-analogue Bodipy-TR-GTP has been used to monitor the GEF-
mediated nucleotide exchange on GTPases. The fluorescence intensity of Bodipy-TR-GTP was 
shown to increase upon binding to at least some GTP binding proteins231. The fluorescence 
intensity was measured at 595 nm (excitation) and 620 nm (emission) and was expected to 
increase over time upon binding to the GTPase in presence of the corresponding GEF. Figure 
15 shows the structure of Bodipy-TR-GTP. The fluorophore is attached to the ribose ring via 
an aminoethylcarbamoyl linker. 
 
 
Figure 15: The structure of Bodipy-TR-GTP. In the mixed-isomer analogue the fluorophore is attached to the 2’ 
or 3’ position on the ribose ring via an aminoethylcarbamoyl linker. 
 
The GEFs were expected to concentration-dependently catalyse the nucleotide exchange 
reaction on their corresponding GTPases33,131. Different concentrations of the GEFs were 
assayed on a fixed GTPase concentration of 1 µM with 2 µM Bodipy-TR-GTP. The 
fluorescence intensity was plotted against the time and the resulting curves are shown in 
figure 16. All GEF constructs were capable to catalyse the nucleotide exchange on their 
corresponding GTPases. Rin1C, Rin1-TS and Rabex-5GEF activated Rab5a with Rabex-5GEF 
showing noticeably higher exchange activity than both Rin1-constructs (figure 16a – c). DrrA 
catalysed the nucleotide exchange on Rab1 (figure 16d). Both Rabs did not show a 
remarkable intrinsic nucleotide exchange activity as can be seen by essentially constant 
fluorescence intensity over time in the negative controls in absence of a GEF (black curves). 
Tiam1DHPH catalysed the nucleotide exchange on Rac2 only when used in considerably 
higher concentrations compared to all other GEFs (figure 16e). The intrinsic nucleotide 
exchange activity of Rac2 was high as reflected by a strong increase in fluorescence intensity 
over time in the negative control without Tiam1DHPH. Rac1 also showed a fairly strong 
intrinsic nucleotide exchange activity albeit not as strong as Rac2. Vav1 activated Rac1 even 
when used in concentrations below 25 nM (figure 16f). The ARNO-Sec7-mediated nucleotide 
exchange on Arf1 could be shown when ARNO-Sec7 was used in concentrations higher than 
20 nM (figure 16f). The intrinsic nucleotide exchange activity was considerably high for Arf1. 
From those activity tests, the GEF concentrations that have later been used to assay 
compound specificity have been derived. The chosen concentrations can be found in section 
7.2.3.1, table 24.  
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Figure 16: GEF-concentration-dependent activation of GTPases. The different GTPases were used at 1 µM with 
2 µM of Bodipy-TR GTP. The GEFs were used at increasing concentrations to determine adequate conditions for 
the respective nucleotide exchange assays. a: Rin1C-mediated nucleotide exchange on Rab5a. b: Rin1-TS-
mediated Rab5a activation. c: Rabex-5GEF-mediated activation of Rab5a. d: Activation of Rab1 by DrrA. e: 
Tiam1DHPH dependent Rac2 activation. f: Vav1-mediated nucleotide exchange on Rac1. g: ARNO-Sec7-
mediated Arf1 activation.  
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3.3 Screening for small molecule inhibitors 
 
A functional nucleotide exchange assay was to be established with regard to screening for 
small molecule inhibitors of the Rin1-mediated Rab5 activation. The compounds were, as in 
most HTS approaches, only tested in single values. Therefore the assay had to be exact and 
sensitive in the identification of hits and also robust enough to avoid false positives232. This 
required a wide span between the signals of the positive control (GEF-mediated nucleotide 
exchange) and the negative control (no GEF-mediated nucleotide exchange)233. The assay 
properties could be quantified by use of the Z’ factor. It describes the assay quality and 
enables to judge, whether an assay is in general suitable for HTS approaches234. 
 
3.3.1 Establishing the Bodipy-TR-GTP nucleotide exchange screening assay 
 
The fluorescently labelled GTP analogue Bodipy-TR-GTP has previously been used in similar 
screening approaches and led to promising results214,235. The Rin1C/Rab5a Bodipy-TR-GTP 
exchange assay was chosen to be optimized for HTS. Rin1C catalysed the nucleotide 
exchange on Rab5a in a concentration-dependent manner (cp. figure 16a), similar as 
previously described for Rabex-5131. First, different concentrations of Rin1C were tested 
again over a longer period to find conditions with a linear phase long enough to allow 
appropriate calculation of the slope. Figure 17 shows the Rin1C-mediated nucleotide 
exchange on Rab5a. As expected, higher concentrations of Rin1C again led to a faster 
nucleotide exchange. The reaction reached saturation at approx. 2100 fluorescence units. 
The use of 200 nM Rin1C resulted in a linear increase of the fluorescence intensity over the 
first 20 minutes and was therefore chosen as appropriate to be used during the screening.  
 
 
 
Figure 17: The Rin1C-mediated Bodipy-TR-GTP nucleotide exchange on Rab5a. Rin1C dose-dependently 
catalysed the nucleotide exchange on Rab5a. The nucleotide exchange was measured by monitoring the 
Bodipy-TR-GTP fluorescence at 595 / 620 nm (Ex. / Em.). Without Rin1C almost no nucleotide binding occurred 
(black curve). 1 µM Rab5a and 2 µM Bodipy-TR-GTP have been used. 200 nM Rin1C resulted in a linear increase 
of the fluorescence intensity over the first 1200 seconds.  
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3.3.2 Assay optimization for HTS 
 
To increase the sample throughput, the assay had to be converted to an endpoint 
measurement instead of measuring the kinetics. This allowed the measurement of a whole 
384 well plate at once in a time-delayed manner as described in section 7.2.3.1.1. The 
fluorescence intensity was measured once directly after Bodipy-TR-GTP addition (t = 0 min.) 
and then again after 20 minutes. From those values, the difference in fluorescence intensity 
(ΔFI) was calculated for each well. A small ΔFI could be measured for the negative control 
without Rin1C while the ΔFI in presence of 200 nM Rin1C was much higher. Figure 18a and b 
illustrate the conversion from the kinetic to the endpoint measurement. Since the library 
compounds were dissolved in dimethyl sulfoxide (DMSO), the DMSO tolerance had to be 
tested. The results are shown in Figure 18c. There was no significant difference between 0 – 
6 % DMSO detectable. 4 % DMSO was necessary to use 40 µM as the final compound 
concentration and was found to be tolerated in the Bodipy-TR-GTP exchange assay.  
 
 
 
Figure 18: Adjustment of the Bodipy-TR-GTP assay for a HTS approach. a → b: Conversion of the kinetic 
measurement to an endpoint measurement. ΔFI could be calculated from the fluorescence intensities at t = 0 
min. and t = 20 min. c: DMSO tolerance of the Bodipy-TR-GTP exchange assay. There was no significant 
difference in the ΔFI between 0 – 6 % DMSO. The significance was calculated by one-way ANOVA, p < 0.05 
using GraphPad Prism software. 
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With this conversion, the assay was expected to be suitable for HTS. During the screening 
the hits should exhibit lower ΔFI values compared to the DMSO controls (32 per plate). 
Other important considerations were the type of plate to be used, the buffer conditions and 
the order of sample preparation. Bodipy-TR-GTP turned out to be sticky on most plastic 
surfaces, therefore only plates with non-binding surface (NBS) yielded reasonable results. 
Moreover the use of detergents (tested: Tween-20, Triton X-100, Nonidet P-40, sodium 
cholate, CHAPS and IGEPAL CA-630, data not shown) dramatically increased the fluorescence 
signal of Bodipy-TR-GTP and simultaneously the error between replicates, leading to bad 
assay quality. In terms of assay preparation order, robot-assisted addition of 
compounds/DMSO into the plates followed by mixing Rab5a and Rin1C in exchange buffer 
and manual addition of the proteins gave the best results (lowest variance between 
replicates). Bodipy-TR-GTP was finally injected at the Tecan infinite M1000 pro plate reader 
directly before starting the time-delayed measurement.  
 
3.3.3 Calculation of the Z’ factor 
 
To minimize the probability of false positives and false negatives during a HTS, the screening 
assay has to meet certain quality criteria. False positives would be time- and material 
consuming to be re-tested after the screening while false negatives would mean missing out 
on promising compounds. The Z’ factor, a statistical parameter to judge assay quality, has 
been calculated as follows: 
 
𝑍′𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −
3(𝜎𝑝 + 𝜎𝑛)
|𝜇𝑝 − 𝜇𝑛|
 
 
It is defined in terms of the means (µ) and the standard deviations (σ) of the positive (p) and 
the negative (n) controls. The closer the Z’ factor to its maximum 1, the higher the assay 
quality. A Z’ factor between 0.5 and 1 defines an excellent assay that is suitable for HTS 
approaches234.  
A 384 well plate with 192 positive controls and 192 negative controls (without Rin1C) has 
been measured in the time-delayed setup described in section 7.2.3.1.1. The corresponding 
results are shown in figure 19. The Z’ factor was calculated to be 0.57 for the Bodipy-TR-GTP 
screening assay, indicating suitability for HTS.  
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Figure 19: Determination of the Z’ factor for the Bodipy-TR-GTP screening assay. 192 positive controls (green 
dots, 4% DMSO, 1 µM Rab5a, 200 nM, Rin1C and 2 µM Bodipy-TR-GTP) and 192 negative controls (red squares, 
without Rin1C) were measured in the time-delayed screening setup followed by calculation of the means ± 
standard deviations. The Z’ factor was calculated to be 0.57.  
 
3.3.4 The compound library 
 
An in-house compound library has been used for the screening. It contained 20 328 
compounds in total of which the majority has been purchased at ComGenex. The library also 
contained many additional molecules that have been synthesized by members of the groups 
of Prof. Dr. M. Famulok, Prof. Dr. M. Gütschow and other groups from the University of 
Bonn. 
 
3.3.5 High-throughput screening results 
 
The screening of 20 328 compounds was performed under the conditions described in 
section 3.3.2 with 32 DMSO controls per plate (in columns 1 and 24). During the evaluation 
the ΔFI values for each compound sample and each control sample were calculated. 
Compounds that resulted in ≥ 80 % inhibition (equalling ≤ 20 % residual nucleotide exchange 
activity) compared to the DMSO controls from the same plate were defined as hits. This 
procedure identified 239 primary hits, which correlates to 1.2 % of the total compounds.  
 
3.3.6 Identification of secondary hits 
 
The primary hits were re-screened manually as duplicates in two different concentrations: 
40 µM and 10 µM. By this, 26 secondary hits showing ≥ 50 % inhibition (at 40 µM) could be 
identified. This equals 10.9 % of the primary hits. Correspondingly 213 (89.1 %) of the 
primary hits were found to be false positives of which some compounds had to be excluded 
due to strong quenching of the Bodipy-TR-GTP fluorescence signal. Quenchers usually 
interfere with the read-out rather than with the nucleotide exchange reaction. The results of 
the re-screen are depicted in figure 20. The 26 secondary hits were then tested from frozen 
10 mM compound stock solutions to assure the inhibition does not result from degradation 
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products in the library plates. Degradation could have occurred during several thaw-freezing 
cycles in earlier screening approaches. Only 10 of the 26 secondary hits were found to inhibit 
the nucleotide exchange when the stock solution was tested. Due to insufficient information 
on possible degradation byproducts, the 16 compounds that did not show an inhibitory 
effect were omitted from further investigation. The 10 remaining compounds were chosen 
to be characterized. A complete list of the secondary hits is provided in the appendix 
(section 8.3). 
 
 
 
Figure 20: Manual re-screening of the 239 primary hit compounds. The positive controls (4 % DMSO, 1 µM 
Rab5a200 nM, Rin1C and 2 µM Bodipy-TR-GTP) are shown as green dots and the negative controls (without 
Rin1C) as red squares. The re-screened compounds (40 µM, mean of duplicates) are depicted as blue triangles. 
Compounds that exhibited ≥ 50 % inhibition at 40 µM were defined as secondary hits. Those are represented 
by the 26 blue triangles beneath the dotted line. The grey diamonds represent the compounds tested at a 
concentration of 10 µM (mean of duplicates). Only four molecules showed ≥ 50 % inhibition at 10 µM. 
 
3.4 Characterization of secondary hit compounds 
 
The 10 compounds chosen for characterization should be analysed in terms of their activity 
profile (IC50 and Hill coefficient), specificity for the Rin1C-mediated nucleotide exchange on 
Rab5a and their potential to induce protein aggregation. The IC50 and the Hill coefficient 
describe the potency and possible cooperative binding of small molecule inhibitors, 
respectively236,237. Activity and specificity are crucial in the definition of a lead compound 
specified by J. G. Lombardino and J. A. Lowe as “a chemical structure or series of structures 
that show activity and selectivity in a pharmacological or biochemically relevant screen”238. 
Protein aggregation is a known source of promiscuous inhibition caused by small molecules. 
So-called aggregators are unlikely to act specifically and are prone to exhibit off-target 
effects239. By the characterization of these 10 compounds their suitability as lead structures 
should be surveyed.  
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3.4.1 Compound activity profiles and structures 
 
The kinetic format of the Bodipy-TR-GTP exchange assay of the Rin1C-mediated Rab5a 
activation has been used to determine the IC50 values for the 10 secondary hits. They were 
tested as triplicates in concentrations between 0 and 50 µM with a final DMSO 
concentration of 2 %. The structures were named after their position and well in the library 
e.g. CG1 05 F09. The activity profiles and the structures of those compounds are depicted in 
the figures 21 and 22, respectively. The IC50 and the Hill coefficient were determined using 
GraphPad Prism software by fitting the linear phases (the first 5 min.) of the kinetic reactions 
and calculation of the slopes. The slopes have then been plotted against the logarithmic 
compound concentrations and a sigmoidal fit (log(inhibitor) vs. response – variable slope) 
has been applied. The slopes of the negative and positive controls have been set as lower 
and upper limits for the fitting. The IC50 was given by the turning point of this curve while its 
slope at this point described the Hill coefficient. The Hill coefficient gives information on 
possible cooperative binding. A Hill coefficient of |1| indicates non-
cooperative/independent binding. Positively cooperative binding is assumed for a Hill 
coefficient > |1|, meaning once a ligand molecule is bound to a protein, its affinity for 
further ligand molecules increases. The other way around, a Hill coefficient between 0 and 
|1| indicates negatively cooperative binding. In this case the binding of a ligand molecule 
decreases the proteins affinity for further ligand molecules237. The negative Hill coefficients 
found during the measurements result from the decreasing slopes with increasing 
compound concentration, leading to a decreasing sigmoidal curve. The raw data used for 
fitting can be found in section 8.4.1 in the appendix. The determined IC50 values all were in 
the low micromolar range qualifying the compounds as promising inhibitors at this point. 
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Figure 21: Activity profiles of the secondary hits. The compounds were tested as triplicates in concentrations 
between 1 and 50 µM in the kinetic Bodipy-TR-GTP nucleotide exchange assay. The Rin1C-mediated Rab5a 
activation was monitored as an increase in fluorescence intensity signal over time. 1 µM Rab5a, 150 nM Rin1C, 
2 µM Bodipy-TR-GTP and a final DMSO concentration of 2 % have been used. A linear fit has been applied on 
the curves representing the nucleotide exchange over the first 5 minutes. The slopes of those curves have then 
been plotted against the logarithmic compound concentration and a sigmoidal fit has been applied, using the 
slopes of the positive control (1 µM Rab5a, 150 nM Rin1C, 2 µM Bodipy-TR-GTP and 2 % DMSO) and the 
negative control (without Rin1C) as boundaries. The IC50 values could be deduced from the turning points of 
these sigmoidal curves while their slopes represented the Hill coefficients. The values are given with the 95 % 
confidence intervals.  
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Figure 22: Structures of the 10 secondary hits. The 10 secondary hits that have been found to be active when 
the library stock solutions were tested are depicted here. There are no obvious structural similarities. 
Results 
 
60 
 
3.4.2 Specificity in other GEF/GTPase assays 
 
Specificity has been tested by applying the compounds in nucleotide exchange assays using 
other GEF/GTPase pairs. The compounds were tested on the Sec7 domain-containing GEF 
ARNO and the GTPase Arf1, the Dbl homology domain-containing GEFs Vav1 and Tiam1 on 
the GTPases Rac1 and Rac2, and the Legionella pneumophila GEF DrrA and Rab1. Moreover 
the closely Rin1-related GEF Rabex-5 has been used to test the compounds for specificity. 
The GEFs ARNO and DrrA act through a mechanism similar to that of Rin1 but do not contain 
a catalytic Vps9 domain32. They are suitable controls to analyse specificity towards Vps9 
domain-containing GEFs. Rabex-5 contains a Vps9 domain and, like Rin1, activates Rab5128. A 
compound able to inhibit the Rin1-mediated Rab5 activation without interfering with the 
Rabex-5 GEF function would be considered highly specific. The GEFs Vav1 and Tiam1 are less 
related to Rin1 and built controls to analyse, whether a compound generally targets 
nucleotide exchange reactions on small GTPases216,240. All nucleotide exchange assays were 
performed with Bodipy-TR-GTP in a similar way as the Rin1C/Rab5a nucleotide exchange 
assay. This additionally assured that compounds acting unspecific due to disturbance of the 
read out got sorted out during the characterization. 
 
3.4.2.1 ARNO-Sec7 and Arf1 
 
The 10 compounds have first been tested as triplicates at a concentration of 50 µM with 2 % 
DMSO in the ARNO-Sec7-mediated nucleotide exchange assay on Arf1. The data points 
generated during the first 5 minutes of the kinetic measurements have been fitted linearly to 
calculate the slopes. These slopes have been compared to a positive control and a negative 
control (without ARNO-Sec7). The results are depicted in figure 23. The compounds CG1 05 
F09, CG1 06 A03, CG3 05 B06, CG5 05 F05, CG6 26 F10 and KR1 04 F03 were found to inhibit 
the ARNO-Sec7-mediated nucleotide exchange on Arf1 and were therefore classified as 
unspecific. Little to no inhibitory effect could be seen for the compounds CG3 05 A02, CG5 
08 H06, CG6 24 G06 and CG6 25 G08.  
 
 
 
Figure 23: Specificity of the 10 secondary hits in the ARNO-Sec7/Arf1 nucleotide exchange assay. 50 µM of 
each compound were tested on 100 nM ARNO-Sec7, 1 µM NΔ17 Arf1 and 2 µM Bodipy-TR-GTP with a final 
concentration of 2 % DMSO. CG1 05 F09, CG1 06 A03, CG3 05 B06, CG5 05 F05, CG6 26 F10 and KR1 04 F03 
were found to inhibit the ARNO-Sec7-mediated nucleotide exchange on Arf1 while CG3 05 A02, CG5 08 H06, 
CG6 24 G06 and CG6 25 G08 showed little to no inhibitory effect. Pure DMSO was used in the positive control 
sample and the negative control lacked ARNO-Sec7. The significance was calculated by one-way ANOVA, p < 
0.05 using GraphPad Prism software.  
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3.4.2.2 Vav1 and Rac1 
 
The compound CG3 05 A02 was re-synthesized by Dr. Jeffrey Hannam from the Famulok 
group and CG6 25 G08 was commercially available (ChemDiv, V005-7464). The other two 
compounds, CG5 08 H06 and CG6 24 G06, that were found to be specific over ARNO-
Sec7/Arf1, were used from the library stock solutions. The compounds were tested as 
triplicates at a concentration of 50 µM with a final DMSO concentration of 2 % in the Vav1-
mediated nucleotide exchange assay on Rac1. The Bodipy-TR-GTP fluorescence intensity was 
measured every 15 seconds and the data generated during the first 5 minutes was fitted 
linearly. From those fits the slopes were calculated and compared with a DMSO control and 
a negative control lacking Vav1. The results are depicted in figure 24. CG3 05 A02 did not 
inhibit the Vav1-mediated nucleotide exchange on Rac1. Slight inhibition could be found by 
the compounds CG6 24 G06 and CG6 25 G08. CH5 08 H06 led to a decrease in the nucleotide 
exchange of about 50 % and was classified as unspecific at this point.  
 
 
 
Figure 24: CG3 05 A02, CG5 08 H06, CG6 24 G06 and CG6 25 G08 in the Vav1/Rac1 nucleotide exchange assay. 
50 µM of each compound were tested on 25 nM Vav1, 1 µM Rac1 and 2 µM Bodipy-TR-GTP with a final 
concentration of 2 % DMSO. CG3 05 A02 did not show an inhibitory effect on the Vav1-mediated nucleotide 
exchange on Rac1. A slight inhibitory effect could be seen for the compounds CG6 24 G06 and CG6 25 G08. The 
compound CG5 08 H06 reduced the nucleotide exchange to about 50 % and was classified as unspecific at this 
point. DMSO was used in the positive control sample and the negative control lacked Vav1. The significance 
was calculated by one-way ANOVA, p < 0.05 using GraphPad Prism software. 
 
3.4.2.3 DrrA and Rab1 
 
Since CG5 08 H06 and CG6 24 G06 were only available in limited amounts from the library 
stocks, their aggregation properties were checked next as described in section 7.2.4. CG3 05 
A02 and CG6 25 G08 were tested in further nucleotide exchange assays, starting with the 
DrrA-mediated nucleotide exchange on Rab1. 50 µM of each compound were used as 
triplicates with a final assay DMSO concentration of 2 %. 25 nM DrrA and 1 µM Rab1 have 
been used with 2 µM of Bodipy-TR-GTP. The nucleotide exchange reaction was monitored by 
measuring the fluorescence of Bodipy-TR-GTP every 15 seconds. Data generated during the 
first 5 minutes was fitted linearly to calculate the slopes depicted in figure 25. No inhibitory 
effect on the DrrA-mediated nucleotide exchange on Rab1 could be detected for any of the 
compounds. 
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Figure 25: CG3 05 A02 and CG6 25 G08 in the DrrA/Rab1 nucleotide exchange assay. 50 µM of each 
compound were tested on 25 nM DrrA, 1 µM Rab1 and 2 µM Bodipy-TR-GTP with a final concentration of 2 % 
DMSO. No inhibitory effect could be observed for any of the compounds. DMSO was used as positive control 
and the negative control lacked DrrA. The significance was calculated by one-way ANOVA, p < 0.05 using 
GraphPad Prism software. 
 
3.4.2.4 Tiam1 and Rac2 
 
CG3 05 A02 and CG6 25 G08 were tested in the Tiam1-mediated nucleotide exchange on 
Rac2 next. 50 µM of each compound were used as triplicates with a final assay DMSO 
concentration of 2 %. 2 µM Tiam1 and 1 µM Rab1 have been used with 2 µM of Bodipy-TR-
GTP. The fluorescence of Bodipy-TR-GTP was measured every 15 seconds and the data 
generated during the first 5 minutes was fitted linearly. The slopes of those linear fits are 
depicted in figure 26 and they were compared with those of a DMSO control and a negative 
control lacking Tiam1. No inhibition caused by any of the compounds could be observed.  
 
 
 
Figure 26: CG3 05 A02 and CG6 25 G08 in the Tiam1/Rac2 nucleotide exchange assay. 50 µM of each 
compound were tested on 2 µM Tiam1, 1 µM Rac2 and 2 µM Bodipy-TR-GTP with a final concentration of 2 % 
DMSO. No inhibitory effect could be seen for any of the compounds. DMSO was used as positive control and 
the negative control lacked Tiam1. The significance was calculated by one-way ANOVA, p < 0.05 using 
GraphPad Prism software. 
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3.4.2.5 Rabex-5GEF and Rab5a 
 
Lastly the compounds CG3 05 A02 and CG6 25 G08 were applied in the Rabex-5GEF-mediated 
nucleotide exchange assay on Rab5a. 50 µM of the compounds were tested as triplicates on 
10 nM Rabex-5GEF and 1 µM Rab5a using 2 µM Bodipy-TR-GTP and a final concentration of 2 
% DMSO. DMSO has been used in the positive control sample and the negative control 
lacked Rabex-5GEF. The Bodipy-TR-GTP fluorescence was measured every 15 seconds. The 
data generated during the first 5 minutes was fitted linearly to calculate the slopes depicted 
in figure 27. Both compounds significantly inhibited the nucleotide exchange.  
 
 
 
Figure 27: CG3 05 A02 and CG6 25 G08 in the Rabex-5GEF/Rab5a nucleotide exchange assay. 50 µM of each 
compound were tested on 10 nM Rabex-5GEF, 1 µM Rab5a and 2 µM Bodipy-TR-GTP with a final concentration 
of 2 % DMSO. Both compounds significantly reduced the nucleotide exchange. DMSO was used in the positive 
control sample and the negative control lacked Rabex-5GEF. The significance was calculated by one-way ANOVA, 
p < 0.05 using GraphPad Prism software. 
 
3.4.3 Aggregation properties of the secondary hit compounds 
 
Some small molecules are prone to form aggregates that may inhibit many proteins 
unspecifically. They form large aggregation colloids to which the proteins adsorb, making 
them unable to execute their functions241. To test for aggregation, the compounds were 
incubated with Rin1C and Rab5a at room temperature for 20 minutes followed by 
centrifugation at maximum speed for 10 minutes. Afterwards the protein content of the 
supernatant was compared to a sample without compound addition (DMSO control). 
Another usual approach to test for aggregation is to apply compounds in a completely 
unrelated assay. In case of aggregation as the mechanism of inhibition, the compounds 
might also have an inhibitory effect in unrelated assays241. Here the insulin receptor auto-
phosphorylation assay has been performed to check for inhibition in an unrelated assay.  
 
3.4.3.1 The centrifugation-based aggregation assay 
 
In a simple centrifugation-based approach, Rin1C and Rab5a were mixed with 50 µM of each 
compound and the amount of soluble protein was determined after 20 minutes of 
incubation. 2 % DMSO were used as a control. The compounds CG3 05 A02, CG5 08 H06, CG6 
24 G06 and CG6 25 G08 were checked for their potential to aggregate with Rin1C and Rab5a 
and the results are depicted in the western blots shown in figure 28. An anti-His5 primary 
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antibody has been used followed by incubation with a fluorescently labelled secondary 
antibody. The upper bands represent HT-Rin1C (∼ 55 kDa) while the lower bands show HT-
Rab5a (∼ 21 kDa). The compound CG3 05 A02 was found not to induce aggregation of Rin1C 
or Rab5a (figure 28a, lane 3). About 50 % aggregation of Rin1C could be seen for CG5 08 H06 
(figure 28b, lanes 3 and 4). The compounds CG6 24 G06 and CG6 25 G08 completely 
aggregated Rin1C (figure 28b, CG6 24 G06: lanes 5 and 7; CG6 25 G08: lanes 9 and 10). Since 
aggregation is likely to be unspecific and to cause promiscuous off-target inhibition, the 
compound CG3 05 A02 was considered the most promising candidate at this point. 
 
 
 
Figure 28: Aggregation properties of the compounds CG3 05 A02, CG5 08 H06, CG6 24 G06 and CG6 25 G08. 
Western blots from 12.5 % SDS-PAGE gels. The proteins were histidine-tagged and visualized with an anti-His5 
primary antibody and a fluorescently labelled secondary antibody. A pre-stained molecular weight marker has 
been loaded in lane 1 on both blots. a: Aggregation assay with the compound CG3 05 A02. The initial sample 
before addition of compound/DMSO is shown in lane 2. Lane 3 shows the supernatant after 20 minutes of 
incubation with 2% DMSO and centrifugation. The sample in lane 4 represents the supernatant after 20 
minutes of incubation with 50 µM CG3 05 A02 after centrifugation. Little to no difference in the amount of 
Rin1C (upper bands) and Rab5a (lower bands) could be seen when comparing the lanes 3 and 4. b: Aggregation 
assay with the compounds CG5 08 H06, CG6 24 G06 and CG6 25 G08. The initial samples before addition of 
compound/DMSO are shown in lanes 2, 5, 8 and 11. Lane 3 shows the supernatant after 20 minutes of 
incubation with 50 µM CG5 08 H06 and centrifugation. The corresponding pellet is shown in lane 4. About 50 % 
of the initial Rin1C (compare: lane 2 and lane 4) could be found in the pellet. Lane 6 shows the supernatant 
after 20 minutes of incubation with 50 µM CG6 24 G06 and centrifugation. The corresponding pellet is shown in 
lane 7. All of the initial Rin1C (compare: lane 5 and lane 7) could be found in the pellet. Lane 9 shows the 
supernatant after 20 minutes of incubation with 50 µM CG6 25 G08 and centrifugation. The corresponding 
pellet is shown in lane 10. Again all of the initial Rin1C (compare: lane 8 and lane 10) could be found in the 
pellet. The DMSO control is depicted in lane 12 (supernatant) and lane 13 (pellet). DMSO did not cause any 
aggregation as none of the proteins could be found in the pellet.  
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3.4.3.2 The insulin receptor auto-phosphorylation assay 
 
The insulin receptor auto-phosphorylation assay has been used as an additional control to 
supposedly exclude aggregation as possible mechanism of inhibition. The ATP-dependent 
auto-phosphorylation of the insulin receptor intracellular domain (IR-ICD) has been 
monitored after 0, 20 and 60 seconds in presence and absence of 50 µM of the compound 
CG3 05 A02. The phosphorylation has afterwards been visualized on a western blot using an 
anti-phospho-tyrosine antibody followed by a fluorescently labelled secondary antibody. 
Figure 29 shows the total amount of IR-ICD on a coomassie stained SDS-PAGE gel (a) and the 
degree of phosphorylation on a western blot (b) in samples without treatment, treated with 
DMSO and treated with CG3 05 A02. The compound had no effect on the IR-ICD auto-
phosphorylation when compared to both controls. This argues against promiscuous 
unspecific aggregation around proteins as the mechanism of inhibition. 
 
 
 
Figure 29: IR-ICD auto-phosphorylation assay in presence and absence of CG3 05 A02. a: 10 % SDS-PAGE gel 
stained with coomassie brilliant blue. A pre-stained molecular weight marker has been loaded in lane 1. The gel 
shows that equal amounts of IR-ICD (∼ 46 kDa) have been loaded (lanes 2 – 10). b: Western blot from a 10 % 
SDS-PAGE gel. An anti-phospho-tyrosine primary antibody has been used followed by incubation with a 
fluorescently labelled secondary antibody. A pre-stained molecular weight marker has been loaded in lane 1. 
The lanes 2, 3 and 4 show the auto-phosphorylation of untreated IR-ICD after 0, 20 and 60 seconds, 
respectively. In the lanes 5, 6 and 7 the auto-phosphorylation after 0, 20 and 60 seconds of the samples treated 
with DMSO is shown. The auto-phosphorylation after 0, 20 and 60 seconds of the samples treated with CG3 05 
is shown in lanes 8, 9 and 10. No difference in the degree of auto-phosphorylation could be seen for the 
samples treated with CG3 05 A02 in comparison to the controls.  
 
3.4.4 Purity of CG3 05 A02 
 
The purity of the CG3 05 A02 library stock was checked using HPLC-MS before re-synthesis to 
ensure the inhibitory effect stems from the compound expected to be present in the library. 
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0.1 mg/mL of the compound diluted in 10 % acetonitrile was subjected to a C18 reversed 
phase column and the eluate was analysed by MS (figure 30b). The library stock was found 
to be 81.4 % pure (peak 14, figure 30a) with a mass of 373.3 g/mol [CG3 05 A02 + H+]. The 
mass 431 g/mol could not be assigned to a structure and 767.5 g/mol most likely stemmed 
from [2 x CG3 05 A02 + Na+]. The theoretical mass of CG3 05 A02 was calculated to be 
372.42 g/mol. 
 
 
 
Figure 30: HPLC-MS analysis of the compound CG3 05 A02. a: HPLC chromatogram of the library stock. Several 
peaks could be found. The main peak (14) covers 81.4 % of the area under all peaks. b: MS analysis of peak 14. 
The chromatogram covers the masses found between 14.3 and 14.7 minutes during the HPLC run. Three 
masses could be found. 373.3 g/mol likely corresponded to the compound (theor. mass: 372.42 g/mol) [CG3 05 
A02 + H
+
], 431 g/mol could not be assigned to a structure and 767.5 g/mol most likely stemmed from [2 x CG3 
05 A02 + Na
+
]. 
 
3.4.5 Solubility of CG3 05 A02 
 
Solubility of the compound was measured in a photometric approach on the NanoDrop 
2000. The absorption maximum of CG3 05 A02 was determined in a spectral measurement 
using the compound at a concentration of 50 µM in buffer and was found to be at 350 nm. 
The compound was diluted in buffer in concentrations ranging from 1.6 – 200 µM with a 
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final DMSO concentration of 2 %. The absorption of the supernatant before and after 
centrifugation is shown in table 4. The compound was found to be insoluble at 
concentrations > 2.3 µM.  
 
Table 4: Determination of the solubility of CG3 05 A02. 
Concentration [µM] A350 before centrifugation A350 after centrifugation 
200 0.148 0.001 
150 0.156 0.001 
100 0.135 0.000 
75 0.118 0.002 
50 0.070 0.003 
37.5 0.074 0.002 
25 0.056 0.000 
18.75 0.044 - 0.001 
12.5 0.030 0.001 
9.4 0.026 0.003 
6.25 0.020 0.003 
4.7 0.017 0.001 
3.13 0.013 0.002 
2.3 0.010 0.008 
1.6 0.008 0.005 
 
3.4.6 Structure activity relationship of CG3 05 A02 
 
Several derivatives of the compound CG3 05 A02 have been synthesized by Dr. J. Hannam 
from the Famulok group to examine the structure activity relationship. The analytical data 
for CG3 05 A02 and the derivatives can be found in section 7.2.8. Single functional groups 
have been removed, exchanged or repositioned and the inhibitory activity was checked in 
the kinetic Rin1C/Rab5a Bodipy-TR-GTP nucleotide exchange assay. The compounds were 
tested in different concentrations between 0.1 and 200 µM. If the derivatives had an 
inhibitory effect, the IC50 was determined as described in section 3.4.1 and compared to that 
of the original structure. Table 5 summarizes the structures of the derivatives, the IC50 values 
and the 95 % confidence intervals. The raw data used for linear fitting and the slopes plotted 
against the logarithmic compound concentrations can be found in section 8.4.2 in the 
appendix. 
 
Table 5: Structure activity relationship of the compound CG3 05 A02. 
Name Structure IC50 [µM] 95 % CI [µM] 
CG3 05 A02 
 
35.4 24.3 – 46.5 
010A 
 
n. i. n. i.  
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066A 
 
n. i. n. i. 
068A 
 
28.9  21.7 – 38.5 
071A 
 
n. i. n. i. 
099A 
 
n. i. n. i. 
103A 
 
85.8 80.0 – 92.0 
137B 
 
21.3 17.3 – 26.2 
146A 
 
n. i.  n. i. 
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148A 
 
n. i.  n. i.  
160A 
 
n. i.  n. i.  
162A 
 
63.5 56.0 – 72.0 
163A 
 
n. i.  n. i.  
165A 
 
38.8 32.1 – 46.9 
166A 
 
72.9 64.9 – 81.9 
167A 
 
138.8 127.6 – 151.1  
170A 
 
23.7 18.5 – 30.4  
179A 
 
n. i.  n. i.  
 
Results 
 
70 
 
The core structure of CG3 05 A02 that comprises four ring structures, a secondary amine and 
a ketone group has been conserved in all compounds. The compound was modified at the 
positions of the methyl- and methoxy groups attached to the heterocycle and the phenyl 
rings. Deletion of both methyl groups and the methoxy group as in compound 163A led to 
complete loss of the inhibitory effect. Deletion of either one of the methyl groups as in the 
compounds 165A and 170A did not affect the inhibition but deletion of both at the same 
time (compound 162A) led to an IC50 about two fold higher compared to the original 
structure. Removing the methoxy group in combination with either one of the methyl groups 
(compounds 166A and 167A) led to a 2 – 5-fold higher IC50. A complete loss of inhibitory 
potential resulted from elimination of only the methoxy group as in compound 160A. The 
same was the case if the position of this group on the ring has been changed (compounds 
179A and 010A). This led to the assumption, that the methoxy group might be needed to 
perform a ring closure with the secondary amine to unfold the full inhibitory effect. To test 
this hypothesis, compound 066A has been synthesized with a methyl group attached to the 
nitrogen originally employed in the secondary amine. This compound did not inhibit the 
Bodipy-TR-GTP nucleotide exchange. The collected results pointed towards a tolerance for 
changes at the position of the methyl group on the heterocycle. Two compounds with 
different groups at this position have been synthesized: 137B with a hydroxyl group and 
068A with a methoxy group. Both groups did not influence the inhibition but they also did 
not improve the solubility (data in the appendix in section 8.5). This position has then been 
picked to try to attach a fluorescein label for binding studies via different linkers. First the 
compound has been modified with the linkers and tested for inhibition in the Bodipy-TR-GTP 
nucleotide exchange assay. Attachment of a tert-butyloxycarbonyl protecting group with a 
long linker led to loss of the inhibitory effect (compound 071A). The compound 103A with a 
shorter linker and a tert-butyloxycarbonyl protecting group had an IC50 about three times 
higher than CG3 05 A02. However, de-protection and fluorescein labelling resulted in the 
completely inactive compound 148A. The approach to use an ethanolamine group as linker 
to attach the fluorophore as in compound 146A also eliminated the inhibitory effect. In a 
final labelling approach the short linker with the tert-butyloxycarbonyl protecting group has 
been attached at the position of the methoxy group (compound 099A) but this structure also 
proved to be inactive. 
 
3.4.7 Influence of CG3 05 A02 on the ABL1-mediated Rin1 phosphorylation 
 
The screening was performed with Rin1C – a construct lacking the ABL kinase interaction site 
of Rin1. This made an influence of the compound CG3 05 A02 on the ABL1-mediated Rin1 
phosphorylation unlikely. Nevertheless an ABL1/Rin1 phosphorylation assay has been 
performed to ensure the compound does not have a domain-unspecific effect on the ABL1-
Rin1 interaction. Rin1-TS and ABL1-6 x His have been incubated with ATP and the compound 
at a concentration of 50 µM. The phosphorylation state of both proteins has been analysed 
after 0, 1 and 15 minutes on a Western blot using an anti-phospho-tyrosine antibody 
followed by a fluorescently labelled secondary antibody. Figure 31 shows the total and 
equally loaded amounts of ABL1-6 x His (∼ 125 kDa) and Rin1-TS (∼ 89 kDa) on a coomassie 
stained SDS-PAGE gel (a) and the degree of phosphorylation on a western blot (b) in samples 
without treatment, treated with DMSO and treated with CG3 05 A02. Both proteins notably 
behaved untypically in the SDS-PAGE. They ran much higher than expected when compared 
to the molecular weight marker. This can be caused by certain hydrodynamic properties held 
by non-globular proteins. The compound had no effect on the phosphorylation of Rin1-TS. 
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This argues against a domain-unspecific inhibitory effect of the compound CG3 05 A02 on 
the proline rich region of Rin1. An increase in ABL1-6xHis auto-phosphorylation could not be 
detected during this assay.  
 
 
 
Figure 31: The ABL1-mediated Rin1 phosphorylation assay in presence and absence of CG3 05 A02. a: 8 % 
SDS-PAGE gel stained with coomassie brilliant blue. A pre-stained molecular weight marker has been loaded in 
lane 1. The gel shows that equal amounts of HT-ABL1 (∼ 125 kDa) and Rin1-TS (∼ 89 kDa) have been loaded 
(lanes 2 – 10). b: Western blot from an 8 % SDS-PAGE gel. An anti-phospho-tyrosine primary antibody has been 
used followed by incubation with a fluorescently labelled secondary antibody. A pre-stained molecular weight 
marker has been loaded in lane 1. The lanes 2, 3 and 4 show the phosphorylation of untreated HT-ABL1 and 
Rin1-TS after 0, 1 and 15 minutes, respectively. In the lanes 5, 6 and 7 the samples treated with DMSO for 0, 1 
and 15 minutes are shown. The samples treated with CG3 05 A02 for 0, 1 and 15 minutes are shown in lanes 8, 
9 and 10. No difference in the degree of Rin1-TS phosphorylation could be seen for the samples treated with 
CG3 05 A02 in comparison to the controls. HT-ABL1 auto-phosphorylation could not be seen in this assay. 
 
3.4.8 Influence of CG3 05 A02 on Bodipy-TR-GTP binding to Rab5a 
 
The influence of CG3 05 A02 on Bodipy-TR-GTP binding GEF-independently to Rab5a was 
analysed to gain insights on the mechanism of inhibition employed by the compound. Based 
on the setup of the screening assay it could not be estimated, whether it interacts with 
Rin1C and Rabex-5GEF, with the complex between them and Rab5a or GTP-competitively with 
Rab5a alone. To investigate possible GTP-competitive binding, Rab5a was loaded with 
Bodipy-TR-GTP in the absence of a nucleotide exchange factor by treatment with EDTA as 
described in section 7.2.7 in presence of different concentrations of CG3 05 A02. During the 
15 minutes of incubation the Bodipy-TR-GTP fluorescence was measured at 595 nm 
(excitation) and 620 nm (emission) and a linear fit was applied on the data generated in the 
first 100 seconds. The slopes were calculated and compared to that of a DMSO control. In 
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case of reduced Bodipy-TR-GTP binding, a decrease in steepness was to be expected. The 
results are depicted in figure 32. No concentration-dependent effect on the Bodipy-TR-GTP 
binding to Rab5a could be determined in presence of the compound. The raw data used for 
fitting, as well as an extended interpretation, can be found in the appendix in section 8.6.  
 
 
Figure 32: Influence of CG3 05 A02 on Bodipy-TR-GTP binding to Rab5a. Rab5a was loaded with Bodipy-TR-
GTP in presence of CG3 05 A02 concentrations between 0.05 and 200 µM. The Bodipy-TR-GTP fluorescence was 
measured over 15 minutes and a linear fit was applied to the data generated during the first 100 seconds. From 
those fits the depicted slopes were calculated and compared to that of a DMSO control. There was no 
significant difference between any of the samples in comparison to the control. The significance was calculated 
by one-way ANOVA, p < 0.05 using GraphPad Prism software. 
 
3.4.9 CG3 05 A02 in the Rin1C/Rab5a Bodipy-FL-GTP nucleotide exchange assay 
 
To exclude that the inhibitory effect of CG3 05 A02 in the Rin1C/Rab5a Bodipy-TR-GTP 
nucleotide exchange assay is artificially related to the use of Bodipy-TR-GTP, the GTP 
analogue Bodipy-FL-GTP has been used in another nucleotide exchange assay. Bodipy-FL is a 
smaller fluorophore attached via an aminoethylcarbamoyl linker to the 2’ or 3’ position of 
the GTP ribose ring. The fluorescence of Bodipy-FL-GTP may increase upon interaction with 
GTP-binding proteins and could be measured at 490 nm (excitation) and 520 nm 
(emission)231. Bodipy-FL-GTP was used in a 1-fold excess over Rab5a. CG3 05 A02 was tested 
as triplicates in concentrations between 0.025 and 200 µM. Figure 33 shows the structure of 
Bodipy-FL-GTP (a) as well as the concentration-dependent inhibition of the Bodipy-FL-GTP 
nucleotide exchange by CG3 05 A02 (b). The fluorescence intensity of Bodipy-FL-GTP has 
been measured every 15 seconds and the data generated during the first 5 minutes was 
fitted linearly to calculate the slopes depicted in figure 33b. The IC50 and the Hill coefficient 
were determined using GraphPad Prism software. The IC50 measured here was about seven 
times higher compared to that measured in the Bodipy-TR-GTP nucleotide exchange assay 
(cp. section 3.4.1). Thus, additional controls had to be performed to survey and ensure the 
inhibitory effect of the compound CG3 05 A02. The raw data used for linear fitting can be 
found in section 8.4.3 in the appendix. 
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Figure 33: CG3 05 A02 in the Rin1C/Rab5a Bodipy-FL-GTP nucleotide exchange assay. a: Structure of Bodipy-
FL-GTP. In the mixed-isomer analogue the fluorophore is attached to the 2’ or 3’ position on the ribose ring via 
an aminoethylcarbamoyl linker. b: Concentration-dependent inhibition of the Rin1C/Rab5a Bodipy-FL-GTP 
nucleotide exchange assay by the compound CG3 05 A02. The Rin1C-mediated nucleotide exchange on Rab5a 
was monitored as an increase in fluorescence intensity signal over time. A linear fit has been applied on the 
data collected during the first 5 minutes of the measurement to calculate the depicted slopes dep. The IC50 and 
the Hill coefficient are given with the 95 % confidence intervals.  
 
3.4.10 CG3 05 A02 in the Rin1C/Rab5a Bodipy-FL-GDP release assay 
 
The Bodipy-FL-GDP release assay has been employed as an additional control to ensure the 
inhibitory effect of the compound CG3 05 A02 on the Rin1C-mediated nucleotide exchange 
on Rab5a. The compound was tested as triplicates in concentrations between 0.05 and 200 
µM with a final DMSO concentration of 2 %. Rab5a has been pre-loaded with Bodipy-FL-GDP 
before addition of Rin1C and GTP. The Bodipy-FL-GDP release was measured every 15 
seconds as a decrease in fluorescence intensity at 490 nm (excitation) and 520 nm 
(emission). Data generated during the first 5 minutes have been fitted linearly and the slope 
of each curve was calculated and plotted against the logarithmic compound concentration. 
The results are shown in figure 34. The IC50 estimated here was about six times higher 
compared to that measured in the Bodipy-TR-GTP nucleotide exchange assay (cp. section 
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3.4.1). Since the use of two different fluorophores resulted in contradicting data, a 
fluorescence-independent assay had to be performed as a more native-like control to 
exclude artificial effects that could originate from the use of fluorophore labels. The raw 
data used for linear fitting can be found in section 8.4.4 in the appendix. 
 
 
 
Figure 34: CG3 05 A02 in the Rin1C/Rab5a Bodipy-FL-GDP release assay. Concentration-dependent inhibition 
of the Rin1C/Rab5a Bodipy-FL-GDP release assay by the compound CG3 05 A02. Rab5a has been pre-loaded 
with Bodipy-FL-GDP prior to the addition of Rin1C and excess GTP. The Rin1C-mediated nucleotide exchange on 
Rab5a was monitored as a decrease in fluorescence intensity signal over time when Rab5a-bound Bodipy-FL-
GDP got released. A linear fit has been applied on the data collected during the first 5 minutes of the 
measurement to calculate the depicted slopes. The IC50 and the Hill coefficient are given with the 95 % 
confidence intervals and could merely be estimated, since the concentration range of the IC50 was not covered 
during the measurement.. 
 
3.4.11 CG3 05 A02 in the [α-32P]-GTP nucleotide exchange assay 
 
GTP labelled with radioactive 32P in the α-position has been used in a Rin1C/Rab5a 
nucleotide exchange assay to perform a more native-like control. The results using two 
different fluorescence-labelled GTP analogues have been contradictional (cp. sections 3.4.1 
and 3.4.9), suggesting one data set to be erroneous. Therefore a fluorescence-independent 
approach has been necessary to survey the inhibitory effect of the compound CG3 05 A02. 
The compound has been tested as triplicates in concentrations between 1.56 and 100 µM. 
The amount of Rab5a-bound [α-32P]-GTP was analysed by filter binding and scintillation 
counting after 20 minutes of incubation with Rin1C. The results were compared to a DMSO 
control and a negative control lacking Rin1C as depicted in figure 35. No concentration-
dependent inhibition of the nucleotide exchange by CG3 05 A02 could be seen.  
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Figure 35: CG3 05 A02 in the [α-32P]-GTP exchange assay. The compound was used in concentrations between 
1.56 and 100 µM on Rin1C and Rab5a in presence of excess nucleotide. After 20 minutes the amount of 
protein-bound [α-32P]-GTP was measured by filter binding and scintillation counting. 2 % DMSO have been used 
in the positive control sample and the negative control lacked Rin1C. No concentration-dependent inhibition by 
the compound CG3 05 A02 could be seen. The significance was calculated by one-way ANOVA, p < 0.05 using 
GraphPad Prism software. 
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4 Discussion 
 
Small molecule modulators have proven to be powerful tools to study the functions and 
interactions of proteins in vitro and in vivo. This project aimed on the identification of a small 
molecule inhibitor of the Rin1-mediated Rab5 activation. Ten secondary hits were found in 
an in vitro HTS approach using a fluorescently labelled GTP analogue. During the 
characterization of those molecules the compound CG3 05 A02 turned out to be the most 
specific and aggregation seemed unlikely to be the cause of inhibition. Further controls 
revealed that the compound was only active under certain conditions. 
 
4.1 Protein expression and purification 
 
Several proteins had to be expressed and purified to perform the experiments performed 
during this project. In the beginning active Rab5a and Rin1C needed to be purified to 
establish the screening assay and perform the high throughput screening (HTS). To test for 
specificity of the resulting hit compounds, other GTPases and GEFs have been purified: 
Rab5a/Rabex-5GEF, Rab1/DrrA, Rac2/Tiam1DHPH and Rac1/Vav1. Strep-tagged full length 
Rin1 (Rin1-TS) was purified to study the effects of the hit compound on the Rin1/ABL1 
interaction. All constructs could successfully be purified and were found to be active in the 
desired assays. However, there were several issues with the expression and purification of 
Rin1 constructs. 
 
4.1.1 Rin1 constructs could only be retrieved from Sf9 insect cells 
 
After failing to purify a Rin1 construct similar to Rabex-5GEF in E. coli and Sf9 insect cells, His-
tagged Rin1C was purified from Sf9 insect cells as described in Tall, 2001102, followed by and 
additional gel filtration step to increase the purity. Yin Dongsheng from the Famulok group 
simultaneously tried to express and purify several different shorter Rin1 constructs in E. coli 
as well as in Sf9 cells over the last years but all his efforts to retrieve a shorter construct 
failed. Aim of his approach was to generate a construct covering only the minimal motif 
necessary for Rin1-GEF activity. By now Rin1C is still the shortest GEF-active construct. Rin1C 
could be enriched in the Ni-NTA affinity chromatography and eluted in fractions 14-22 
during the gel filtration. The sample contained several impurities that could not be 
separated from the target protein during the purification process. Especially two strong 
bands could be found that corresponded to proteins with molecular weights between 15 and 
25 kDa. Those two bands were detected in every HT-Rin1C purification attempt and they 
most likely contained degradation products of the target protein itself. HT-Rin1C has a 
molecular weight of approx. 55 kDa. However, it notably behaved untypically during SDS-
PAGE, running considerably above the 55 kDa marker band. This behaviour can be caused by 
posttranslational modifications or the proteins folding and the resulting hydrodynamic 
properties. Since the impurities could not be further separated and HT-Rin1C was found to 
be active after the purification (cp. section 3.2), the quality was decided to be sufficient to 
perform the screening.  
Moreover a small amount of full-length Rin1-TS has been purified, again from bacculovirus-
infected Sf9 insect cells. 24.1 µg were yielded from a 10 mL culture. The 89.4 kDa protein of 
interest was mainly pure, containing only a few traces of impurities. Noticeably similar low 
molecular weight impurities as during the purification of Rin1C could be found. This further 
Discussion 
 
77 
 
supported the hypothesis that they might originate from Rin1 itself. A small amount of Rin1-
TS appeared to be insoluble as it could be found in the cell debris fraction after clearance of 
the lysate. Moreover some amount was lost during the Streptavidin affinity binding. There, 
unbound Rin1-TS could be found in the flow-through fraction. This might have been 
avoidable by using a larger amount of Streptavidin resin to circumvent saturation. 
Nevertheless the yield was high enough to perform the ABL1-mediated Rin1-
phosphorylation assay.  
 
4.2 All constructs were found to be active in nucleotide exchange assays 
 
The activity of the purified proteins was subsequently determined. Therefore the nucleotide 
exchange activity of the GEFs was assayed in different GEF concentrations on the 
corresponding GTPases. It was aimed to find conditions that allow testing of the hit 
compounds after the screening. A critical point here was the intrinsic nucleotide exchange 
activity of the GTPases. Strong intrinsic nucleotide exchange activity can lead to a small 
measurement window between the samples with and without GEF, making it hard to 
observe a potential concentration-dependent inhibition.  
The intrinsic nucleotide exchange activity of Rab5a was reported to be relatively low. Tall et 
al. observed about 20 % nucleotide exchange in 30 minutes in absence of a GEF102. Using 
Bodipy-TR-GTP and Rab5a no nucleotide exchange could be detected in absence of Rin1C or 
Rabex-5GEF. This might have been caused by a lower affinity of Rab5a for Bodipy-TR-GTP 
compared to GTP.  
For Rab1 only about 5 – 10 % Bodipy-TR-GTP association within 20 minutes could be seen in 
absence of DrrA.  
The strongest intrinsic Bodipy-TR-GTP binding capacity was seen for Rac2. Even in absence of 
Tiam1DHPH about 55 % of Bodipy-TR-GTP bound to Rac2 within 20 minutes. Similar results 
have already been obtained for GTP by B. Niebel from the Famulok group during an earlier 
project242.  
Approximately 45 % of intrinsic Bodipy-TR-GTP binding within 20 minutes could be seen for 
Rac1. This was contradictory to the < 10 % intrinsic GTP binding observed by B. Niebel242.  
Likewise results were found for Arf1. The approximately 50 % of intrinsic nucleotide 
exchange activity within 20 minutes observed when Bodipy-TR-GTP was used dissented from 
data observed by B. Weiche from the Famulok group, who only found about 20 % of intrinsic 
nucleotide exchange when using GTP243. A phenomenon like this has been discussed 
extensively in Goody, 2014244. Here the author elaborates how fluorescently labelled GTP 
analogues can bind to GTPases in absence of a GEF, even when they have a lower affinity 
compared to GDP and GTP. By simple considerations of equilibria it becomes clear why the 
analogues can bind to GTPases, depending of course on the concentrations of GTPase, GDP 
and GTP-analogue used in an experiment. From this it also becomes apparent that intrinsic 
nucleotide exchange does not only depend on the GTPases affinity for the GTP analogue but 
also on the GDP dissociation rate. The faster GDP can dissociate from a GTPase, the more 
GTP (or analogue) can bind. However, the intrinsic GDP dissociation rate should not be 
influenced by the use of GTP analogues instead of GTP, presupposed they have a similar 
affinity towards the GTPase. Therefore this does not explain the differences in the results 
obtained with Bodipy-TR-GTP compared to those obtained with GTP. These results suggest 
that Rac1 and Arf1 possess a stronger affinity for Bodipy-TR-GTP than they do for GTP (and 
GDP, therefore the faster dissociation). 
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When looking at the GEF-mediated nucleotide exchange, Rin1C, Rin1-TS and Rabex-5GEF 
concentration-dependently catalysed the Bodipy-TR-GTP association on Rab5a. When 
Rabex-5GEF was used at 25 nM the Bodipy-TR-GTP association reached saturation after 
around 400 seconds. With 200 nM of Rin1C saturation was not reached within the 
measurement time of 20 minutes. 200 nM of Rin1-TS led to saturation after 20 minutes. 
Resultant the catalytic effect was much stronger for Rabex-5GEF than for the two Rin1-
constructs as was to be expected and conclusive with data found in the literature82,102,131. 
DrrA catalysed the Bodipy-TR-GTP association on Rab1 concentration-dependently and with 
100 nM of DrrA saturation was reached after about 400 seconds. 
Tiam1DHPH had to be used in much higher concentrations compared to all the other GEFs in 
order to efficiently catalyse the nucleotide exchange. With 2 µM of Tiam1DHPH the 
nucleotide exchange reaction on Rac2 reached saturation after approximately 900 seconds. 
Using 800 nM of Tiam1DHPH the reaction did not reach saturation within the 20 minutes 
measurement time. Consistently B. Niebel observed saturation only after 8000 seconds with 
770 nM Tiam1DHPH using GTP242. 
Vav1 strongly catalysed the Bodipy-TR-GTP association on Rac1. With the highest 
concentration (400 nM) tested the reaction was saturated within the first 100 seconds. Using 
this concentration the linear phase of the reaction was way too short to appropriately 
calculate a slope. 25 nM Vav1 yielded saturation after around 400 seconds. This 
concentration was eventually chosen to be used during compound specificity 
measurements.  
ARNO-Sec7 was capable to concentration-dependently catalyse the Bodipy-TR-GTP 
association on Arf1. The highest concentration (100 nM) tested did not lead to saturation of 
the reaction within the 20 minutes measured.  
In both cases (GEF-mediated catalysis of the nucleotide exchange and intrinsic GTPase 
nucleotide binding capacity) the literature comparisons can only serve as reference points, 
as Bodipy-TR-GTP has been used in all nucleotide exchange assays performed during this 
study while the literature describes the activities when using GTP. It is well possible that the 
affinity of the proteins for Bodipy-TR-GTP differs from that observed with GTP. 
The GEF concentrations listed in section 7.2.3.1, table 24 were chosen for specificity testing 
of the hit compounds because a linear increase in fluorescence intensity could be observed 
during at least the first five minutes. 
 
4.3 Screening for small molecule inhibitors 
 
Establishing a suitable screening assay to target a certain protein or a single domain within a 
multi-domain protein can be challenging. The screenings described throughout the history of 
drug discovery differ e.g. in format, library design and read-out. Screening approaches 
monitoring protein activity are often advantageous over those assaying the compounds 
ability to bind the target protein since here the read-out gives direct information on whether 
inhibition occurs. Binding does not necessarily equal inhibition, therefore several inactive 
compounds have been found in screenings monitoring target binding193,242,245. Based on this 
knowledge a functional assay using Rin1C, Rab5a and a fluorescently labelled GTP analogue 
was to be designed. A drawback of this assay might be that inhibition could arise from 
targeting either of the two proteins or the complex between them. For example the 
screening could yield a GTP-competitive Rab5a-binder. Since there is no inhibitor known for 
Rin1 as well as Rab5, both proteins were attractive targets and the actual target should later 
be determined during characterization of the hit compounds.  
Discussion 
 
79 
 
Another disadvantage could be the use of a fluorophore label (Bodipy-TR) on the nucleotide. 
This always bears the risk of changing the interaction properties between the nucleotide and 
the nucleotide-binding protein. Using nucleotide-dependent changes in the intrinsic 
tryptophan fluorescence of Rab5a as read-out could have helped to overcome this problem. 
However, during an earlier screening approach with the same small molecule library, many 
compounds were found to be highly auto-fluorescent at the wavelengths required to 
monitor tryptophan fluorescence82. It has been previously reported that the UV range 
generally is the characteristic absorbance range for many different small molecules246. Thus, 
not only autofluorescence of the compounds but also quenching of the tryptophane signal 
by the compounds limits the usability of the tryptophane fluorescence assay for screening. 
Another common approach would be the use of a radioactively labelled GTP analogue and a 
filter retention read-out. The major drawback of this kind of assays is that they are very 
time-consuming and usually not suitable for a high sample throughput. Such a radioactive 
assay should later be used to verify the inhibitory effect of promising compounds in a 
fluorescence-independent setup. 
During an earlier screening approach, a reduction-sensitive lead compound has been 
identified by a member of the Famulok group82. Compounds that are inactive under reducing 
conditions are unlikely to exhibit an effect in an intracellular environment48. To prevent the 
finding of a reduction-sensitive small molecule during the present screening, the screening 
buffer has been equipped with 1 mM DTT to apply reducing conditions. 
To use the 1 mM library compounds in a final concentration of 40 µM the assay had to 
tolerate 4 % DMSO. DMSO concentrations between 0 and 10 % have been tested in the 
nucleotide exchange assay. The ΔFI was not significantly influenced by DMSO concentrations 
between 2 and 6 % when compared to the 0 % DMSO sample. 8 and 10 % DMSO led to 
significantly higher ΔFI values compared to the control. This effect might have either been 
caused by an influence of DMSO on the fluorescence properties of Bodipy-TR-GTP, by DMSO 
increasing the general solubility of the assay components or by an increase in the GEF-
independent nucleotide exchange.  
With those adjustments a Z’ factor of 0.57 could be calculated for the Rin1C/Rab5a Bodipy-
TR-GTP nucleotide exchange assay. The assay was therefore suitable for HTS234 and the 
screening was subsequently performed with a library of 20 328 small molecule compounds. 
Compounds that reduced the ΔFI by ≥ 80 % (equalling ≤ 20 % residual nucleotide exchange 
activity) compared to the DMSO controls on the same plate were defined as primary hits. 
The screening identified 239 primary hits, representing 1.2 % of the total compounds that 
have been tested. Primary hit rates between 0.6 and 1.6 % are commonly found in HTS 
approaches247–249. Notably the in-house compound library used during this screening was 
considerably small compared to those used in other recent screening approaches250–253. 
The primary hits were then tested as duplicates in two different concentrations in a manual 
re-screening. Here 213 of the primary hits were found to be false positives. It is common 
that many of the primary hits found during HTS approaches are false positives that can not 
be confirmed in a re-screening254. The false positives here were mainly caused by 
compounds either quenching the fluorescence signal of Bodipy-TR-GTP or being auto-
fluorescent at 595/620 nm. This could not be deduced from the ΔFI values calculated during 
the HTS but was easily detectable as an up- or downshift of the FI value measured at t = 0 
min when compared to that of the DMSO control. Another reason for false positive results 
could have been air bubbles in the wells that occurred during injection of Bodipy-TR-GTP at 
the plate reader. 26 compounds inhibited the nucleotide exchange by ≥ 50 % at a 
concentration of 40 µM and were defined as secondary hits.  
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The compound library plates have been stored at -20 °C for some time and have been 
exposed to several thaw/freezing cycles during earlier screening approaches. Those 
conditions can lead to degradation and insolubility of instable compounds as explained in 
greater detail in section 5.2.2. It had to be assured that the inhibitory effect originates from 
the compounds expected at the corresponding library positions and not from degradation 
products of those. Subsequently the secondary hits were re-tested from frozen library stock 
solutions. Those solutions have been stored at -80 °C without recurring thaw/freezing cycles. 
Only 10 of the 26 secondary hits were found to inhibit the nucleotide exchange when the 
stock solutions were tested. For the other 16 compounds the inhibitory effect likely 
stemmed from degradation products that accumulated in the compound library plates. They 
were excluded from further analysis due to lack of structural knowledge of the inhibitory 
molecules.  
 
4.4 Concentration-dependent inhibition of the Rin1C/Rab5a Bodipy-TR-GTP 
nucleotide exchange assay 
 
The 10 secondary hits all inhibited the Rin1C-mediated Bodipy-TR-GTP nucleotide exchange 
on Rab5a in a concentration-dependent manner. The IC50 and the Hill coefficient describe 
the potency and possible cooperative binding of small molecule inhibitors, respectively236,237. 
Activity and specificity are crucial in the concept of a lead compound as defined by J. G. 
Lombardino and J. A. Lowe as “a chemical structure or series of structures that show activity 
and selectivity in a pharmacological or biochemically relevant screen”238.  
The IC50 values of the 10 secondary hits all were in the low micromolar range, characterizing 
them as potential inhibitors.  
Their Hill coefficients were between -0.9 and -2.8 so some compounds were likely to bind 
independently while others seemed to bind positively cooperative. Independent binding was 
assumed for the compounds CG3 05 B06, CG5 08 H06, CG6 24 G06 and KR1 04 F03. The 
compounds CG1 05 F09, CG1 06 A03, CG5 05 F05, CG6 25 G08 and CG6 25 F10 showed Hill 
coefficients that indicated positive cooperative binding. The compounds CG3 05 A02 and 
CG3 05 B06 exhibited Hill coefficients of -1.6 ± 0.7 and -0.7 ± 0.6, respectively. Because of 
the large standard deviations no conclusions could be drawn whether independent or 
positively cooperative binding might take place in those cases.  
The 10 secondary hit compounds were moreover not noticeable structurally related.  
 
4.5 The majority of the secondary hits were either unspecific or aggregators 
 
During specificity testing using other GEF/GTPase pairs, most of the 10 secondary hits 
exhibited unspecific off-target effects on one or more of the selected protein pairs. The 
compounds CG1 05 F09, CG1 06 A03, CG3 05 B06, CG5 05 F05, CG6 26 F10 and KR1 04 F03 
were found to also inhibit the ARNO-Sec7/Arf1 nucleotide exchange assay. They were 
therefore classified as unspecific and unsuitable as lead compounds. CH5 08 H06 caused 
approximately 50 % inhibition in the nucleotide exchange assay using Vav1 and Rac1 and 
was therefore also categorized as unspecific.  
Many small molecule compounds are known to form colloidal aggregates around and with 
proteins, leading to promiscuous artificial inhibition239,241,255. A compound can for example 
bridge protein monomers, leading to inappropriate polymerization, disordered protein 
domains and aggregation256. The compounds were therefore tested in a simple 
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centrifugation-based aggregation assay. During this analysis the compound CG5 08 H06 was 
found to take about 50 % of Rin1C out of solution. The compounds CG6 24 G06 and CG6 25 
G08 completely aggregated Rin1C. Surprisingly none of the compounds aggregated with 
Rab5a. Supposing that bringding of monomers would be the mechanism behind the Rin1C 
aggregation, an explanation could be a lack of the cavities required for bridging in Rab5a. 
Moreover there are a few examples of specific aggregator described in the literature255,256. 
Since aggregators usually are prone to exhibit off-target effects239, these compounds were 
excluded from further investigations. 
 
4.6 CG3 05 A02 specifically inhibited the Vps9 domain-containing Rab5a-GEF 
constructs Rin1C and Rabex-5GEF without inducing aggregation 
 
The compound CG3 05 A02 inhibited the Rin1C- and Rabex-5GEF-mediated Bodipy-TR-GTP 
nucleotide exchange on Rab5a with IC50 values of 35.4 ± 11.1 µM and 40.7 ± 4.1 µM (data in 
the appendix, section 8.7), respectively. Since Rabex-5 and Rin1 share the homologous 
catalytic Vps9 domain it was not unexpected that a compound might be able to inhibit both 
GEFs. Another possibility would be that CG3 05 A02 interacts with Rab5a instead as this 
would also lead to inhibition in both setups.  
Binding studies using microscale thermophoresis (MST, data in the appendix, section 8.8) 
unfortunately did not deliver reasonable results indicating binding to either of the two 
proteins or both proteins combined. The latter was done to analyse possible binding to the 
complex between Rin1C and Rab5a.  
Other methods to generate binding data also failed for different reasons. Isothermal 
titration calorimetry (ITC) would have required higher solubility of the compound in buffer, 
ideally in a range at least 10-fold higher than the IC50.  
The solubility of CG3 05 A02 was found to be poor. An explanation for the measured IC50 
values in a range far above the determined solubility could be that the compound gets 
solubilized upon binding to proteins. During the exchange assays the compound was at no 
time exposed to buffer without the presence of the two proteins. The compounds 
synthesized for structure activity relationship (SAR) studies that had an inhibitory effect 
comparable to that of CG3 05 A02 did not show improved solubility in buffer (data in the 
appendix in section 8.5).  
For fluorescence polarization (FP) experiments the compound needed to be labelled with a 
fluorophore. During the SAR studies several linkers at different positions have been tested 
and even a fluorescein-labelled compound was synthesized. All modifications led to a partial 
or complete loss of the inhibitory effect.  
To assess the possibility that CG3 05 A02 might interact GTP-competitively with Rab5a, 
Rab5a was loaded GEF-independently with Bodipy-TR-GTP in presence of different 
concentrations of the compound. No concentration-dependent effect on the GTP-binding 
could be found, therefore it seemed unlikely that GTP-competitive binding is the mechanism 
of inhibition employed by the compound CG3 05 A02. It could not be determined at this 
point whether CG3 05 A02 interacts with Rin1C and Rabex-5GEF or with the GEF/GTPase 
complex.  
CG3 05 A02 did not inhibit any of the other GEF/GTPase pairs although the exchange 
mechanisms of some of the GEF domains are similar32. DrrA and ARNO-Sec7 built quite 
rigorous controls due to similarity in the catalytic nucleotide exchange mechanism. To 
further analyse the inhibition on another Vps9 domain-containing GEF, GAPVD1 has been 
tried to be purified. Unfortunately the resulting protein turned out to be inactive after each 
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purification attempt (data in the appendix, section 8.9). At this point it could be concluded 
that CG3 05 A02 specifically inhibits the nucleotide exchange of at least two Vps9 domain-
containing Rab5 GEFs. It remains to be tested whether this is the case for other Vps9 
domain-containing Rab5 GEFs as well.  
Little to no aggregation of Rin1C and Rab5a could be seen in the centrifugation-based 
aggregation assay when CG3 05 A02 has been tested. To investigate possible off-target 
effects that could arise from unspecific protein aggregation, the compound was tested in the 
GEF/GTPase unrelated insulin receptor (IR) auto-phosphorylation assay. CG3 05 A02 
exhibited no effect on the IR auto-phosphorylation, rating IR aggregation unlikely. To further 
exclude off-target effects, whether they are aggregation-based or not, compound-centric 
proteomics257 could have been performed. However, this would have required labelling the 
compound with a structure that allows immobilization. Since modification of CG3 05 A02 
with different linkers led to partial or complete loss of inhibition this approach has been 
omitted.  
 
4.7 A methoxy group is important for CG3 05 A02 to exhibit its inhibitory 
effect 
 
During SAR studies on the compound CG3 05 A02 several functional groups have been 
removed, exchanged or repositioned. Some derivatives have been synthesized to modify the 
compound with a label or to improve the solubility in buffer as already shortly discussed in 
section 4.6. Others were generated to gain insights on the substituents required for 
inhibition. The core structure of CG3 05 A02 is depicted in figure 36. This structure was 
modified at the positions R1, R2 and R3 as well as on the secondary amine during the SAR 
studies. 
 
 
 
Figure 36: Core structure of CG3 05 A02. It comprises four ring structures, a secondary amine and a ketone 
group that have been conserved in all derivatives. The molecule was modified at the positions R1, R2 and R3 as 
well as on the position of the amine during the SAR studies. 
 
A methoxy group is attached at position R3 in CG3 05 A02. This group turned out to be 
crucial for the compound to exhibit its full inhibitory effect. Removing or repositioning of this 
group to meta- or para position led to a loss of activity. These observations suggested that a 
covalent ring closure might take place between the methoxy group and the secondary 
amine, attended by the release of H2. To further investigate this possibility the compound 
066A has been synthesized. A methyl group has been attached, generating a tertiary amine 
and preventing the formation of a covalent bond. This compound was completely inactive. It 
was therefore possible that the inhibitory structure is actually the closed form.  
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Removing the methyl group at position R1 had no effect on the inhibition, neither had 
replacing it with a methoxy or a hydroxyl group. This certain tolerance for changes at the R1 
position led to the attempt to label the compound at this position. However, attachment of 
different linkers and a fluorophore led to partial or complete loss of the inhibitory potential. 
This could possibly arise from the sheer increase in molecule size, hindering it from 
interaction with the target or from intramolecular interactions between the linker and a 
substituent required for inhibition. 
Attachment of the linker at position R3 also extinguished the inhibition. This could result 
from preventing the ring closure mentioned above, in case this is the actual inhibitory form 
of the compound.  
No effect on the inhibitory potential was observed when the methyl group at position R2 
was removed. This indicated a certain tolerance towards changes at this position as well. 
However, the R2 position is more in the centre of the molecule, therefore it was assumed 
that modifications there could more likely cause intramolecular reactions than modifications 
at the R1 position. 
When both methyl groups at the R1 and R2 positions were removed, the IC50 approximately 
doubled. This indicated that their presence is not completely irrelevant. They might 
somehow stabilize the correct orientation of the compound within a potential binding site. 
The compound 166A is the only derivative that delivered results that were inconclusive with 
the remaining SAR data. This compound had an inhibitory effect, although the methoxy 
group at position R3 is lacking. The IC50 was about two times as high compared to CG3 05 
A02. To gain further insights on the SAR and this specific matter some more derivatives 
should be synthesized. For example molecules with various substituents at the position R3, 
differing for example in size and reactivity.  
Nevertheless the methoxy group at position R3 seems to be important for the compound 
CG3 05 A02 to exhibit its full inhibitory potential. Without this group the potency either 
decreased drastically or completely vanished. Unfortunately no gain of potency or solubility 
could be obtained with any of the molecules synthesized for the SAR studies.  
 
4.8 CG3 05 A02 inhibits the GEF function of Rin1 without affecting the 
interaction with ABL1 
 
In a Rin1-phosphorylation assay using full-length Rin1-TS and ABL1 the effect of CG3 05 A02 
on the interaction between Rin1 and ABL1 has been investigated. It was analysed whether 
inhibition of the GEF domain influences the function of a neighbouring domain, the proline-
rich region. This region interacts with ABL kinases, leading to Rin1-phosphorylation at 
Tyr36113,258. By binding to a certain domain on a multi-domain protein, a compound could 
affect neighbouring domains for example by inducing conformational changes, by blocking 
them with overhanging substituents or by sheer bulkiness. The phosphorylation of Rin1-TS 
was not altered by CG3 05 A02. Hence, the compound either interacts specifically with the 
Vps9 domain without influencing the proline-rich region required for interaction with ABL1 
or does not interact with Rin1 at all. Additionally, this result once again argues against the 
compound acting as a general protein aggregator. As already previously discussed in section 
4.6 CG3 05 A02 possibly interacts with the complex between the GEF domains of 
Rin1/Rabex-5 and Rab5a. To further analyse this matter the Rin1-TS-phosphorylation in 
presence of Rab5a should be contemplated. In a cellular environment a Vps9 domain-
specific small molecule inhibitor could be used to smother tumorigenic effects resulting from 
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Rin1-mediated Rab5 over-activation without influencing the tumour suppressive ABL1 
signalling functions of Rin1123–126,150. 
 
4.9 The inhibitory effect of CG3 05 A02 depends on the use of a labelled GTP 
analogue 
 
During the course of this study additional control experiments were performed that aimed 
on showing the inhibitory effect of CG3 05 A02 is not related to the use of Bodipy-TR-GTP. 
The use of Bodipy-TR-GTP in the specificity studies with other GEF/GTPase pairs already 
excluded that the effect simply stemmed from interaction of the compound with Bodipy-TR-
GTP. If that was the case, the compound should have had an effect in every one of the 
consulted assays. It therefore seemed unlikely that the inhibition was linked to the use of 
Bodipy-TR-GTP at this point. Since there are differences in the affinities and binding 
properties of GTPases reported for GTP analogues compared to GTP244 the controls have 
been performed nevertheless. However, their priority was set low in comparison to the 
characterization experiments performed beforehand. 
First, another GTP analogue has been used: Bodipy-FL-GTP. Surprisingly the IC50 for CG3 05 
A02 was estimated to be about 7-fold higher with Bodipy-FL-GTP compared to the 
experiments performed with Bodipy-TR-GTP. The IC50 could merely be estimated here due to 
the compound concentration range used (0.025 – 200 µM) for solubility reasons. At this 
point it could not be concluded which one of those results is erroneous. Actually, the 
biochemically most relevant situation is that where GTP is used instead of a labelled 
analogue. To overcome this issue and get a more native-like glimpse on the situation, an 
experiment using radioactively labelled GTP has been performed. Unfortunately, no 
concentration-dependent inhibition of the Rin1C-mediated nucleotide exchange on Rab5a 
could be found.  
As already mentioned above, the inhibition seen in the Bodipy-TR-GTP nucleotide exchange 
assay is unlikely to originate from the compound directly interacting with Bodipy-TR-GTP. 
Moreover the GEF-independent loading of Rab5a with Bodipy-TR-GTP in presence of CG3 05 
A02 showed no effect of the compound on nucleotide binding. GTP-competitive binding to 
Rab5a is therefore also unlikely. This means in turn that, if there is an effect of CG3 05 A02 
that does not descend from assay artefacts, the compound likely interacts with either 
Rin1C/Rabex-5GEF or the complex of those with Rab5a. Supposing that CG3 05 A02 interacts 
specifically with or adjacent to the Vps9 domain of the GEFs in complex with Rab5a, or close 
to the GTP binding site with the complex itself, it could prevent Bodipy-TR-GTP from 
entering the binding site due to steric hindrance, caused by the Bodipy-TR moiety. The 
complex would normally get disrupted by high concentrations of GTP in the cell129. The much 
smaller GTP without a fluorescent label is still able to bind to Rab5a in presence of CG3 05 
A02, as seen in the radioactive approach. The Bodipy-FL label is smaller than the Bodipy-TR 
label (cp. structures from figures 15 and 33). Bodipy-FL-GTP can accordingly, to some extent, 
still bind to Rab5a even in presence of high concentrations of the compound. However, the 
binding of the “bulkier” Bodipy-TR-GTP is inhibited by CG3 05 A02 with an IC50 of 35.4 µM. 
This also can explain the lack of inhibition in the Bodipy-FL-GDP release assay. Here Rab5a 
got pre-loaded with Bodipy-FL-GDP in absence of CG3 05 A02 and then mixed with Rin1C 
and the compound. Upon interaction with Rin1C, Bodipy-FL-GDP gets released as expected, 
independent of the presence of the compound. GTP binding should afterwards not be 
influenced by the compound binding to Rin1C or the Rin1C/Rab5a complex. To further 
investigate this hypothesis other fluorescently labelled GTP analogues could be tested. The 
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fluorophores should differ in size but they should all be attached to the ribose ring as it was 
the case for the Bodipy labels used in this study.  
These findings unfortunately classify the compound unsuitable for cellular application 
because no inhibitory effect is to be expected, since the nucleotide exchange for GTP is not 
influenced by CG3 05 A02 in vitro.  
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5 Outlook 
 
5.1 Perspectives for CG3 05 A02 
 
Although CG3 05 A02 seems to be highly specific for at least two Vps9 domain-containing 
Rab5 GEFs, Rin1 and Rabex-5, its dependence on the use of a fluorescently labelled GTP 
analogue prevents its use as a tool to study these GEFs in vivo. It can be used to modify in 
vitro kinetic experiments and may help to gain insights on the differences between Rin1- and 
Rabex-5-mediated Rab5 activation in the presence of Bodipy-TR-GTP.  
Clarifying the inhibitory mechanism of this compound could be interesting to obtain a 
deeper understanding of the effects the addition of a label can have on GTP binding to 
GTPases. Therefore it would be helpful to generate structural data of CG3 05 A02 in complex 
with Rin1, Rabex-5 or the complex between those and Rab5. X-ray crystallization efforts 
have already been initiated by D. Yin from the Famulok group. This could also answer the 
question, whether the compound really interacts with the complex between the Rab5 GEFs 
and Rab5 as assumed based on the data generated during this study.  
Identification of the binding site of CG3 05 A02 could help to model potential inhibitory 
molecules into this protein cavity. Finding suitable cavities on GEFs and GTPases can often be 
challenging due to their globular surface lacking obvious grooves and pockets176. This could 
be a good starting point for in silico screenings that have yielded promising results in other 
screening approaches for GTPase and GEF inhibitors182,185,186,197,201,222. By this a second 
generation of Rin1 inhibitors might be identified that may also be able to inhibit the 
nucleotide exchange in presence of unlabelled GTP.  
 
5.2 Considerations for future screening approaches 
 
5.2.1 Insights from the Rin1C/Rab5a Bodipy-TR-GTP nucleotide exchange assay 
 
Scientists planning on performing a HTS can certainly benefit from this study.  
First of all it has to be kept in mind that the use of fluorophore labels influences the assay 
conditions in one way or the other. Therefore a fluorescence-independent control should be 
performed at an early stage after the screening, when a fluorescence-based method has 
been employed. By this, artefacts resulting from the use of fluorescently labelled material 
can be sorted out at an early time.  
Next the use of a detergent in the screening buffer might have prevented hitting compounds 
that later turned out to be aggregators. This is, of course, only possible when the detergent 
does not interfere with the assay read-out, as it was seen in this study.  
Lastly it has to be noted that in retrospect an assay monitoring the release of fluorescently 
labelled GDP (rather than the association of fluorescently labelled GTP) would have been 
preferable as in this setting CG3 05 A02 had no inhibitory effect.  
 
5.2.2 Successful HTS approaches crucially depend on library size and quality  
 
Many recent HTS approaches have been performed with libraries containing a way larger 
number of small molecules than the library used during this study250–253. Certainly a larger 
number of compounds raises the probability to find a suitable inhibitor.  
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Moreover the appropriate storage of compound libraries was described to be as important 
as the HTS itself259. Reoccurring freeze-thaw cycles have been reported to induce compound 
precipitation and therefore change the compound concentration in the long term260. A 
mixture of water, DMSO and glycerol (10:45:45) was described to prevent compound 
precipitation and could be contemplable as a solvent for long-term storage261. 
Compounds were also described to decay over longer storage periods, leading to the 
accumulation of impurities in the library262. Impurities can falsify screening results as they 
either might show effects in the screening assay, leading to false positive hits, or are inactive 
in contrast to the compound they originate from. The latter would result in false negative 
data, meaning missing out on a potentially promising compound. 
Automated compound quality control should be undertaken at frequent intervals to assure 
the actual compound concentrations correspond to the theoretically desired library 
concentrations263. Solubility and purity should also be checked during quality controls. 
Library composition, age and storage conditions influence the outcome of HTS approaches 
and should always be considered during the planning of such.  
Conclusions 
88 
 
6 Conclusions 
 
GTPases are molecular switches that are extensively involved in the regulation of gene 
expression, membrane trafficking and endocytosis18. They become activated by GEFs and 
inactivated via the hydrolysis of GTP with the help of catalytic GAPs12. Often a variety of 
different GEFs can activate the same GTPase and their distinct functions in the affected 
signalling cascades are not completely understood. The GTPase Rab5 can get activated by 
several GEFs, amongst them Rin1 and Rabex-5. Rab5 GEFs contain a catalytic Vps9 domain 
that mediates the nucleotide exchange100.  
Small molecule inhibitors have proven to be valuable tools in the investigation of protein-
protein interactions154. GTPases and GEFs are interesting and yet challenging targets due to 
their smooth surface that lacks obvious grooves and pockets suitable for small molecule 
interactions21,160,176. The homologous Vps9 domain shared by Rab5 GEFs makes it moreover 
difficult to target them specifically100. Small molecule inhibitors of Rab5 GEFs would help to 
shine light on the complex signalling networks around Rab5.  
This study aimed on the identification of an inhibitor of the Rin1-mediated Rab5 activation in 
an in vitro high-throughput screening (HTS) approach. The screening yielded the small 
molecule CG3 05 A02 that specifically inhibited the Rin1C and Rabex-5GEF-mediated Bodipy-
TR-GTP nucleotide exchange on Rab5a without aggregating the proteins involved. The IC50 
values of CG3 05 A02 in both cases were in the low micromolar range. The compound did 
not inhibit the Bodipy-TR-GTP nucleotide exchange between several other GEF/GTPase pairs, 
although the exchange mechanisms were described to be similar. However, it might still be 
able to inhibit other Vps9 domain containing Rab5 GEFs, as by now only Rin1C and Rabex-
5GEF have been tested. No unspecific inhibition could be seen in an unrelated insulin receptor 
auto-phosphorylation assay and the compound did moreover not influence the interaction 
between Rin1 and ABL1. This interaction is mediated by the proline-rich region of Rin1 that 
is located adjacent to the Vps9 domain. Accordingly CG3 05 A02 did not show a domain-
unspecific intramolecular effect on the proline-rich region of Rin1. A compound like this 
could, theoretically, be used to oppress tumorigenic effects mediated by Rab5 over-
activation without influencing the tumour suppressive ABL1 signalling functions of Rin1123–
126,150.  
During several control experiments it became, however, apparent that CG3 05 A02 does not 
inhibit the Rin1C and Rab3x-5GEF-mediated nucleotide exchange when radioactively labelled 
GTP is being used. This unfortunately characterizes the compound as unsuitable for cellular 
or in vivo applications.  
Structure-activity relationship analyses revealed the importance of a methoxy group that 
might perform a ring closure reaction with a neighbouring secondary amine. This group 
seems to be crucial for the compound to exhibit its inhibitory effect.  
Binding studies failed to unravel whether Rin1C/Rabex-5GEF, Rab5a or the complex between 
those proteins is the actual target of CG3 05 A02. However, loading of Rab5a with Bodipy-
TR-GTP was not influenced by CG3 05 A02 and therefore GTP-competitive binding to Rab5a 
is unlikely. The compound could hypothetically bind close to the GTP binding site on the 
complex between Rin1C/Rabex-5GEF and Rab5a and prevent Bodipy-TR-GTP binding due to 
steric hindrance. The Bodipy-TR moiety could prevent the nucleotide from entering the 
binding site when CG3 05 A02 is attached to the complex. This mode of action could also 
apply when the compound binds Rin1C and Rabex-5GEF at or adjacent to the Vps9 domain 
and this protein-compound complex stays intact upon interaction with Rab5a. The much 
smaller GTP can, however, still enter the binding pocket, even when CG3 05 A02 is bound.  
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To avoid investing in label-dependent compounds that might be found in future screenings a 
fluorescence-independent control should be performed promptly after the HTS. The right 
choice of the compound library to be screened is also an important issue that has to be 
thoroughly considered when a HTS should be performed259.  
Identification of a possible binding site of CG3 05 A02 on Rin1C/Rabex-5GEF or the complex of 
those with Rab5a in crystallization studies might pinpoint a protein cavity that could 
potentially be used for in silico HTS approaches. By this a second generation of inhibitors of 
the Rin1-mediated Rab5 activation could be identified. These second generation compounds 
could help to create a greater understanding of the signalling cascades involving Rab5 
activation.  
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7 Materials & Methods 
 
7.1 Materials 
 
7.1.1 Equipment 
 
Table 6: Equipment. 
Equipment Manufacturer 
Agilent 1100 HPLC BRUKER 
ÄKTA FPLC GE Healthcare 
Analytical balance CPA 324S sartorius AG 
Balance BL 1500S sartorius AG 
Blotting chamber (semi dry) PHASE HL 
Blotting chamber (wet) Criterion BioRad 
Centrifuge 5427 R Eppendorf 
Centrifuge 5804 R Eppendorf 
Centrifuge Avanti J-26S XP Beckman Coulter 
Electrophoresis power supply E802 CONSORT 
Esquire HCT (ESI MS & ion trap) BRUKER 
French Press cell disrupter Thermo Scientific 
Gelfiltration column Superdex 200 HiLoad 16/600 pg GE Healthcare 
HPLC column MultoHigh Bio 200-5 C18 CS-Chromatography 
Incubator (bacteria) Multitron pro INFORS-HT 
Incubator (bacteria) HERAtherm Thermo Scientific 
Incubator (Sf9 cells) innova 42 Eppendorf 
Liquid Scintillation Counter 1409 Wallac 
Magnetic stirrer IKAMAG RCT IKA Works 
Magnetic rack Promega 
Microscope Eclipse TS 100 Nikon 
MST Monolith NT.115 NanoTemper 
Multipette Advanced Eppendorf 
NanoDrop 2000 Thermo Scientific 
Odyssey gel documentation system 9260 LI-COR 
Over head tumbler PTR-30 Grant-bio 
Peristaltic pump 2115 Multiperpex LKB Bromma 
pH-meter FiveEasy Mettler Toledo 
Pipettes research plus Eppendorf 
Plate Reader infinite M1000 pro & injector TECAN 
Screening Robot Freedom Evo TECAN 
SDS-Page electrophoresis apparatus BioRad 
Sonifier Sonics Vibra Cell Heinemann 
Spectrophotometer BioSpectrometer basic Eppendorf 
Thermomixer comfort Eppendorf 
Vortexer MS2 Minishaker IKA Works 
Water bath 1008 GFL 
Water purification system MicroPure UV Thermo Scientific 
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7.1.2 Chemicals 
 
Table 7: Chemicals. 
Reagent Manufacturer 
[α-32P] GTP PerkinElmer 
β-mercaptoethanol Roth 
Acetic acid Roth 
Acetonitrile, LC-MS grade Merck 
Agar agar Fluka Chemica 
Alexa Fluor 647 NHS-ester invitrogen 
Ammonium persulfate Roth 
Ampicillin Roth 
ATP AppliChem 
Bac-to-Bac system Thermo Scientific 
Bodipy-TR GTP life technologies 
Bodipy-FL GTP life technologies 
Bodipy-FL GDP life technologies 
Bromophenol blue Merck 
Chloramphenicol Sigma Aldrich 
ComGenex compound library ComGenex 
Coomassie brilliant blue G-250 Serva 
DMSO (anhydrous) Sigma Aldrich 
Dithiothreitol Roth 
EDTA AppliChem 
Ethanol Roth 
GDP Sigma 
Gentamycin AppliChem 
Glutathione AppliChem 
Glutathione Sepharose 4B GE Healthcare 
Glycerol Roth 
Glycine Roth 
GppNHp JenaBioscience 
GTP Sigma 
Hydrochloric acid VWR Chemicals 
Imidazole Roth 
IPTG AppliChem 
Isopropanol Roth 
Kanamycin Roth 
LB Medium Roth 
Methanol Roth 
MgCl2 Fluka Chemica 
NaCl Roth 
NaOH Roth 
NHS-Fluorescein Thermo Scientific 
Ni-NTA Agarose Beads Macherey-Nagel 
100 x Protease Inhibitor Mix: 
1 mM AEBSF 
Components by Serva 
In-house preparation of stock 
Materials & Methods 
92 
 
5 µM E-64 
5 µM Bestatin 
5 µM Phosphoramidon 
Protein Assay Dye Reagent Concentrate BioRad 
Protein Ladder PageRuler Plus Prestained Thermo Scientific 
SDS AppliChem 
Strep-Tactin Superflow Iba 
Streptavidin Superflow Iba 
TEMED Roth 
Tween20 AppliChem 
Rotiphorese Gel 30 Roth 
Ultima Gold LSC Cocktail Perkin Elmer 
 
7.1.3 Consumables 
 
Table 8: Consumables. 
Product Manufacturer 
384 well plates, NBS, black, flat bottom Corning 
96 well plates, half area, MB, black, flat bottom  Greiner Bio One 
96 well plates, transparent, round bottom  Greiner Bio One 
Blotting paper Macherey-Nagel 
Capillaries, standard treated NanoTemper 
Centrifugation tubes (15 mL / 50 mL) Sarstedt 
Dialysis tubing SpectraPor PC 10 K MWCO SpectrumLabs 
Disposable columns BioRad 
Disposable cuvettes Roth 
Multipette combitips advanded Eppendorf 
NAP-5 columns GE Healthcare 
Needles Henke Sass Wolf 
Nitrocellulose membrane GE Healthcare 
Petridishes Sarstedt 
Pipette tips Sarstedt 
Protein LoBind reaction tubes (1.5 mL) Eppendorf 
Reaction tubes (1.5 mL / 2 mL) Sarstedt 
Reaction tubes (0.2 mL) Sarstedt 
Sterile filters GE Healthcare 
Super Polyethylene LSC Vials Perkin Elmer 
Syringes BD Discardit 
VivaSpin turbo 15 centrifugal filters  sartorius AG 
 
7.1.4 Compounds 
 
Table 9: Compounds. 
Name Manufacturer Corresponding library No. 
V005-7464 ChemDiv, Inc. CG6 25 G08 
Sulfobromophthalein Sigma Aldrich KR1 04 F03 
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7.1.5 Nucleic acids 
 
Table 10: Nucleic acids. 
Plasmid Cloning 
sites 
Resistance Purification Tag Cleavage 
site 
Insert 
pAB1 NcoI 
NotI 
Gent Strep TEV Rin1-TS (human, aa 
1-783) 
pDL2 BamHI 
SalI 
Amp 6 x His none Rabex-5GEF (human, 
aa 132-391) 
pET19mod NdeI 
XhoI 
Amp 6 x His TEV DrrA (human, aa 40-
533) 
pET15 NcoI 
EcoRV 
Amp 6 x His Thrombin NΔ17 Arf1 (aa 1-164) 
pET15b NdeI 
BamHI 
Amp 10 x His none Rab5a (human, aa 
17-184) 
pET52b(+) XmaI 
SalI 
Amp 6 x His / Strep Thrombin Tiam1DHPH (mouse, 
aa 1033-1406) 
pET SUMO TA 
cloning 
Kan 6 x His / SUMO none Rac2 (human, aa 1-
192) 
pFBHT EcoRI 
XhoI 
Gent 6 x His TEV Rin1C (human, aa 
293-783) 
pFBHT EheI 
SalI 
Amp 6 x His TEV IR-ICD (human, aa 
953-1355) 
pGEX2T BamHI 
EcoRI 
Amp GST TEV Vav1 (human, aa 
189-575, M351T) 
pGEX2T BamHI 
EcoRI 
Amp GST Thrombin Rac1 (human, aa 1-
184) 
pIBA101HT BsmBI 
HindIII 
Amp 6 x His  TEV ARNO-Sec7 (human, 
aa 61-246) 
pMAL NdeI 
XhoI 
Amp 6 x His / MBP TEV Rab1 (human, aa 1-
205) 
pMAL-C2 SacI 
BamHI 
Amp 7 x His / MBP TEV TEV Protease (tev, aa 
1-304, S219V) 
 
7.1.6 Enzymes & Proteins 
 
Table 11: Enzymes & Proteins. 
Protein Manufacturer 
ABL1 (His6-tagged) ThermoFisher 
ARNO-Sec7 In-house production, Benjamin Weiche 
BSA PAN Biotech 
EGF PeproTech Inc. 
Insulin receptor (intracellular domain) In-house production, Christian Sieg 
Lysozyme Thermo Scientific 
NΔ17 Arf1 In-house production, Benjamin Weiche 
TEV Protease In-house production, Volkmar Fieberg 
Thrombin, bovine Calbiochem 
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7.1.7 Antibodies 
 
Table 12: Antibodies. 
Target Species Dilution Manufacturer, No. 
5 x His mouse 1:1000 Qiagen, 34660 
Phospho-Tyrosine mouse 1:500 Santa Cruz, sc-7020 
Rab5 mouse 1:1000 Santa Cruz, sc-46692 (D11) 
Rab5a  rabbit 1:500 Santa Cruz, sc-309 (S-19) 
EGFR-CT rabbit 1:1000 Santa Cruz, sc-03  
Mouse IgG IRDye® 800CW goat 1:20000 LI-COR 
Rabbit IgG IRDye® 800CW goat 1:20000 LI-COR 
 
7.1.8 Bacterial strains 
 
Table 13: Bacterial strains. 
Strain Genotype Manufacturer 
BL21-CodonPlus®(DE3)-RIL E. coli B F- ompT hsdS(rB
- mB
-) dcm+ Tetr gal 
λ(DE3) endA Hte [argU ileY leuW Camr] 
Agilent 
Technologies 
 
7.1.9 Software 
 
Table 14: Software. 
Software Manufacturer 
ChemDraw Prime 15.1 PerkinElmer 
GraphPad Prism® GraphPad Software Inc. 
Image Studio Lite LI-COR 
Office 2003 Microsoft 
 
7.2 Methods 
 
7.2.1 Miscellaneous Methods 
 
7.2.1.1 SDS-PAGE 
 
SDS-PAGE was used to separate proteins according to their mass as described by Laemmli 
264,265. The anionic detergent sodium dodecyl sulfate (SDS) was used to denature the 
proteins and charge them negatively. The longer the peptide chain, the stronger the 
negative charge. This allowed a separation by protein size in an electric field using a 
polyacrylamide (PAA) gel. The gel consisted of a 4 % acrylamide stacking gel on top of an 8 – 
15 % acrylamide separating gel. The percentage of the separating gel depended on the size 
range of the proteins desired to separate. Low percentages were advantageous to resolute 
big proteins whilst high percentages have been used for small ones. The gels have been 
prepared according to table 15. Polymerisation was initiated by addition of ammonium 
persulfate (APS) and the catalyst N,N,N’,N’-tetramethylethylenediamine (TEMED). The gel 
was prepared between two glass plates held apart by spacers with a thickness of 1 mm. A 
comb was inserted into the stacking gel prior to polymerisation to create pockets for sample 
loading. The gel was placed inside a running chamber filled with 1 x running buffer. Protein 
samples were mixed with loading buffer in a final concentration of 1 x and boiled at 95 °C for 
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5 minutes before loading them to the gel pockets. 3 µL of a pre-stained protein marker were 
loaded as a size reference. The gel was run at 200 V for approx. 1 h and afterwards either 
stained with coomassie brilliant blue or used for western blotting as described in section 
7.2.1.3. 
 
4 x stacking gel buffer:   4 x separating gel buffer: 
0.5 M Tris, pH 6.8    1.5 M Tris pH 8.8 
14 mM SDS     14 mM SDS 
 
5 x running buffer:    6 x loading buffer 
125 mM Tris     1 M Tris pH 6.8 
960 mM Glycine    30 % Glycerol 
17 mM SDS     15 % w/v SDS 
      600 mM DTT 
      Small amount of bromophenol blue 
 
Table 15: Composition of SDS-PAA-gels. 
Amounts for  
1 gel 
Separating gel Stacking gel 
8 % 10 % 12.5 % 15 % 4 % 
Acrylamide [µL] 1333 1667 2083 2500 213 
Water [µL] 2379 2045 1629 1212 975 
Separating gel 
buffer [µL] 
1250 
 
- 
 
 
Stacking gel 
buffer [µL] 
 
 
- 
 
 
400 
 
TEMED 8 2 
APS 30 10.4 
 
7.2.1.2 Coomassie staining of PAA-gels 
 
The coomassie blue staining method was adapted from the protocol described by Sasse266. 
The gel was incubated in coomassie staining solution for 30 minutes at room temperature on 
an orbital shaker. Afterwards the gel was rinsed with water and destained in destaining 
solution until the background staining faded away. The destaining solution was exchanged 
every 15 minutes. Finally the gel was documented in the Odyssey scanner system using the 
700 nm channel. Protein bands could be quantified using the Image Studio Lite software. 
 
Coomassie staining solution:   Destaining solution: 
30 % v/v Methanol    10 % v/v Acetic acid 
10 % v/v Acetic acid  
0.82 mM Coomassie brilliant blue G-250 
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7.2.1.3 Western blotting (Immunoblotting) 
 
Immunoblots were performed to detect, analyze and quantify proteins. The protein samples 
were run on PAA-gels as described in section 7.2.1.1 and then transferred to a nitrocellulose 
membrane by either semi dry or wet blotting. The membrane was then blocked with 5 % 
w/v BSA in TBST for 1 h at room temperature. Afterwards it was incubated with the desired 
primary antibody in the corresponding dilution (see section 7.1.7) in TBST + 5 % w/v BSA 
either 1 h at room temperature or over night at 4 °C on an orbital shaker. The membrane 
was washed three times for 5 minutes at room temperature under agitation before the 
fluorescently labelled secondary antibody was added. The secondary antibody was diluted in 
TBST with 5 % w/v BSA and 0.02 % w/v thimerosal as described in section 7.1.7. After 
another 1 h incubation at room temperature under light protection and agitation the blot 
was washed with TBST as before. Finally the proteins of desire were visualized using the 800 
nm channel in the odyssey scanner to detect the secondary antibodies. Protein bands could 
be quantified using the Image Studio Lite software.  
 
TBST: 
20 mM Tris, pH 7.6 
136 mM NaCl 
0.1 % v/v Tween 20 
 
7.2.1.3.1 Semi-dry blotting 
 
Semi dry blotting was performed as described by Kyhse-Andersen267 in 1984 with slight 
buffer modifications. The gel and membrane were stacked between pieces of blotting paper 
equilibrated in different buffers (cathode, three pieces of paper equilibrated with cathode 
buffer, gel equilibrated with cathode buffer, membrane equilibrated with anode buffer II, 
two pieces of paper equilibrated with anode buffer II, one piece of paper equilibrated with 
anode buffer I, anode). The proteins were transferred by applying a current of 2 mA/cm2 gel 
(108 mA for a 6 x 9 cm gel) for 50 minutes in a PHASE HL blot chamber.  
 
Cathode buffer:     Anode buffer I: 
25 mM Tris, pH 9.4    300 mM Tris, pH 10.4 
40 mM Glycine 
 
Anode buffer II: 
25 mM Tris, pH 10.4    
 
 
7.2.1.3.2 Wet blotting 
 
Wet blotting was performed similar to the protocol described by Towbin268 in 1979 but in a 
methanol-free buffer. Gel, membrane, two sponges (parts of the Criterion wet blot chamber) 
and two pieces of blotting paper were equilibrated with cold wet blot buffer. The blot was 
assembled in a blot holder (starting from the black cathode side of the holder: one sponge, 
one piece of paper, gel, membrane, the second piece of paper, the second sponge, the red 
anode side of the blot holder). The blot holder, a – 20 °C cold thermal pack and a magnetic 
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stir bar were placed inside the Criterion wet blot chamber filled with wet blot buffer. The 
proteins were transferred by applying a total current of 2000 mA for 50 minutes. 
 
Wet blot buffer: 
25 mM Tris 
192 mM Glycine 
 
7.2.2 Protein biosynthesis and purification 
 
7.2.2.1 Transformation of BL21-CodonPlus®(DE3)-RIL competent cells 
 
The E. coli strain BL21-CodonPlus®(DE3)-RIL was used for protein expression. This strain 
supplies additional copies of tRNAs genes that are naturally rare in E. coli (arginine, leucine 
and isoleucine), thereby the protein expression level can be enhanced. 1 x 107 cells were 
thawed on ice, mixed with 100 ng plasmid DNA and incubated on ice for 10 minutes. A heat 
shock was performed for 1 minute at 42 °C in a thermomixer under agitation. Afterwards the 
cells were incubated for another 5 minutes on ice before 900 µL of LB medium were added 
followed by 1 h incubation in the thermomixer at 37 °C and 750 rpm. Finally the cells were 
plated onto a LB-agar-plate containing the appropriate antibiotic for selection of cells 
carrying the desired resistance encoded in the plasmid (see section 7.1.5). For the BL21-
CodonPlus®(DE3)-RIL strain chloramphenicol was always added to the plate to maintain the 
plasmid encoding the additional tRNAs. The plate was incubated upside down at 37 °C over 
night. 
 
LB medium:     LB-agar-plates: 
20 g/L LB broth in water   15 g/L agar agar in LB medium 
 
Antibiotic concentrations: 
Ampicillin: 100 µg/mL 
Chloramphenicol: 50 µg/mL 
Kanamycin: 50 µg/mL 
Gentamycin: 7 µg/mL 
 
7.2.2.2 Protein expression in E. coli 
 
To express the protein of interest, a single clone from the plate generated during the 
transformation (see section 7.2.2.1) was picked to inoculate 100 mL LB medium 
supplemented with the appropriate antibiotic (see section 7.1.5) and chloramphenicol. 
Alternatively a glycerol cryoculture prepared during an earlier expression of the same 
protein could be used to inoculate the pre-culture. To conserve a certain clone after 
transformation, 500 µL of a 100 mL pre-culture were mixed with 500 µL glycerol and stored 
at – 80 °C. The pre-culture was incubated at 37 °C and 120 rpm in a Multitron pro incubator 
overnight. For large scale protein expression 2 L of LB medium supplemented with the 
appropriate antibiotics were inoculated with the 100 mL pre-culture. This main culture was 
grown at 37 °C until the OD600 reached 0.4 – 0.5. The OD could be measured repeatedly 
using a spectrophotometer and disposable cuvettes. Gene expression of the desired protein 
was induced by addition of 0.1 mM IPTG. IPTG releases the lac repressor from the lac operon 
so genes encoded under its promoter can be expressed. The cells were then grown at 21 °C 
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and 120 rpm overnight. The final OD600 was measured before the cells were harvested by 
centrifugation at 8000 x g and 4 °C for 30 minutes. Cell pellets could be stored at – 80 °C until 
further use. All proteins except for Rin1C, which was expressed in Sf9-cells, were expressed 
in E. coli. 
 
7.2.2.2.1 Monitoring of protein expression in E. coli whole cell lysates 
 
To verify that the protein of interest has been expressed, a whole cell lysate of E. coli cells 
before and after induction of the expression was prepared and run on a PAA-gel. 1 mL 
samples of the main culture before and after induction were harvested at 1000 x g and 4 °C 
for 5 minutes, respectively. The supernatant was discarded and the pellets were re-
suspended in an appropriate amount of quicklysis buffer (amount [µL] = OD600 ∙ 100 µL). 
After 30 minutes of incubation at room temperature, loading buffer has been added to a 
final concentration of 1 x (for buffer formulation see section 7.2.1.1). The samples were 
sonicated with 5 pulses (1 second on / 1 second off, 40 % Amplitude) to shear genomic DNA, 
boiled at 95 °C for 5 minutes and finally loaded on a PAA-gel. SDS-PAGE was performed as 
described in section 7.2.1.1 followed by coomassie blue staining (see section 7.2.1.2). 
 
Quicklysis buffer: 
50 mM Tris, pH 7.8 
50 mM NaCl 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Small amount of lysozyme 
 
7.2.2.3 Protein expression in Sf9-cells 
 
The proteins Rin1C and Rin1-TS were expressed in baculovirus-infected Sf9 (Spodoptera 
frugiperda)-cells by Yvonne Aschenbach-Paul from the Famulok group. The pFBHT-Rin1C and 
pFB-Rin1-TS constructs were designed by Dr. Anton Schmitz. The virus was used for infection 
in a ratio of 1:1000 and the protein was expressed for three days at 27 °C. Sf9-cells were 
harvested by centrifugation at 500 x g and 4 °C for 20 minutes. 
 
7.2.2.4 E. coli and Sf9-cell lysis 
 
Prior to protein purification the cells were lysed using the French Press. The frozen cell pellet 
from the main culture was re-suspended in 10 mL of cold lysis buffer, sucked up into the pre-
chilled French Press chamber and released under a pressure of approx. 18000 psi through a 
small hole. This process of sucking up and releasing was repeated a total of five times for E. 
coli cells and three times for Sf9 cells until the cells were completely disrupted. Finally the 
lysate was cleared by centrifugation at 48 000 x g and 4 °C for 40 minutes.  
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Table 16: Lysis buffers. 
Buffer Composition 
Lysis Buffer DrrA 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Rab1 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Rab5a 50 mM Tris, pH 7.8 
50 mM NaCl 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Rabex-5GEF 50 mM Tris, pH 7.8 
50 mM NaCl 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Rac1 50 mM Tris, pH 7.8 
300 mM NaCl 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Rac2 50 mM Tris, pH 7.8 
300 mM NaCl 
20 mM Imidazole 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Rin1C 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Rin1-TS 20 mM MES, pH 6 
300 mM NaCl 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Tiam1DHPH 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
Lysis Buffer Vav1 50 mM Tris, pH 7.8 
300 mM NaCl 
0.1 % v/v β-Mercaptoethanol 
1 x Protease inhibitor mix (from 100 x) 
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7.2.2.5 Affinity chromatography 
 
Affinity chromatography was used to separate the expressed protein carrying an affinity tag 
from other proteins in a cell lysate. The proteins either carried a Histidine tag that can bind 
to a Ni-NTA resin by complexing nickel ions immobilized on agarose beads269 or were 
expressed as Glutathione S-transferase (GST)-fusion proteins270. GST is a short protein that 
binds glutathione. Glutathione can be immobilized on sepharose beads. After binding the 
protein of interest can be eluted using a competitor: imidazole for His-tagged proteins and 
glutathione for GST-fusion proteins, respectively. 
 
7.2.2.5.1 Nickel-NTA affinity chromatography 
 
Approx. 10 mL of the cleared cell lysate from a 2 L culture were incubated with 5 mL of the 
Ni-NTA resin (50 % slurry, equilibrated with cold lysis buffer) for 1 h at 4 °C in an overhead 
tumbler. The mixture was transferred to a 10 mL disposable column and the flow through 
was collected. 50 mL cold washing buffer were added step by step and the wash fraction was 
collected. Afterwards the protein of interest was eluted by adding five times 1 mL cold 
elution buffer to the beads. The elution fractions were collected and pooled on ice. The 
insoluble pellet from the cleared lysate was re-suspended in 10 mL lysis buffer. A 30 µL 
aliquot for SDS-PAGE analysis was taken at each step: lysate (soluble), lysate (pellet), flow 
through, wash and elution. The lysate samples and the flow through were diluted 1:2 with 
lysis buffer before addition of loading buffer in a final concentration of 1 x, the other 
samples were not pre-diluted. SDS-PAGE was performed as described in section 7.2.1.1 
followed by coomassie blue staining (see section 7.2.1.2). 
 
Table 17: Washing buffers for His-tagged proteins. 
Buffer Composition 
Washing Buffer DrrA 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
Washing Buffer Rab1 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
Washing Buffer Rab5a 50 mM Tris, pH 7.8 
50 mM NaCl 
Washing Buffer Rabex-5GEF 50 mM Tris, pH 7.8 
50 mM NaCl 
Washing Buffer Rac2 50 mM Tris, pH 7.8 
300 mM NaCl 
20 mM Imidazole 
Washing Buffer Rin1C 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
Washing Buffer Tiam1DHPH 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
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Table 18: Elution buffers for His-tagged proteins. 
Buffer Composition 
Elution Buffer DrrA 50 mM Tris, pH 8 
300 mM NaCl 
300 mM Imidazole 
Elution Buffer Rab1 50 mM Tris, pH 8 
300 mM NaCl 
300 mM Imidazole 
Elution Buffer Rab5a 50 mM Tris, pH 7.8 
50 mM NaCl 
300 mM Imidazole 
Elution Buffer Rabex-5GEF 50 mM Tris, pH 7.8 
50 mM NaCl 
300 mM Imidazole 
Elution Buffer Rac2 50 mM Tris, pH 7.8 
300 mM NaCl 
300 mM Imidazole 
Elution Buffer Rin1C 50 mM Tris, pH 8 
300 mM NaCl 
300 mM Imidazole 
Elution Buffer Tiam1DHPH 50 mM Tris, pH 8 
300 mM NaCl 
300 mM Imidazole 
 
7.2.2.5.2 Glutathione affinity chromatography 
 
3 mL of Glutathione Sepharose resin (75 % slurry) were equilibrated with cold lysis buffer 
and then incubated with approx. 10 mL cleared cell lysate from a 2 L culture for 1 h at 4 °C in 
an overhead tumbler. The mixture was transferred to a 10 mL disposable column and the 
flow-through was collected. 50 mL cold washing buffer were added step by step and the 
wash fraction was collected. Afterwards the protein of interest was eluted by adding five 
times 1 mL cold elution buffer to the beads. The elution fractions were collected and pooled 
on ice. The insoluble pellet from the cleared lysate was re-suspended in 10 mL lysis buffer. A 
30 µL aliquot for SDS-PAGE analysis was taken at each step: lysate (soluble), lysate (pellet), 
flow through, wash and elution. The lysate samples and the flow through were diluted 1:2 
with lysis buffer before addition of loading buffer in a final concentration of 1 x, the other 
samples were not pre-diluted. SDS-PAGE was performed as described in section 7.2.1.1 
followed by coomassie blue staining (see section 7.2.1.2). 
 
Table 19: Washing buffers for GSH-fusion proteins. 
Buffer Composition 
Washing Buffer Rac1 50 mM Tris, pH 7.8 
300 mM NaCl 
Washing Buffer Vav1 50 mM Tris, pH 7.8 
300 mM NaCl 
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Table 20: Elution buffers for GSH-fusion proteins. 
Buffer Composition 
Elution Buffer Rac1 50 mM Tris, pH 7.8 
300 mM NaCl 
10 mM Glutathione 
Elution Buffer Vav1 50 mM Tris, pH 7.8 
300 mM NaCl 
10 mM Glutathione 
 
7.2.2.5.3 Strep-Tactin affinity chromatography 
 
10 mL of Strep-Tactin resin (50 % slurry) were transferred to a 15 mL tube and equilibrated 
with dialysis buffer for Tiam1DHPH (cp. section 7.2.2.6.2) and then incubated with the 
sample containing the target protein for 1 h at 4 °C in an over-head tumbler. The mixture 
was transferred to a 10 mL disposable column and the flow-through was collected. After 
washing the beads with 50 mL dialysis buffer and collection of the washing fraction the 
target protein was eluted by addition of five times 1 mL elution buffer. The eluate was 
collected on ice. 30 µL aliquots for SDS-PAGE analysis were taken from the flow-through, the 
washing fraction and the eluate. SDS-PAGE was performed as described in section 7.2.1.1 
followed by coomassie blue staining (see section 7.2.1.2). 
 
Elution buffer Strep-tagged Tiam1DHPH: 
50 mM Tris, pH 7.8 
150 mM NaCl 
2.5 mM Desthiobiotin 
 
7.2.2.5.4 Streptavidin affinity chromatography 
 
1 mL (per 10 mL of expression culture volume) of Streptavidin resin (50 % slurry) was 
transferred to a 15 mL tube and equilibrated with lysis buffer for Rin1-TS (cp. section 7.2.2.4) 
and then incubated with the sample containing the target protein for 1 h at 4 °C in an over-
head tumbler. The mixture was transferred to a 10 mL disposable column and the flow-
through was collected. After washing the beads with 50 mL washing buffer and collection of 
the washing fraction the target protein was eluted by addition of five times 1 mL elution 
buffer. The eluate was collected on ice. 30 µL aliquots for SDS-PAGE analysis were taken 
from the flow-through, the washing fraction and the eluate. SDS-PAGE was performed as 
described in section 7.2.1.1 followed by coomassie blue staining (see section 7.2.1.2). 
 
Washing buffer Strep-tagged Tiam1DHPH: 
20 mM MES, pH 6 
300 mM NaCl 
 
Elution buffer Strep-tagged Rin1: 
20 mM MES, pH 6 
300 mM NaCl 
5 mM Desthiobiotin 
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7.2.2.5.5 Reverse affinity chromatography after tag cleavage 
 
After tag cleavage as described in section 7.2.2.6 the cleaved protein could be separated 
from the former tag and the protease using reverse affinity chromatography. For that the 
dialyzed 5 mL sample was re-used for affinity binding as described in section 7.2.2.5. Since 
the protein of interest no longer contained a purification tag, it did not bind to the resin but 
appeared in the flow-through fraction while the tag and the protease bound and could and 
be eluted later on. Reverse affinity chromatography was applied during the purification of 
DrrA, Rab1, Rac1, Tiam1 and Vav1. 
 
7.2.2.6 Cleavage of purification tags 
 
The presence of a purification tag can sometimes influence the activity and stability of the 
protein of interest271–273. To avoid this, the tags were cleaved using protease digestion when 
an appropriate cleavage site was present (see section 7.1.5).  
 
7.2.2.6.1 Cleavage by TEV digestion 
 
The TEV protease is a cysteine protease that originates from the tobacco etch virus. It was 
expressed and purified as a maltose binding protein (MBP)-fusion protein with the mutation 
S219V by Volkmar Fieberg from the Famulok group. The protein contained a TEV cleavage 
site so it could be separated from MBP after self-cleavage. TEV protease was added to the 
protein of interest in a molar ratio of 1:50 (TEV protease:protein of interest) and the mixture 
was transferred to a dialysis tubing with a molecular weight cut off of 10 kDa. The tubing 
was incubated in 2 L dialysis buffer at 4 °C on a magnetic stirrer over night. During dialysis, 
imidazole/glutathione was removed from the buffer containing the protein of interest via 
dilution. TEV digestion was used during the purification of DrrA, Rab1 and Vav1 followed by 
reverse affinity chromatography (see section 7.2.2.5.5). 
 
Table 21: Dialysis buffers for TEV digestions. 
Buffer Composition 
Dialysis Buffer DrrA1 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
Dialysis Buffer Rab1 50 mM Tris, pH 8 
300 mM NaCl 
20 mM Imidazole 
Dialysis Buffer Vav1 50 mM Tris, pH 7.8 
150 mM NaCl 
 
7.2.2.6.2 Cleavage by Thrombin digestion 
 
Thrombin is a serine protease that is commercially available and was bought at Calbiochem. 
100 units of Thrombin were used for the purification yield from a 2 L culture and the mixture 
was transferred to a dialysis tubing with a molecular weight cut off of 10 kDa. Dialysis was 
performed as described in section 7.2.2.6.1. Thrombin digestion was used during the 
purification of Rac1 and Tiam1 followed by reverse affinity chromatography (see section 
7.2.2.5.5). 
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Table 22: Dialysis buffers for Thrombin digestions. 
Buffer Composition 
Dialysis Buffer Rac1 50 mM Tris, pH 7.8 
300 mM NaCl 
Dialysis Buffer Tiam1DHPH 50 mM Tris, pH 7.8 
150 mM NaCl 
 
7.2.2.7 Size exclusion chromatography 
 
Size exclusion chromatography was used to increase the purity of proteins after affinity 
chromatography. Proteins were separated according to their size since the porous column 
material allows small substances to enter its holes while large ones flow through faster 
without entering. A Superdex 200 HiLoad 16/600 pg column was attached to the Äkta FPLC 
system and equilibrated with two column volumes of filtered and degassed storage buffer 
using a flow rate of 1 mL/min. The 5 mL elution fraction from an affinity chromatography 
was loaded onto the column and the run was performed at 1 mL/min flow rate. The peaks 
visible in the UV monitoring at 280 nm were collected in 2 mL fractions. Aliquots of 30 µL 
were taken from each peak, loading buffer was added in a final concentration of 1 x and SDS-
PAGE analysis was performed as described in section 7.2.1.1. Size exclusion chromatography 
was used during the purification of Rab1, Rab5a, Rabex-5GEF, Rac2 and Rin1C. 
 
Table 23: Storage buffers for size exclusion chromatography. 
Buffer Composition 
Storage Buffer Rab5a 50 mM Tris, pH 7.8 
100 mM NaCl 
2 mM MgCl2 
Storage Buffer Rabex-5GEF 50 mM Tris, pH 7.8 
50 mM NaCl 
Storage Buffer Rac2 50 mM Tris, pH 7.8 
300 mM NaCl 
2 mM MgCl2 
Storage Buffer Rin1C 50 mM Tris, pH 7.8 
300 mM NaCl 
 
7.2.2.8 Handling of purified proteins 
 
After purification the proteins had to be prepared for the experiments to follow. The protein 
concentration had to be determined and in most cases increased before proceeding.  
 
7.2.2.8.1 Determination of protein concentration 
 
The protein concentration could be determined either by a photometric approach or by 
using the Bradford Assay that provides a colorimetric readout. 
 
7.2.2.8.1.1 Photometric determination of protein concentration 
 
The protein concentration can be calculated from the absorbance at 280 nm based on 
Tryptophan, Tyrosine, Histidine, Cysteine and Phenylalanine residues inside the peptide 
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chain. Every protein has a certain molar absorption coefficient (ε) that can be calculated as 
described by Pace et al. in 1995274. The protein concentration could then be calculated via 
the law of Lambert-Beer: 
 
clA  280  
 
A280: Absorption at 280 nm, ε: molar absorption coefficient (M
-1
 cm
-1
), l: length of cuvette (cm) and c: protein 
concentration (M) 
 
The absorption has been measured using a spectrophotometer or a NanoDrop 2000. The 
buffer in which the protein of interest was dissolved was used as blank sample. 
 
7.2.2.8.1.2 Determination of protein concentration via Bradford assay 
 
The Bradford Assay is based on the absorption of Coomassie brilliant blue G-250 that binds 
to basic and aromatic amino acid residues275. The absorption of protein-bound dye could be 
measured at 595 nm. From that, the protein concentration could be estimated by comparing 
the measured absorption with that of a bovine serum albumin (BSA) standard of known 
concentrations (167 µg/mL – 3 mg/mL). The Protein Assay Dye Reagent Concentrate was 
diluted 1:5 with ddH2O and 150 µL of that were mixed with 2 µL of the protein sample or 
lysate that was to be quantified. Lysates were diluted 1:10 before the concentration was 
measured. The mixture was transferred to a transparent 96 well plate and the absorbance 
was measured using the infinite M1000 pro plate reader. 
 
7.2.2.8.2 Increasing the protein concentration and buffer exchange 
 
After purification the protein concentration often had to be increased in order to use the 
protein in different assays later on. VivaSpin Turbo ultrafiltration spin columns were used for 
that. The molecular weight cut off (MWCO) of the column was chosen to be at least 50 % 
smaller than the molecular weight of the protein of interest. The concentrator was filled up 
with the protein sample and centrifuged at 3000 x g and 4 °C until the desired protein 
concentration was reached. For buffer exchange or desalting, the protein sample was 
concentrated until the desired concentration, then the column was filled up with the final 
buffer and the sample was concentrated again. After three such cycles about 99 % of the 
initial salt content was removed. 
 
7.2.3 Nucleotide exchange assays 
 
Nucleotide exchange assays were performed to monitor GEF activity. GEF and GTPase were 
united followed by nucleotide addition. The nucleotide exchange was then monitored using 
a fluorescently labelled nucleotide analogue. Many fluorophores show altered fluorescence 
intensity when free in solution compared to when they are in close proximity to e.g. a 
protein13. This effect could be used to detect binding of the fluorescently labelled 
nucleotides to GTPases. A fluorescence-independent method has also been used. Here 
radioactively labelled GTP was bound to a GTPase in presence of the corresponding GEF. The 
amout of GTPase-bound [α-32P]-GTP was then determined in a filter retention approach.  
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7.2.3.1 Bodipy-TR and –FL-GTP exchange assay 
 
The fluorophores Bodipy-FL and Bodipy-TR are strongly quenched in solution. They are 
attached to the 2' or 3' position of the ribose ring of GTP via an aminoethylcarbamoyl linker. 
Upon GTP binding to a GTPase, the fluorescence signal increases. Generally 1 µM of the 
GTPases has been used with GEF concentrations between 10 nM – 2 µM, depending on the 
GEF activity (see table 24). 2 µM (final concentration) of Bodipy-GTP were added via 
injection prior to repeated fluorescence measurements every 10 – 15 seconds over 30 – 60 
minutes. The fluorescence could be measured in black 384-well plates with non-binding 
surface at 490/520 nm (FL) and 595/620 nm (TR) using the infinite M1000 pro plate reader. 
Compounds were usually tested as triplicates ranging from 0 to 200 µM with a final assay 
concentration of 2 % DMSO. The linear range of the resulting curves was used to calculate 
the slope. To analyze potential concentration-dependent inhibitory effects, the slope was 
plotted against the logarithmic compound concentration. 
 
Table 24: GEF concentrations for Bodipy-GTP nucleotide exchange assay. 
GEF Concentration 
ARNO-Sec7 100 nM 
DrrA 25 nM 
Rabex-5GEF 20 nM 
Rin1C 100 – 200 nM (batch to batch variations) 
Tiam1DHPH 2 µM 
Vav1 25 nM 
 
Nucleotide exchange buffer: 
20 mM MES, pH 6 
100 mM NaCl 
2 mM MgCl2 
1 mM DTT 
 
7.2.3.1.1 Bodipy-TR-GTP high throughput screening (HTS) assay 
 
The Bodipy-TR GTP exchange assay described in section 7.2.3.1 has been modified in order 
to generate an assay potentially suitable for HTS. 40 µM (final concentration) of each library 
compound were tested only once using 1 µM Rab5a and 200 nM Rin1C. The final DMSO 
concentration in the screening assay was again 2 %. The compounds were added to 384-well 
plates using a screening robot followed by manual addition of the proteins diluted in 
nucleotide exchange buffer. The plate was subdivided into eight parts comprising three 
columns each Rab5a and Rin1C were incubated with the compounds for eight minutes at 
room temperature during manual protein addition before injection of Bodipy-TR-GTP to the 
columns 1 – 3 of the 384-well plate. After the injection the fluorescence at 595/620 nm has 
been measured once (t = 0 minutes) and then again after 20 minutes (t = 20 minutes). In 
between injection into the columns 4 – 5 followed exactly one minute after the injection into 
the first three columns, followed by fluorescence measurement. This time-delayed pattern 
was continued until the last thee columns were injected and measured twice. From those 
values the difference in fluorescence intensity (ΔFI) could be calculated. Compounds 
reducing the ΔFI to ≤ 20 % (compared to mean ΔFI of DMSO controls) were defined as hits. 
The nucleotide exchange buffer described in section 7.2.3.1 has been supplemented with 1 
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µM BSA during the screening to reduce protein and Bodipy-TR-GTP adsorption to plastic 
surfaces. 
 
7.2.3.2 Bodipy-FL-GDP release assay 
 
The Bodipy-FL GDP release assay is another method to analyze GEF activity. In contrast to 
the previously described nucleotide exchange assays, where the association of GTP is 
monitored, this assay focuses on the release of GTPase-bound GDP. To pre-load the GTPase 
with the Bodipy-labelled nucleotide, it was incubated in nucleotide exchange buffer without 
MgCl2 but with 1 mM EDTA in presence of 2 µM Bodipy-FL-GDP at 37 °C for 15 minutes. 2 
mM MgCl2 were added to stabilize nucleotide binding followed by another 5 minutes 
incubation at 37 °C. The pre-loaded GTPase was used in a final concentration of 1 µM with 
GEF concentrations as described above (section 7.2.3.1). 100 µM GTP were added to start 
the nucleotide exchange. The fluorescence at 490/520 nm was measured every 10 – 15 
seconds for 30 – 60 minutes. Compounds were usually tested as triplicates ranging from 0 to 
200 µM with a final assay concentration of 2 % DMSO. Upon exchange of Bodipy-FL GDP for 
GTP a decrease in fluorescence intensity was to be expected. The linear range of the 
resulting curves was used to calculate the slope. To analyze potential concentration-
dependent inhibitory effects, the slope was plotted against the logarithmic compound 
concentration. 
 
7.2.3.3 [α-32P]-GTP exchange assay 
 
The [α-32P]-GTP exchange assay provides a fluorescence-independent approach to monitor 
GEF activity in vitro. 1 µM of the GTPase was mixed with the correspondent GEF in the 
concentration described in table 24, section 7.2.3.1 in nucleotide exchange buffer. A mixture 
of GTP and [α-32P]-GTP was added: 0.4 µCi/µL [α-32P]-GTP, adjusted to 100 µM total GTP 
with GTP. Compounds were usually tested as triplicates ranging from 0 to 100 µM with a 
final assay concentration of 2 % DMSO. The amount of protein-bound [α-32P]-GTP was 
analyzed after 20 minutes by filter binding followed by scintillation counting. 10 µL of the 
samples were added as triplicates to approx. 1 x 1 cm sheets of nitrocellulose membrane. 
The proteins were allowed to bind for 5 minutes at room temperature before the sheets 
were washed three times for 5 minutes with nucleotide exchange buffer (see section 7.2.3.1) 
under agitation. The sheets were transferred to scintillation vials and the counts per minute 
(CpM) were measured in each vial. The assay was either performed kinetically with time 
points from 2 – 120 minutes or as an endpoint measurement after 20 minutes. 
 
7.2.4 Protein aggregation assay 
 
Compounds inducing protein aggregation are well known to have unspecific side effects on a 
wide variety of different proteins239,276. To test, whether hit compounds found during the 
HTS are aggregators, a simple centrifugation assay was performed. 1 µM HT-Rab5a and 300 
nM HT-Rin1C were mixed with 2 µM GTP in nucleotide exchange buffer (see section 7.2.3.1). 
A 30 µL sample of that was taken and SDS-PAGE loading buffer (see section 7.2.1.1) was 
added to a final concentration of 1 x. Then 50 µM of the compounds were added in a final 
DMSO concentration of 2 %. DMSO was also used as a positive control. The samples were 
incubated at room temperature for 20 minutes followed by centrifugation at 20 000 x g at 
room temperature for 10 minutes. A 30 µL sample was taken from each supernatant and 
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loading buffer was added to a final concentration of 1 x. The remaining supernatant was 
removed carefully and the pellet was resuspended in an equal amount of buffer. A 30 µL 
aliquot was taken from each pellet sample and loading buffer was added to a final 
concentration of 1 x. All samples were boiled for 5 minutes at 95 °C and then subjected to 
SDS-PAGE and semi-dry western blotting as described in sections 7.2.1.1, 7.2.1.3 and 
7.2.1.3.1. Anti-His5 antibody was added over night at 4 °C under agitation followed by 1 h 
incubation with the secondary fluorescently labelled goat-anti-mouse antibody at room 
temperature under light protection (for antibody dilutions and specifications see section 
7.1.7). The amount of soluble HT-Rin1C and HT-Rab5a in the supernatants and pellets was 
compared to the amount in the DMSO control as well as in the input sample. 
 
7.2.5 The insulin receptor auto-phosphorylation assay 
 
Compounds are often tested in an unrelated assay to check for promiscuous inhibition by 
aggregation241. The insulin receptor auto-phosphorylation assay has been performed to 
check for unspecific inhibition. 250 nM of the insulin receptor intracellular domain (IR-ICD) 
were mixed in IR-ICD Phosphorylation Buffer with 50 µM of the compound to be tested in a 
final assay concentration of 2 % DMSO. Two controls were performed: one with 2 % DMSO 
and one without compound or DMSO. A 30 µL aliquot was taken and SDS-PAGE loading 
buffer (see section 7.2.1.1) was added to a final concentration of 1 x (t = 0 sec.). The sample 
was boiled for 5 min. at 95 °C and then stored at room temperature until SDS-PAGE analysis 
was performed. ATP was added to the remaining sample in a final concentration of 1 mM. 
Further 30 µL aliquots were taken after 20 sec. and 60 sec. and treated as the one before. All 
samples were subjected to SDS-PAGE, coomassie staining and semi-dry western blotting as 
described in sections 7.2.1.1, 7.2.1.2, 7.2.1.3 and 7.2.1.3.1. Anti-phospho-tyrosine antibody 
has been added diluted 1:500 in TBST with 5 % BSA. The blot was incubated with the 
antibody overnight at 4 °C under agitation and washed three times for five minutes with 
TBST before incubation with the secondary goat-anti-mouse antibody as described in section 
7.2.1.3 (for antibody dilution and specifications see section 7.1.7). The intensities of the 
bands corresponding to phosphorylated IR-ICD were compared between the samples with 
and without compound. 
 
IR-ICD phosphorylation buffer: 
20 mM HEPES, pH 7.2 
100 mM NaCl 
30 mM MgCl2 
 
7.2.6 The ABL1-mediated Rin1 phosphorylation assay 
 
To exclude a domain-unspecific effect on the Rin1/ABL interaction by the hit compound an 
ABL1-mediated Rin1 phosphorylation assay has been performed. 500 nM Rin1-TS and 50 nM 
HT-ABL1 were mixed in Rin1 Phosphorylation Buffer before 50 µM of the compound to be 
tested were added in a final assay concentration of 2 % DMSO. Two controls were 
performed: one with 2 % DMSO and one without compound or DMSO. A 30 µL aliquot was 
taken and SDS-PAGE loading buffer (see section 7.2.1.1) was added to a final concentration 
of 1 x (t = 0 sec.). The sample was boiled for 5 min. at 95 °C and then stored at room 
temperature until SDS-PAGE analysis was performed. ATP was added to the remaining 
sample in a final concentration of 1 mM. Further 30 µL aliquots were taken after 1 minute 
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and 15 minutes and treated as the one before. All samples were subjected to SDS-PAGE, 
coomassie staining and semi-dry western blotting as described in sections 7.2.1.1, 7.2.1.2, 
7.2.1.3 and 7.2.1.3.1. Anti-phospho-tyrosine antibody has been added diluted 1:500 in TBST 
with 5 % BSA. The blot was incubated with the antibody overnight at 4 °C under agitation 
and washed three times for five minutes with TBST before incubation with the secondary 
goat-anti-mouse antibody as described in section 7.2.1.3 (for antibody dilution and 
specifications see section 7.1.7). The intensities of the bands corresponding to 
phosphorylated Rin1-TS and HT-ABL1 were compared between the samples with and 
without compound. 
 
Rin1 phosphorylation buffer: 
50 mM Tris, pH 7.2 
100 mM NaCl 
2 mM MgCl2 
 
7.2.7 Analysis of Bodipy-TR-GTP binding to Rab5a 
 
To analyse the influence of the hit compound on GTP-binding to Rab5a, Rab5a was loaded 
with Bodipy-TR-GTP in presence of the compound in different concentrations between 0.05 
and 200 µM. 1 µM of Rab5a was incubated with 1 mM EDTA in presence of 2 µM Bodipy-TR-
GTP at 37 °C for 15 minutes. The fluorescence of Bodipy-TR-GTP was measured every 20 
seconds at 595 nm (excitation) and 620 nm (emission). A linear fit was applied on the data 
generated in the first 100 seconds. The slopes were calculated and compared to that of a 
DMSO control. 
 
7.2.8 Synthesis and characterization of compounds 
 
All compounds listed below were kindly synthesized by Dr. Jeffrey Hannam from the 
Famulok Group. He also delivered the synthesis protocols in this section. Chemicals were 
bought from Acros, Sigma Aldrich, Fluorochem, Alfa Aesar, Iris Biotech or Fisher Scientific. 
Diisopropylethylamine (DIPEA) was distilled over CaH2 under argon and stored over 
potassium hydroxide pellets.  
NMR spectra (1H NMR and 13C NMR) were recorded in deuterated dimethyl sulfoxide (d6-
DMSO) or deuterated chloroform (CDCl3) on DPX 400, DRX 300, DMX 500 MHz or  DPX 600 
MHz Spectrometers from BRUKER, Karlsruhe. The chemical shifts were plotted as δ-values in 
ppm (multiplicity, coupling constant J in Hz, number of protons) for 1H NMR spectra and 
chemical shift δ in ppm for 13C NMR spectra. Multiplicities are abbreviated as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, or combinations thereof. Residual 
solvent peaks of DMSO (δH = 2.50 ppm, δC = 39.5 ppm) were used as an internal reference. 
NMR spectra were assigned using information ascertained from COSY and DEPT135. 
EI-Mass spectra were measured on a MAT-95XL from Finnigan, Bremen. ESI-Mass spectra 
were measured with a microTOF-Q flight time spectrometer from Bruker, Daltonik. Samples 
were analysed by HPLC MS on an Agilent 1100 HPLC system with an Agilent Zorbax RP SB-
C18 (2.1 x 50 mm, 5 μm) coupled to a Bruker HTC Esquire mass spectrometer. LCMS analyses 
were performed using an acetonitrile and water (formic acid 0.1 % v/v) based gradient from 
5 – 100 % acetonitrile over 15 minutes with a flow rate of 0.5 mL/min. 
Reactions were monitored by thin-layer chromatography (TLC) with aluminium sheets 
coated with silica gel 60 F254 (Merck) and visualized by exposure to ultraviolet light (λ = 254 
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nm and λ = 365 nm). Flash column chromatography was performed using silica gel (60 Å, 40-
63 μm, Merck) and a forced flow of eluent. All yields are isolated, unless otherwise specified.  
 
7.2.8.1 Synthesis of Aniline Precursors 
 
Aniline precursors were synthesized as described in figure 37.  
 
 
Figure 37: Synthesis of Aniline Precursors. 
 
7.2.8.1.1 3-Methyl-4-Nitrobenzoic acid chloride (1) 
 
 
 
Oxalyl Chloride (22.6 mL of a 1 M solution in CH2Cl2) was added dropwise to a stirred 
solution of 3-methyl-4-nitrobenzoic acid (10.0 g, 55.2 mmol) in THF (330 mL) at RT. The 
reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated under 
reduced pressure. The resulting residue was distilled under high vacuum to give 1 as a yellow 
solid, which was used without further analysis. Yield 10.0 g, 91 %.  
 
7.2.8.1.2 N-(2-Hydroxy-6-methylphenyl)-3-methyl-4-nitrobenzamine (2a) 
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2-Hydroxy-6-methyl aniline (R1 = CH3) (8.64 g in 50 mL THF, 23.7 mmol) was added dropwise 
to a stirred solution of 1 (7.0 g, 10.8 mmol) in THF (250 mL) at RT over 10 min. The reaction 
mixture was stirred overnight for 18 h and afterwards concentrated under reduced pressure. 
The remaining residue was dissolved in ethyl acetate (250 mL) and was washed with 1 N aq. 
HCl (3 x 75 mL), sat. aq. NaHCO3 (3 x 75 mL), sat. aq. NaCl (1 x 50 mL), dried (MgSO4) and 
concentrated under reduced pressure to give 2a as a red solid. 
 
Yield: 9.51 g, 95 % 
 
1H NMR (300 MHz, d6-DMSO, 298 K) δ 9.74 (s, 1H), 9.70 (s, 1H), 8.09 (d, J = 8.4, 2.0 Hz, 1H), 
8.07 (d, J = 2.0 Hz, 1H), 7.98 (dd, J = 8.4, 2.0 Hz, 1H), 7.63 (dd, J = 8.1, 1.5 Hz 1H), 7.09-7.05 
(m, 1H), 6.94 (dd, J = 8.1, 1.5 Hz, 1H), 6.84 (td, J = 7.6, 1.4 Hz), 2.58 (s, 3H). 
 
13C NMR (75 MHz, d6-DMSO, 298 K) δ 163.7 (s), 153.3 (s), 150.4 (s), 138.4 (s), 136.8 (s), 132.7 
(s), 132.0 (d), 127.4 (d), 126.5 (d), 124.4 (d), 123.4 (s), 120.4 (d), 113.6 (d), 19.4 (q), 17.9 (q). 
 
HRMS (ESI+): Calcd for C15H14N2O2Na: 309.0846 [M+ Na]
+ Found 309.0839. 
 
7.2.8.1.3 N-(2-Hydroxyphenyl)-3-methyl-4-nitrobenzamine (2b) 
 
 
 
2-Aminophenol (R1 = H) (0.995 g in 5 mL THF, 23.7 mmol) was added dropwise to a stirred 
solution of 1 (2.0 g, 10.8 mmol) in THF (25 mL) at RT over 10 min. The reaction mixture was 
stirred overnight for 18 h. The reaction mixture was concentrated under reduced pressure 
and the remaining residue was dissolved in ethyl acetate (250 mL) and was washed with 1N 
aq. HCl (3 x 75 mL), sat. aq. NaHCO3 (3 x 75 mL), sat. aq. NaCl (1 x 50 mL), dried (MgSO4) and 
reduced under reduced pressure to give 2b as a red solid. 
 
Yield: 2.65 g, 90 % 
 
1H NMR (600 MHz, d6-DMSO, 298 K) δ 9.74 (s, 1H), 9.70 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 8.07 
(d, J = 2.0 Hz, 1H), 7.98 (dd, J = 8.3, 2.0 Hz, 1H), 7.63 (dd, J = 8.0, 1.6 Hz, 1H), 7.09-7.05 (m, 
1H), 6.94 (dd, J = 8.0, 1.4 Hz, 1H), 6.84 (td, J = 7.6, 1.4 Hz, 1H), 2.58 (s, 3H). 
 
13C NMR (200 MHz, d6-DMSO, 298 K) δ 163.7 (s), 150.5 (s), 149.9 (s), 138.4 (s), 132.7 (s), 
131.9 (d), 126.4 (d), 126.2 (d), 125.2 (s) 124.9 (d), 124.4 (d), 118.9 (d), 116.0 (d), 19.3 (q). 
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7.2.8.1.4 4-Methyl-2-(3-methyl-4-nitrophenyl benzoxazole (3a) 
 
 
 
p-toluenesulfonic acid monohydrate (12.4 g, 65.3 mmol) was added in one portion to a 
stirred suspension of 2a (8.5 g, 29.7 mmol) in toluene (300 mL) at RT. The reaction mixture 
was heated at 110 °C for 3 h. The reaction mixture was cooled and washed with sat. aq. 
NaHCO3 (3 x 50 mL), water (1 x 50 ml), sat. aq. NaCl (1 x 50 mL), dried (MgSO4) and 
concentrated under reduced pressure to give 3a as a red solid. 
 
Yield: 7.85 g, 99 % 
 
1H NMR (300 MHz, CDCl3, 298 K) δ 8.29 (d, J = 1.9 Hz 1H), 8.23 (dd, J = 8.5 Hz, 1.9 Hz, 1H), 
8.12 (d, J = 8.5 Hz 1H), 7.44 (d, J = 8.5 Hz 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.20 (dt, J = 7.4 Hz, 1H), 
2.73 (s, 3H), 2.70 (s, 3H). 
 
13C NMR (75 MHz, CDCl3, 298 K) δ 159.9 (s), 150.7 (s), 150.3 (s), 141.2 (s), 134.3 (s), 131.6 
(d), 131.3 (s), 131.2 (s), 125.8 (d) 125.7 (d), 125.5 (d), 125.3 (d), 108.0 (s), 20.4 (q), 16.5 (q). 
 
HRMS (ESI+): Calcd for C15H14N2O2Na: 309.0846 [M+ Na]
+ Found 309.0839.  
 
7.2.8.1.5 4-Methyl-2-(4-nitrophenyl benzoxazole (3b) 
 
 
 
p-toluenesulfonic acid monohydrate (6.92 g, 36.4 mmol) was added in one portion to a 
stirred suspension of 2b (4.5 g, 16.5 mmol) in toluene (200 mL) at RT. The reaction mixture 
was heated at 110°C for 3 h. The reaction mixture was cooled and washed with sat. aq. 
NaHCO3 (3 x 50 mL), water (1 x 50 ml), sat. aq. NaCl (1 x 50 mL), dried (MgSO4) and 
concentrated under reduced pressure to give 3b as a red solid. 
 
Yield: 3.92 g, 93 % 
 
1H NMR (300 MHz, CDCl3, 298 K) δ 8.28-8.26 (m, 1H), 8.21 (dd, J = 8.4 Hz, 2.1, 1H), 8.11 (d, J 
= 8.4 Hz, 1H), 7.85-7.78 (m, 1H), 7.66-7.60 (m, 1H), 7.47-7.40 (m, 2H), 2.71 (s, 3H). 
 
13C NMR (75 MHz, CDCl3, 298 K) δ 160.7 (s), 150.9 (s), 150.6 (s), 141.7 (s), 134.4 (s), 131.7 
(d), 131.0 (s), 126.2 (d), 125.8 (d) 125.4 (d), 125.1 (d), 120.5 (d), 110.9 (d), 20.4 (q). 
 
HRMS (ESI+): Calcd for C13H11N2O3: 255.0764 [M+ H]
+ Found 255.0753. 
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7.2.8.2 Synthesis of CG3 05 A02 Analogues 
 
The CG3 05 A02 Analogues were synthesized as described in figure 38.  
 
 
 
Figure 38: Synthesis of CG3 05 A02 Analogues. 
 
7.2.8.2.1 2-Methyl-4-(4-methylbenzoxazol-2-yl)benzamine (4a) 
 
 
 
3a (6.05 g, 22.5 mmol) was suspended in ethanol (300 mL) and water (50 mL). Ammonium 
chloride (6.03 g, 113 mmol), followed by iron powder (6.30 g, 113 mmol) were added both 
on one portion at RT. The reaction mixture was heated to 80 °C for 2 h. The reaction mixture 
was cooled to RT and concentrated under reduced pressure. The remaining residue was 
dissolved in ethyl acetate (500 mL) and washed with sat. aq. NaHCO3 (2 x 50 mL), sat. aq. 
NaCl (1 x 50 mL), dried (MgSO4) and again concentrated under reduced pressure. The 
residue was dry loaded onto silica gel and purified using column chromatography (SiO2) 
using a gradient elution 10% EtOAc in Cyclohexane  50 % EtOAc to give 4a as a beige solid.  
 
Yield: 4.84 g, 90 % 
 
1H NMR (300 MHz, d6-DMSO, 298 K) δ 7.79 (dd, J = 2.0 Hz 0.9 Hz, 1H), 7.76 (dd, J = 8.3 Hz, 
2.1, 1H), 7.51-7.42 (m, 1H), 7.18 (t, J = 7.7 Hz 1H), 7.12 (dt, J = 2.0 Hz 0.9 Hz, 1H), 6.74 (d, J = 
8.3 Hz, 1H), 5.70 (s, 2H), 2.54 (s, 3H), 2.16 (s, 3H). 
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13C NMR (75 MHz, d6-DMSO, 298 K) δ 162.9 (s), 150.5 (s), 149.5 (s), 141.2 (s), 129.3 (d), 
128.6 (d), 126.5 (s), 124.7 (s), 123.6 (d), 120.9 (d),113.5 (d), 113.2 (s), 107.5 (s), 17.3 (q), 16.3 
(q). 
 
HRMS (ESI+): Calcd for C15H14N2ONa: 261.0998 [M+ Na]
+ Found 261.0999. 
 
7.2.8.2.2 4-(Benzoxazol-2-yl)-2-methylaniline (4b) 
 
 
 
3b (3.42 g, 13.5 mmol) was suspended in ethanol (150 mL) and ammonium chloride (3.60 g, 
67.3 mmol), followed by iron powder (3.76 g, 67.3 mmol) were added both on one portion at 
RT. The reaction mixture was heated to 80 °C for 2 h. The reaction mixture was cooled to RT 
and concentrated under reduced pressure. The remaining residue was dissolved in ethyl 
acetate (200 mL) and washed with sat. aq. NaHCO3 (2 x 20 mL), sat. aq. NaCl (1 x 20 mL), 
dried (MgSO4) and concentrated under reduced pressure. The residue was dry loaded onto 
silica gel and purified using column chromatography (SiO2) using a gradient elution 10 % 
EtOAc in Cyclohexane  50 % EtOAc to give 4b as a colorless solid.  
 
Yield: 2.38 g, 79 % 
 
1H NMR (600 MHz, d6-DMSO, 298 K) δ 7.80 (dd, J = 2.1, 0.9 Hz, 1H), 7.76 (dd, J = 8.3, 2.1 Hz, 
1H), 7.68-7.63 (m, 2H), 7.33-7.27 (m, 2H), 6.75 (d, J = 8.3 Hz, 1H), 5.72 (s, 2H), 2.16 (s, 3H). 
 
13C NMR (200 MHz, d6-DMSO, 298 K) δ 163.6 (s), 150.6 (s), 149.9 (s), 142.1 (s), 129.3 (d), 
126.6 (d), 124.2 (d), 123.9 (d), 120.9 (s), 118.6 (d), 113.5 (d), 113.0 (s), 110.2 (d), 17.3 (q). 
 
HRMS (ESI+): Calcd for C14H13N2O: 225.1022 [M+ H]
+ Found 225.1023. 
 
7.2.8.2.3 4-(4-Methylbenzoxazol-2-yl)benzamine (4c) 
 
 
 
Polyphosphoric Acid (50 mL) was added to a round-bottomed flask and heated to 120 °C. 2-
hydroxy-6-methylaniline (5.02 g, 40.8 mmol) was added, followed by 4-Aminobenzoic acid 
(5.59 g, 40.8 mmol) with mechanical stirring. After dissolution of the solids, the reaction 
mixture was heated to 220 °C for 4 h. The reaction mixture was cooled and neutralized 
carefully with cooled sodium hydroxide (2 M) and the resulting precipitate was filtered and 
dried overnight under high vacuum (P2O5). The residue was dry loaded onto silica gel and 
purified using column chromatography (SiO2) using a gradient elution 10 % EtOAc in 
Cyclohexane  50 % EtOAc to give 4c as a colorless solid.  
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Yield: 5.48 g, 60 % 
1H NMR (600 MHz, d6-DMSO, 298 K) δ 7.89-7.85 (m, 2H), 7.45 (dt, J = 8.0 0.9 Hz, 1H),7.18 (t, 
J = 7.7 Hz 1H), 7.12 (dt, J = 7.4, 0.9 Hz, 1H), 6.72-6.69 (m, 2H), 5.94 (s, 2H), 2.53 (s, 3H). 
 
13C NMR (200 MHz, d6-DMSO, 298 K) δ 162.8 (s), 152.3 (s), 149.5 (s), 142.2 (s), 128.8 (d), 
128.6 (s), 124.7 (d) 123.6 (d), 113.5 (d), 113.0 (s), 107.5 (d), 16.2 (q). 
 
HRMS (ESI+): Calcd for C14H13N2O: 225.1022 [M+ H]
+ Found 225.1027. 
 
7.2.8.2.4 4-(Benzoxazol-2-yl)benzamine (4d) 
 
 
Polyphosphoric Acid (160 mL) was added to a round-bottomed flask and heated to 140°C. 
Aminophenol (11.55 g, 106 mmol) was added, followed by 4-Aminobenzoic acid (14.52 g, 
106 mmol) with mechanical stirring. After dissolution of the solids, the reaction mixture was 
heated to 220°C for 4 hours. The reaction mixture was cooled and neutralized carefully with 
cooled sodium hydroxide (2M) and the resulting precipitate was filtered and dried overnight 
under high vacuum (P2O5). The residue was dry loaded onto silica gel and purified using 
column chromatography (SiO2) using a gradient elution 10% EtOAc in Cyclohexane  50% 
EtOAc to give 4d as a colorless solid.  
 
Yield: 11.8 g, 53 % 
 
1H NMR (300 MHz, d6-DMSO, 298 K) δ 7.90-7.85 (m, 2H), 7.66-7.64 (m, 2H),7.34-7.27 (m, 
2H), 6.74-6.68 (m, 2H), 5.98 (s, 2H). 
 
13C NMR (75 MHz, d6-DMSO, 298 K) δ 163.6 (s), 152.5 (s), 149.8 (s), 142.1 (s), 128.9 (d), 
124.3 (d) 124.0 (d), 118.7 (d), 113.5 (d), 112.7 (s), 110.2 (d). 
 
HRMS (ESI+): Calcd for C13H11N2O: 211.0866 [M+ H]
+ Found 211.0883. 
 
7.2.8.2.5 2-Methoxy-N-(2-methyl-4-(4-methylbenzol-2-yl)phenylbenzamine (5a) 
 
 
4a (0.50 g, 2.10 mmol) was dissolved in acetonitrile (25 mL), DIPEA (914 µL, 5.13 mmol) was 
added in one portion and then 2-methoxybenzoyl chloride (423 µL in 5 mL acetonitrile, 3.15 
mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 1 h and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5a as a colorless solid. 
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Yield: 0.578 g, 74 % 
 
1H NMR (300 MHz, d6-DMSO, 298 K) δ 10.12 (s, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 2.0 
Hz, 1H), 8.06 (dd, J = 8.5, 2.0 Hz, 1H), 8.00 (d, J = 7.8, 1.8 Hz, 1H), 7.63-7.53 (m, 2H), 7.33-7.25 
(m, 2H), 4.05 (s, 3H), 2.59 (s, 3H), 2.47 (s, 3H).  
 
13C NMR (75 MHz, d6-DMSO, 298 K) δ 163.1 (s), 161.5 (s), 157.0 (s), 149.8 (s), 140.8 (s), 140.0 
(s), 133.4 (d), 131.1 (d), 129.6 (s), 129.1 (d), 128.9 (s), 125.7 (d), 125.1 (d), 124.9 (d), 121.9 
(s), 121.7 (d), 121.0 (d), 112.4 (d), 108.0 (d), 56.4 (q), 17.6 (q), 16.3 (q). 
 
LCMS (ESI) 373.34 [M+H]+ Rt = 15.6 mins (99 %) 
 
HRMS (ESI+): Calcd for C23H20N2O3Na: 395.1366 [M+ Na]
+. Found 395.1366. 
 
7.2.8.2.6 N-(2-Methyl-4-(4-methylbenzoxazol-2-yl)phenylbenzamine (5b) 
 
 
 
4b (0.688 g, 2.50 mmol) was dissolved in acetonitrile (50 mL), DIPEA (1.39 mL, 5.13 mmol) 
was added in one portion and then 2-methoxybenzoyl chloride (423 µL in 5 mL acetonitrile, 
3.15 mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 1 h and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5b as a colorless solid. 
 
Yield: 0.736 g, 86 % 
 
1H NMR (300 MHz, d6-DMSO, 298 K) δ 10.02 (s, 1H), 8.23-8.16 (m, 2H), 8.10-8.04 (m, 2H), 
8.02-7.96 (m, 2H), 7.80-7.73 (m, 2H), 7.65-7.52 (m, 3H), 7.43-7.36 (m, 2H).  
 
13C NMR (75 MHz, d6-DMSO, 298 K) δ 165.4 (s), 161.4 (s), 149.9 (s), 140.8 (s), 139.8 (s), 134.3 
(s), 133.8 (s), 131.7 (d), 129.7 (s), 129.1 (d), 128.4 (d), 127.7 (d), 126.4 (d), 125.13 (d), 125.09 
(d), 125.0 (d), 123.5 (s), 108.1 (d), 17.9 (q), 16.2 (q). 
 
HRMS (ESI+): Calcd for C22H19N2O2: 343.1441 [M+H]
+. Found 343.1438. 
 
7.2.8.2.7 N-(4-(Benzoxazol-2-yl)-2-methylphenyl)-2-methoxybenzamine (5c) 
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4b (0.688 g, 2.50 mmol) was dissolved in acetonitrile (20 mL), DIPEA (676 µL, 5.13 mmol) was 
added in one portion and then 2-methoxybenzoyl chloride (313 µL in 5 mL acetonitrile, 3.15 
mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 1 h and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5b as a colorless solid. 
 
Yield: 0.510 g, 92 % 
 
1H NMR (600 MHz, d6-DMSO, 298 K) δ 10.12 (s, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.12 (dd, J = 2.0, 
0.9 Hz, 1H), 8.07 (dd, J = 8.5, 2.0 Hz, 1H), 8.01 (dd, J = 7.5, 2.0 Hz, 1H), 7.80-7.74 (m, 2H), 7.59 
(ddd, J = 8.5, 7.5, 2.0 Hz, 1H), 7.44-7.37 (m, 2H), 7.28 (d, J = 8.5 Hz, 1H), 7.15 (td, J = 7.5 Hz, 
1H), 4.05 (s, 3H), 2.47 (s, 3H).  
 
13C NMR (200 MHz, d6-DMSO, 298 K) δ 163.1 (s), 162.2 (s), 157.0 (s), 150.1 (s), 141.6 (s), 
140.1 (s), 133.4 (d), 131.0 (d), 129.1 (d), 128.9 (s), 125.7 (d), 125.1 (d), 124.7 (d), 121.9 (s), 
121.7 (d), 121.5 (s), 121.0 (d), 119.5 (d), 112.4 (d), 110.7 (d), 56.4 (q), 17.5 (q). 
 
LCMS (ESI) 359.2 [M+H]+ Rt = 14.4 min 
  
HRMS (ESI+): Calcd for C23H19N2O: 359.1390 [M+H]
+. Found 359.1394. 
 
7.2.8.2.8 N-(4-(Benzoxazol-2-yl)-2-methylphenyl)benzamine (5d) 
 
 
 
4b (0.50 g, 2.50 mmol) was dissolved in acetonitrile (25 mL), DIPEA (388 µL, 5.13 mmol) was 
added in one portion and then benzoyl chloride (423 µL in 5 mL acetonitrile, 3.15 mmol) was 
added dropwise over 10 min with stirring at 0 °C. The reaction mixture was stirred 1 h and 
the resulting precipitate was filtered and washed with cold acetonitrile to give 5b as a 
colorless solid. 
 
Yield: 0.636 g, 87 % 
 
1H NMR (500 MHz, d6-DMSO, 298 K) δ 10.03 (s, 1H), 8.15-8.13 (m, 1H), 8.07 (dd, J = 8.3, 2.1 
Hz, 1H), 8.03-8.00 (m, 2H), 7.82-7.77 (m, 2H), 7.72 (d, J = 8.3 Hz, 1H), 7.64-7.60 (m, 1H), 7.56 
(dd, J = 8.3, 6.7 Hz, 2H), 7.45-7.39 (m, 2H), 2.40 (s, 3H).  
 
13C NMR (125 MHz, d6-DMSO, 298 K) δ 165.4 (s), 162.1 (s), 150.2 (s), 141.6 (s), 140.0 (s), 
134.3 (s), 133.9 (s), 131.8 (d), 129.2 (d), 128.4 (d), 127.7 (d), 126.4 (d), 125.3 (d), 125.2 (d), 
124.8 (d), 123.4 (s), 119.7 (d), 110.8 (d), 17.9 (q). 
 
LCMS (ESI) 329.23 [M+H]+ Rt = 13.5 mins (90 %)  
 
HRMS (ESI+): Calcd for C21H16N2O2Na: 351.1104 [M+ Na]
+. Found 351.1115. 
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7.2.8.2.9 2-Methoxy-N-(4-(4-methylbenzoxazol-2-yl)phenylbenzamine (5e) 
 
 
 
4b (0.5 g, 2.50 mmol) was dissolved in acetonitrile (25 mL), DIPEA (964 µL, 5.13 mmol) was 
added in one portion and then 2-methoxybenzoyl chloride (450 µL in 5 mL acetonitrile, 3.15 
mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 1 h and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5b as a colorless solid. 
 
Yield: 0.631 g, 79 % 
 
1H NMR (600 MHz, d6-DMSO, 298 K) δ 10.45 (s, 1H), 8.18 (d, J = 8.6 Hz, 2H), 7.99 (d, J = 8.6 
Hz, 2H), 7.64 (dd, J = 7.5, 1.8 Hz, 1H), 7.58-7.55 (m, 1H), 7.53 (ddd, J = 8.6, 7.4, 1.8 Hz 1H), 
7.30 (t, J = 7.4 Hz 1H), 7.22-7.19 (m, 2H), 7.09 (td, J = 7.4, 0.9 Hz, 1H), 3.91 (s, 3H), 2.59 (s, 
3H).  
 
13C NMR (200 MHz, d6-DMSO, 298 K) δ 165.0 (s), 161.5 (s), 156.5 (s), 149.8 (s), 142.1 (s), 
140.8 (s), 132.2 (d), 129.6 (d), 128.0 (d), 125.1 (d), 124.84 (d), 124.80 (s), 121.2 (s), 120.5 (d), 
119.7 (d), 112.0 (d), 55.9 (q), 16.2 (q). 
 
LCMS (ESI) 359.18 [M+H]+ Rt = 14.7 min 
  
HRMS (ESI+): Calcd for C22H19N2O2: 359.1390 [M+ H]
+. Found 359.1383. 
 
7.2.8.2.10 N-(4-(4-Methylbenzoxazol-2-yl)phenylbenzamine (5f) 
 
 
 
4b (0.5 g, 2.50 mmol) was dissolved in acetonitrile (25 mL), DIPEA (964 µL, 5.13 mmol) was 
added in one portion and then 2-methoxybenzoyl chloride (388 µL in 5 mL acetonitrile, 3.15 
mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 1 h and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5b as a colorless solid. 
 
Yield: 0.658g, 90 % 
 
1H NMR (500 MHz, d6-DMSO, 298 K) δ 10.58 (s, 1H), 8.19 (d, J = 8.4 Hz, 2H), 8.06 (d, J = 8.4 
Hz, 2H), 8.02-7.96 (m, 2H), 7.65-7.59 (m, 1H), 7.58-7.53 (m, 3H), 7.28 (t, J = 7.8 Hz 1H), 7.19 
(d, J = 7.4 Hz, 1H), 2.58 (s, 3H).  
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13C NMR (125 MHz, d6-DMSO, 298 K) δ 165.9 (s), 161.5 (s), 149.8 (s), 142.4 (s), 140.8 (s), 
134.6 (s), 131.8 (d), 129.6 (s), 128.4 (d), 127.9 (d), 127.8 (d), 125.1 (d), 124.8 (d), 121.4 (s), 
120.3 (d), 108.0 (d), 16.2 (q). 
 
LCMS (ESI) 329.18 [M+H]+ Rt = 13.7 min (99 %) 
 
HRMS (ESI+): Calcd for C21H16N2O2Na: 351.1104 [M+ Na]
+. Found 351.1105. 
 
7.2.8.2.11 N-(4-(benzoxazol-2-yl)phenyl)-2-methoxybenzamine (5g) 
 
 
 
4b (0.65 g, 2.50 mmol) was dissolved in acetonitrile (25 mL), DIPEA (1.34 mL, 5.13 mmol) was 
added in one portion and then 2-methoxybenzoyl chloride (623 µL in 5 mL acetonitrile, 3.15 
mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 90 min and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5b as a colorless solid. 
 
Yield: 0.883 g, 83 % 
 
1H NMR (300 MHz, d6-DMSO, 298 K) δ 10.48 (s, 1H), 8.19 (d, J = 8.8 Hz, 2H), 7.99 (d, J = 8.8 
Hz 2H), 7.81-7.73 (m, 2H), 7.65 (dd, J = 7.6, 1.8 Hz, 1H), 7.53 (ddd, J = 9.0, 7.4, 1.8 Hz, 1H), 
7.43-7.37 (m, 2H), 7.20 (d, J = 8.4 Hz, 1H), 7.09 (td, J = 7.4, 1.0 Hz, 1H), 3.91 (s, 3H).  
 
13C NMR (75 MHz, d6-DMSO, 298 K) δ 165.0 (s), 162.2 (s), 156.5 (s), 150.1 (s), 142.3 (s), 141.6 
(s), 132.2 (d), 129.6 (d), 128.2 (d), 125.2 (d), 124.8 (d), 124.7 (d), 121.1 (s), 120.5 (d), 119.7 
(d), 119.5 (d), 112.0 (d), 110.7 (d), 55.9 (q). 
 
HRMS (ESI+): Calcd for C21H16N2O3Na: 367.1053 [M+ Na]
+. Found 367.1057. 
 
7.2.8.2.12 N-(4-(Benzoxazol-2-yl)phenyl)benzamine (5h) 
 
 
 
4b (0.7 g, 2.50 mmol) was dissolved in acetonitrile (25 mL), DIPEA (1.45 mL, 5.13 mmol) was 
added in one portion and then benzoyl chloride (580 µL in 5 mL acetonitrile, 3.15 mmol) was 
added dropwise over 10 min with stirring at 0 °C. The reaction mixture was stirred 1 h and 
the resulting precipitate was filtered and washed with cold acetonitrile to give 5b as a 
colorless solid. 
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Yield: 0.836 g, 80 % 
1H NMR (300 MHz, d6-DMSO, 298 K) δ 10.59 (s, 1H), 8.23-8.16 (m, 2H), 8.10-8.04 (m, 2H), 
8.02-7.96 (m, 2H), 7.80-7.73 (m, 2H), 7.65-7.52 (m, 3H), 7.43-7.36 (m, 2H).  
 
13C NMR (75 MHz, d6-DMSO, 298 K) δ 165.9 (s), 162.2 (s), 150.1 (s), 142.5 (s), 141.6 (s), 134.6 
(s), 131.8 (d), 128.4 (d), 128.0 (d), 127.8 (d), 125.1 (d), 124.7 (d), 121.2 (s), 120.3 (d), 119.5 
(d), 110.7 (d). 
 
LCMS (ESI) 315.10 [M+H]+ Rt = 13.6 min (99 %). 
 
HRMS (ESI+): Calcd for C20H14N2O2Na: 337.0947 [M+ Na]
+. Found 337.0959 
 
7.2.8.3 Synthesis of the Control Compounds 
 
The control compounds were synthesized as described in figure 39. 
 
 
Figure 39: Synthesis of the control compounds. 
7.2.8.3.1 4-Methoxy-N-(2-methyl-4-(4-methylbenzol-2-yl)phenylbenzamine (5i) 
 
 
 
4b (0.50 g, 2.50 mmol) was dissolved in acetonitrile (25 mL), DIPEA (914 µL, 5.13 mmol) was 
added in one portion and then 2-methoxybenzoyl chloride (423 µL in 5 mL acetonitrile, 3.15 
mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 1 h and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5b as a colorless solid. 
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Yield: 0.620 g, 79 % 
 
1H NMR (600 MHz, d6-DMSO, 298 K) δ 9.84 (s, 1H), 8.11 (dd, J = 2.1, 0.9 Hz, 1H), 8.05 (dd, J = 
8.3, 2.1 Hz 1H), 8.00 (d, J = 8.8 Hz, 2H), 7.70 (m, J = 8.3 Hz, 1H), 7.58-7.56 (m, 1H), 7.30 (t, J = 
7.8 Hz, 1H), 7.22-7.20 (m, 1H), 7.08 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H), 2.60 (s, 3H), 2.39 (s, 3H).  
 
13C NMR (200 MHz, d6-DMSO, 298 K) δ 164.8 (s), 162.0 (s), 161.4 (s), 149.9 (s), 140.8 (s), 
140.0 (s), 133.7 (s), 129.68 (s), 129.64 (d), 129.1 (d), 126.35 (s), 126.30 (d), 125.11 (d), 125.04 
(d), 124.96 (d), 123.3 (s), 113.6 (d), 108.0 (d), 55.4 (q), 17.9 (q), 16.2 (q). 
 
LCMS (ESI) 373.22 [M+H]+ Rt = 13.8 min (98 %) 
 
HRMS (ESI+): Calcd for C23H21N2O3: 373.1547 [M+H]
+. Found 373.1545. 
 
7.2.8.3.2 3-Methoxy-N-(2-methyl-4-(4-methylbenzol-2-yl)phenylbenzamine (5j) 
 
 
 
4b (0.688 g, 2.50 mmol) was dissolved in acetonitrile (25 mL), DIPEA (914 µL, 5.13 mmol) was 
added in one portion and then 2-methoxybenzoyl chloride (423 µL in 5 mL acetonitrile, 3.15 
mmol) was added dropwise over 10 min with stirring at 0 °C. The reaction mixture was 
stirred 1 h and the resulting precipitate was filtered and washed with cold acetonitrile to 
give 5b as a colorless solid. 
 
Yield: 0.566 g, 72 % 
 
1H NMR (600 MHz, d6-DMSO, 298 K) δ 9.98 (s, 1H), 8.12 (d, J = 2.0 Hz, 1H), 8.05 (dd, J = 8.3, 
2.0 Hz 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.59 (dt, J = 7.8, 1.0 Hz, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.55-
7.53 (m, 1H), 7.46 (t, J = 7.8 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.22-7.19 (m, 1H), 7.18 (ddd, J = 
8.3, 2.7, 1.0 Hz, 1H), 3.84 (s, 3H), 2.59 (s, 3H), 2.39 (s, 3H).  
 
13C NMR (200 MHz, d6-DMSO, 298 K) δ 165.1 (s), 161.4 (s), 159.2 (s), 149.9 (s), 140.8 (s), 
139.7 (s), 135.7 (s), 134.0 (s), 129.7 (s), 129.7 (d), 129.6 (d), 129.1 (d), 126.5 (d), 125.12 (d), 
125.07 (d), 124.99 (d), 123.6 (s), 119.9 (d), 117.5 (d), 112.9 (d), 108.0 (d), 55.3 (q), 17.9 (q), 
16.2 (q). 
 
LCMS (ESI) 373.22 [M+H]+ Rt = 13.9 min (95 %) 
 
HRMS (ESI+): Calcd for C23H21N2O3: 373.1547 [M+H]
+. Found 373.1551. 
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7.2.8.3.3 N-(2-Methyl-4-(4-methylbenzoxazol-2-yl)phenyl)acetamide (6) 
 
 
4b (0.25 g, 2.50 mmol) was dissolved in acetonitrile (15 mL), DIPEA (817 µL, 5.13 mmol) was 
added in one portion and then acetyl chloride (224 µL, 3.15 mmol) was added dropwise over 
10 min with stirring at 0 °C. The reaction mixture was stirred 3 h and reaction mixture. The 
residue purified using column chromatography (SiO2) using a gradient elution 10 % EtOAc in 
Cyclohexane  75 % EtOAc to give 6 as a colorless solid.  
 
Yield: 83 mg, 31 % 
 
1H NMR (400 MHz, d6-DMSO, 298 K) δ 9.41 (s, 1H), 8.03 (d, J = 2.1 Hz 1H), 7.98 (dd, J = 8.5, 
2.1 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.28 (t, J = 7.8 Hz, 1H), 7.19 (dt, J = 
7.5, 1.0 Hz, 1H), 2.57 (s, 3H), 2.35 (s, 3H), 2.13 (s, 3H).  
 
13C NMR (100 MHz, d6-DMSO, 298 K) δ 166.6 (s), 161.4 (s), 149.8 (s), 140.8 (s), 139.9 (s), 
130.9 (s), 129.6 (s), 129.1 (d), 125.09 (d), 125.08 (d), 124.9 (d), 124.1 (d), 108.0 (d), 23.6 (q), 
17.8 (q), 16.2 (q). 
 
HRMS (ESI+): Calcd for C17H16N2O2Na: 303.1104 [M+ Na]
+. Found 303.1106. 
 
7.2.8.3.4 2-Methoxy-N-methyl-N-(2-methyl-4-(4-methylbenzol-2-yl)phenylbenzamine (7) 
 
 
 
5a (0.438 mg, 0.934 mmol) was dissolved in dry THF (15 mL) under argon at room 
temperature. Subsequently, the reaction mixture was cooled to 0 °C and potassium t-
butoxide (934 µL of a 1M solution in tBuOH, 0.934 mmol) was added dropwise over 10 min. 
The reaction mixture was maintained at 0 °C for further 30 min, after which time methyl 
iodide (64 µL, 1.03 mmol) was added in one portion. The reaction mixture was allowed to 
warm to RT and stirred overnight for 16 h. The reaction mixture was quenched with water 
and concentrated under reduced pressure. The resulting residue was dissolved in ethyl 
acetate (100 mL) and washed with water (2 x 20 mL) and sat. aq. NaCl (1 x 10 mL), dried 
(MgSO4) and concentrated under reduced pressure. The residue was purified using column 
chromatography (SiO2) using a gradient elution 20 % EtOAc in cyclohexane  50 % EtOAc to 
give 7 as a colorless solid.  
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Yield: 280 mg, 78 % 
1H NMR (2.5:1 rotamer ratio, asterisks denote minor rotamer peaks, 600 MHz, d6-DMSO, 
298 K) δ 8.17* (d, J = 2.1 Hz, 1H), 8.11* (d, J = 8.1, 2.1 Hz, 1H), 7.95 (d, J = 2.1 Hz, 1H), 7.78 (d, 
J = 8.1 Hz, 1H), 7.60-7.57* (m, 1H), 7.51 (dt, J = 8.1, 0.9 Hz, 2 x 1H), 7.47* (ddd, J = 8.3, 7.4, 
1.7 Hz, 1H), 7.37* (d, J = 7.3 Hz, 1H), 7.32* (t, J = 7.8 Hz, 1H), 7.30-7.26 (m, 2 x 1H), 7.28 (t, J = 
7.8 Hz, 2 x 1H), 7.24-7.21 (m, 1H), 7.19 (dt, J = 7.5, 1.0 Hz, 1H),  7.17-7.15* (m, 1H), 7.15* (dd, 
J = 1.7, 0.9 Hz, 1H), 7.14* (d, J = 1.7 Hz, 1H), 7.08* (td, J = 7.4, 0.9 Hz, 1H), 6.80 (td, J = 7.4, 
0.9 Hz, 1H), 6.78-6.75 (m, 1H), 3.91* (s, 3H), 3.64 (s, 3H), 3.27 (s, 3H), 3.06* (s, 3H), 2.60* (s, 
3H), 2.54 (s, 3H), 2.39* (s, 3H), 2.35 (s, 3H).  
13C NMR (asterisks denote minor rotamer peaks, 200 MHz, d6-DMSO, 298 K) δ 167.7 (s), 
161.1* (s), 160.8 (s), 155.0 (s), 154.6* (s), 150.0* (s), 149.9 (s), 145.2* (s), 144.9 (s), 140.7* 
(s), 140.6 (s), 136.8* (s), 136.3 (s), 130.7* (d), 130.3 (d), 129.9* (s), 129.8 (s), 129.5 (d), 
129.4* (d), 129.2 (d), 128.4 (d), 125.4 (s), 125.3 (s), 125.21 (d), 125.19 (d), 125.16 (d), 124.7 
(d), 120.8* (d), 119.7 (d), 111.5* (d), 110.8 (d), 108.1* (d), 108.0 (d), 55.7* (q), 54.9 (q), 38.4* 
(q), 35.6 (q), 17.3 (q), 17.2* (q), 16.2 (q), 16.1* (q). 
 
LCMS (ESI) 387.27 [M+H]+ Rt = 13.7 min (99 %) 
 
7.2.9 Handling of compounds 
 
The small molecules used during the screening as well as the re-synthesized hits and 
derivatives were dissolved in anhydrous DMSO. The ComGenex library compounds were 
stored as 10 mM stock solutions as well as ready-to-use 2 mM solutions in 96-well plates at – 
20 °C. Solid compound stock powders of in-house synthesized compounds were stored at 4 
°C in the dark. 10 mM stock solutions of the in-house synthesized compounds were stored at 
room temperature in the dark. The compounds were synthesized by Dr. Jeffrey Hannam 
from the Famulok lab. 
 
7.2.9.1 HPLC-MS 
 
Compounds were analyzed with HPLC-MS to check their mass and purity. The samples were 
diluted in 20 % acetonitrile (LCMS grade) to a concentration of 0.1 mg/mL. The samples were 
analyzed using an Agilent Zorbax SB-C18 (2.1 x 5 mm) column followed by a Bruker Esquire 
HTC mass spectrometer with atmospheric pressure interface-electrospray ionisation (API-
ESI). Compounds and impurities were detected by absorption measurement at 254 nm. A 
gradient of 20 – 100 % acetonitrile was run over 20 minutes with a flow rate of 0.4 
mL/minute.  
 
Eluent A: 
0.1 % formic acid in water (LCMS grade) 
 
Eluent B: 
Acetonitrile (LCMS grade) 
 
7.2.9.2 Determination of solubility 
 
The solubility of the compounds in buffer was determined by absorption measurements277. 
The wavelength of maximal absorption for the specific compounds was identified in an 
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absorption scan using the NanoDrop 2000 and 50 µM of the compound in buffer with 2 % 
final DMSO concentration. A serial dilution of the compound ranging from 200 µM to 0.1 µM 
was prepared in the buffer of interest with 2 % DMSO. The absorption of the individual 
samples was measured at the previously determined wavelength. The samples were then 
incubated at room temperature for 20 minutes followed by centrifugation at 20 000 x g for 
10 minutes. Finally the absorption of the supernatants was measured at the same 
wavelength as before. A decrease in the absorption signal compared to before centrifugation 
indicated that precipitation or aggregation of the compound had occurred. 
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8 Appendix 
 
8.1 Sequences 
 
8.1.1 Plasmid maps 
 
pDL2 
 
 
 
Supporting figure 1: Plasmid map of pDL2.  
 
pET19mod 
 
 
 
Supporting figure 2: Plasmid map of pET19mod. The plasmid contains the DrrA construct as insert. 
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pET15b 
 
 
 
Supporting figure 3: Plasmid map of pET15b. 
 
pET52b(+) 
 
 
 
Supporting figure 4: Plasmid map of pET52b(+). 
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pET SUMO 
 
 
 
Supporting figure 5: Plasmid map of pET SUMO. 
 
pFBHT 
 
 
 
Supporting figure 6: Plasmid map of pFBHT. 
 
pET SUMO
5643 bp
PCR product
SUMO
His Tag
T7
AvaI (1939)
ClaI (2122)
EcoR I (572)
HindIII (659)
SmaI (194 1)
XmaI (1939)
ApaLI (2699 )
ApaLI (3196 )
ApaLI (5131)
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pAB1 
 
 
 
Supporting figure 7: Plasmid map of pAB1. 
 
pGEX-2T 
 
 
 
Supporting figure 8: Plasmid map of pGEX-2T. 
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pIBA101HT 
 
 
 
Supporting figure 9: Plasmid map of pIBA101HT. 
 
pMAL-C2 
 
 
Supporting figure 10: Plasmid map of pMAL-C2. 
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8.1.2 Protein sequences 
 
ARNO-Sec7 
 
MASRGSHHHH HHGAGDRGPE FENLYFQSET RNRKMAMGRK KFNMDPKKGI QFLVENELLQ      
NTPEEIARFL YKGEGLNKTA IGDYLGEREE LNLAVLHAFV DLHEFTDLNL VQALRQFLWS      
FRLPGEAQKI DRMMEAFAQR YCLCNPGVFQ STDTCYVLSF AVIMLNTSLH NPNVRDKPGL      
ERFVAMNRGI NEGGDLPEEL LRNLYDSIRN EPFKIP 
 
DrrA 
 
MVTRIENLEN AKKLWDNANS MLEKGNISGY LKAANELHKF MKEKNLKEDD LRPELSDKTI      
SPKGYAILQS LWGAASDYSR AAATLTESTV EPGLVSAVNK MSAFFMDCKL SPNERATPDP      
DFKVGKSKIL VGIMQFIKDV ADPTSKIWMH NTKALMNHKI AAIQKLERSN NVNDETLESV      
LSSKGENLSE YLSYK 
 
IR-ICD 
 
MSHHHHHHEN LYFQGARKRQ PDGPLGPLYA SSNPEYLSAS DVFPCSVYVP DEWEVSREKI      
TLLRELGQGS FGMVYEGNAR DIIKGEAETR VAVKTVNESA SLRERIEFLN EASVMKGFTC      
HHVVRLLGVV SKGQPTLVVM ELMAHGDLKS YLRSLRPEAE NNPGRPPPTL QEMIQMAAEI      
ADGMAYLNAK KFVHRDLAAR NCMVAHDFTV KIGDFGMTRD IYETDYYRKG GKGLLPVRWM      
APESLKDGVF TTSSDMWSFG VVLWEITSLA EQPYQGLSNE QVLKFVMDGG YLDQPDNCPE      
RVTDLMRMCW QFNPKMRPTF LEIVNLLKDD LHPSFPEVSF FHSEENKAPE SEELEMEFED      
MENVPLDRSS HCQREEAGGR DGGSSLGFKR SYEEHIPYTH MNGGKKNGRI LTLPRSNPS 
 
NΔ17 Arf1 
 
MGSSHHHHHH SSGLVPRGSH MCMRILMVGL DAAGKTTILY KLKLGEIVTT IPTIGFNVET      
VEYKNISFTV WDVGGQDKIR PLWRHYFQNT QGLIFVVDSN DRERVNEARE ELMRMLAEDE      
LRDAVLLVFA NKQDLPNAMN AAEITDKLGL HSLRHRNWYI QATCATSGDG LYEGLDWLSN      
QLRNQK 
 
Rab1 
 
MNPEYDYLFK LLLIGDSGVG KSCLLLRFAD DTYTESYIST IGVDFKIRTI ELDGKTIKLQ      
IWDTAGQERF RTITSSYYRG AHGIIVVYDV TDQESYANVK QWLQEIDRYA SENVNKLLVG      
NKSDLTTKKV VDNTTAKEFA DSLGIPFLET SAKNATNVEQ AFMTMAAEIK KRMGPGAASG      
GERPNLKIDS TPVKPAGGGC C 
 
Rab5a 
 
MGSSHHHHHH SSGLVPRGSH MKICQFKLVL LGESAVGKSS LVLRFVKGQF HEFQESTIGA      
AFLTQTVCLD DTTVKFEIWD TAGQERYHSL APMYYRGAQA AIVVYDITNE ESFARAKNWV      
KELQRQASPN IVIALSGNKA DLANKRAVDF QEAQSYADDN SLLFMETSAK TSMNVNEIFM      
AIAKKLPKN 
 
Rabex-5GEF 
 
MGHHHHHHGS IETDRVSKEF IEFLKTFHKT GQEIYKQTKL FLEGMHYKRD LSIEEQSECA      
QDFYHNVAER MQTRGKVPPE RVEKIMDQIE KYIMTRLYKY VFCPETTDDE KKDLAIQKRI      
RALRWVTPQM LCVPVNEDIP EVSDMVVKAI TDIIEMDSKR VPRDKLACIT KCSKHIFNAI      
KITKNEPASA DDFLPTLIYI VLKGNPPRLQ SNIQYITRFC NPSRLMTGED GYYFTNLCCA      
VAFIEKLDAQ SLNLSQEDFD RYMSGQTSP 
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Rac1 
 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID      
GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV      
DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK      
KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGSMQAI KCVVVGDGAV      
GKTCLLISYT TNAFPGEYIP TVFDNYSANV MVDGKPVNLG LWDTAGQEDY DRLRPLSYPQ      
TDVFLICFSL VSPASFENVR AKWYPEVRHH CPNTPIILVG TKLDLRDDKD TIEKLKEKKL      
TPITYPQGLA MAKEIGAVKY LECSALTQRG LKTVFDEAIR AVLCPPPVKK RKRKCLLL 
 
Rac2 
 
MGSSHHHHHH GSGLVPRGSA SMSDSEVNQE AKPEVKPEVK PETHINLKVS DGSSEIFFKI      
KKTTPLRRLM EAFAKRQGKE MDSLRFLYDG IRIQADQTPE DLDMEDNDII EAHREQIGGM      
QAIKCVVVGD GAVGKTCLLI SYTTNAFPGE YIPTVFDNYS ANVMVDSKPV NLGLWDTAGQ      
EDYDRLRPLS YPQTDVFLIC FSLVSPASYE NVRAKWFPEV RHHCPSTPII LVGTKLDLRD      
DKDTIEKLKE KKLAPITYPQ GLALAKEIDS VKYLECSALT QRGLKTVFDE AIRAVLCPQP      
TRQQKRACSL L 
 
Rin1C 
 
MSHHHHHHEN LYFQGAMEFV GYRVPAGSGP SLPPMPSLQE VDCGSPSSSE EEGVPGSRGS 
PATSPHLGRR RPLLRSMSAA FCSLLAPERQ VGRAAAALMQ DRHTAAGQLV QDLLTQVRAG      
PEPQELQGIR QALSRARAML SAELGPEKLL SPKRLEHVLE KSLHCSVLKP LRPILAARLR      
RRLAADGSLG RLAEGLRLAR AQGPGAFGSH LSLPSPVELE QVRQKLLQLL RTYSPSAQVK      
RLLQACKLLY MALRTQEGEG AGADEFLPLL SLVLAHCDLP ELLLEAEYMS ELLEPSLLTG      
EGGYYLTSLS ASLALLSGLG QAHTLPLSPV QELRRSLSLW EQRRLPATHC FQHLLRVAYQ      
DPSSGCTSKT LAVPPEASIA TLNQLCATKF RVTQPNTFGL FLYKEQGYHR LPPGALAHRL      
PTTGYLVYRR AEWPETQGAV TEEEGSGQSE ARSRGEEQGC QGDGDAGVKA SPRDIREQSE      
TTAEGGQGQA QEGPAQPGEP EAEGSRAAEE 
 
Rin1-TS 
 
MESPGESGAG SPGAPSPSSF TTGHLAREKP AQDPLYDVPN ASGGQAGGPQ RPGRVVSLRE      
RLLLTRPVWL QLQANAAAAL HMLRTEPPGT FLVRKSNTRQ CQALCMRLPE ASGPSFVSSH      
YILESPGGVS LEGSELMFPD LVQLICAYCH TRDILLLPLQ LPRAIHHAAT HKELEAISHL      
GIEFWSSSLN IKAQRGPAGG PVLPQLKARS PQELDQGTGA ALCFFNPLFP GDLGPTKREK      
FKRSFKVRVS TETSSPLSPP AVPPPPVPVL PGAVPSQTER LPPCQLLRRE SSVGYRVPAG      
SGPSLPPMPS LQEVDCGSPS SSEEEGVPGS RGSPATSPHL GRRRPLLRSM SAAFCSLLAP      
ERQVGRAAAA LMQDRHTAAG QLVQDLLTQV RAGPEPQELQ GIRQALSRAR AMLSAELGPE      
KLLSPKRLEH VLEKSLHCSV LKPLRPILAA RLRRRLAADG SLGRLAEGLR LARAQGPGAF      
GSHLSLPSPV ELEQVRQKLL QLLRTYSPSA QVKRLLQACK LLYMALRTQE GEGAGADEFL      
PLLSLVLAHC DLPELLLEAE YMSELLEPSL LTGEGGYYLT SLSASLALLS GLGQAHTLPL      
SPVQELRRSL SLWEQRRLPA THCFQHLLRV AYQDPSSGCT SKTLAVPPEA SIATLNQLCA      
TKFRVTQPNT FGLFLYKEQG YHRLPPGALA HRLPTTGYLV YRRAEWPETQ GAVTEEEGSG      
QSEARSRGEE QGCQGDGDAG VKASPRDIRE QSETTAEGGQ GQAQEGPAQP GEPEAEGSRA      
AEEENLYFQG MDEKTTGWRG GHVVEGLAGE LEQLRARLEH HPQGQREPSG  
 
TEV Protease 
 
MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI      
IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK      
DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK      
DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK      
VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL      
GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVDE      
ALKDAQTNSS SNNNNNNNNN NLGIEGRGEN LYFQGHHHHH HHGESLFKGP RDYNPISSTI      
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CHLTNESDGH TTSLYGIGFG PFIITNKHLF RRNNGTLLVQ SLHGVFKVKN TTTLQQHLID      
GRDMIIIRMP KDFPPFPQKL KFREPQREER ICLVTTNFQT KSMSSMVSDT SCTFPSSDGI      
FWKHWIQTKD GQCGSPLVST RDGFIVGIHS ASNFTNTNNY FTSVPKNFME LLTNQEAQQW      
VSGWRLNADS VLWGGHKVFM VKPEEPFQPV KEATQLMNRR RRR 
 
Tiam1DHPH 
 
MASWSHPQFE KGALEVLFQG PGRQLSDADK LRKVICELLE TERTYVKDLN CLMERYLKPL      
QKETFLTQDE LDVLFGNLTE MVEFQVEFLK TLEDGVRLVP DLEKLEKVDQ FKKVLFSLGG      
SFLYYADRFK LYSAFCASHT KVPKVLVKAK TDTAFKAFLD AQNPRQQHSS TLESYLIKPI      
QRVLKYPLLL RELFALTDAE SEEHYHLDVA IKTMNKVASH INEMQKIHEE FGAVFDQLIA      
EQTGEKKEVA DLSMGDLLLH TSVIWLNPPA SLGKWKKEPE LAAFVFKTAV VLVYKDGSKQ      
KKKLVGSHRL SIYEEWDPFR FRHMIPTEAL QVRALPSADA EANAVCEIVH VKSESEGRPE      
RVFHLCCSSP ESRKDFLKSV HSILRDKHRR QLLKTEVDAA AELALVPRGS SAHHHHHHHH       
HH 
 
Vav1 
 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID      
GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV      
DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKQQYIA      
WPLQGWQATF GGGDHPPKSD LVPRGSDYDI PTTENLYFQG AHMGGSMTEY DKRCCCLREI      
QQTEEKYTDT LGSIQQHFLK PLQRFLKPQD IEIIFINIED LLRVHTHFLK EMKEALGTPG      
AANLYQVFIK YKERFLVYGR YCSQVESASK HLDRVAAARE DVQMKLEECS QRANNGRFTL      
RDLLMVPMQR VLKYHLLLQE LVKHTQEAME KENLRLALDA MRDLAQCVNE VKRDNETLRQ      
ITNFQLSIEN LDQSLAHYGR PKIDGELKIT SVERRSKMDR YAFLLDKALL ICKRRGDSYD      
LKDFVNLHSF QVRDDSSGDR DNKKWSHMFL LIEDQGAQGY ELFFKTRELK KKWMEQFEMA      
ISNIYPENAT ANGHDFQMFS FEETTSCKAC QMLLRGTFYQ GYRCHRCRAS AHKECLGRVP      
PCGRHGQDFP GTM 
 
8.2 Original gels and blots 
 
8.2.1 Protein expression and purification 
 
Expression and purification of Rab5a 
 
 
 
Supporting figure 11: Expression of Rab5a. Different volumes of the same samples have been loaded. Un-
labelled original coomassie gel. 
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Supporting figure 12: Purification of Rab5a. Un-labelled original coomassie stained gel. 
 
Purification of Rin1C 
 
 
 
Supporting figure 13: Ni-NTA affinity chromatography of Rin1C. Un-labelled original coomassie stained gel. 
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Supporting figure 14: First part of the Rin1C size exclusion chromatography. Un-labelled original coomassie 
stained gel. 
 
 
 
Supporting figure 15: Second part of the Rin1C size exclusion chromatography. Un-labelled original coomassie 
stained gel. 
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Purification of Rin1-TS 
 
 
 
Supporting figure 16: Purification of Rin1-TS. Un-labelled original coomassie stained gel. 
 
Expression and purification of Rabex-5GEF 
 
 
 
Supporting figure 17: Expression of Rabex-5GEF and Rab5c. The right half of this gel contains samples 
corresponding to a simultaneously performed expression of Rab5c. Data covering Rab5c have not been used in 
this thesis. Un-labelled original coomassie stained gel. 
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Supporting figure 18: Purification of Rabex-5GEF. Un-labelled original coomassie stained gel. 
 
Expression of Rab1, DrrA, Vav1 and Tiam1DHPH 
 
 
 
Supporting figure 19: Expression of Rab1, DrrA, Vav1 and Tiam1DHPH. This un-labelled original gel contains 
samples corresponding to four protein expressions that have been dealt separately with in this thesis. In the 
results part it is therefore cut and shown in four parts.  
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Purification of Rab1 
 
 
 
Supporting figure 20: First part of the Rab1 purification. Ni-NTA affinity chromatography and reverse Ni-NTA 
affinity chromatography. Un-labelled original coomassie stained gel. 
 
 
 
Supporting figure 21: Second part of the Rab1 purification. Size exclusion chromatography. Un-labelled 
original coomassie stained gel. 
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Purification of DrrA 
 
 
 
Supporting figure 22: Purification of DrrA. Un-labelled original coomassie stained gel. 
 
Expression of Rac1 and Rac2 
 
 
 
Supporting figure 23: Expression of Rac1 and Rac2. This un-labelled original gel contains samples 
corresponding to both protein expressions that have been dealt separately with in this thesis. In the results 
part it is therefore cut and shown in two parts. Two different volumes of the same samples have been loaded. 
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Purification of Rac2 
 
 
 
Supporting figure 24: Purification of Rac2. Un-labelled original coomassie stained gel. 
 
Purification of Tiam1DHPH 
 
 
 
Supporting figure 25: Purification of Tiam1DHPH. Un-labelled original coomassie stained gel. 
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Supporting Figure 26: Final sample of Tiam1DHPH. The left side of this gel contains samples from an unrelated 
experiment performed by C. Sieg from the Famulok group. Un-labelled original coomassie stained gel. 
 
Purification of Rac1 
 
 
 
Supporting figure 27: Purification of Rac1. Un-labelled original coomassie stained gel. 
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Purification of Vav1 
 
 
 
Supporting figure 28: Purification of Vav1. Un-labelled original coomassie stained gel. 
 
8.2.2 Aggregation assay 
 
 
 
Supporting figure 29: Aggregation assay with the compounds CG3 05 A02 and CG6 25 G08. This Western blot 
was originally prepared to compare an aggregator (CG6 25 G08) with a non-aggregator (CG3 05 A02). All the 
samples have been loaded three times in the same order. Only the marker and the three lanes next to it have 
been shown in the results part. The lane next to those three contains the CG6 25 G08 sample. The colours have 
been inverted in the blot shown in the results part to match it with the other aggregation assay results. Un-
labelled original anti-His5 Western blot.  
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Supporting figure 30: Aggregation assay with the compounds CG55 08 H06, CG6 24 G06 and CG6 25 G08. Un-
labelled original anti-His5 Western blot.  
 
8.2.3 The insulin receptor auto-phosphorylation assay 
 
 
 
Supporting figure 31: Coomassie gel of the insulin receptor auto-phosphorylation assay. The un-labelled 
original coomassie stained gel shows that equal amounts of IR-ICD have been loaded. 
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Supporting figure 32: Western blot of the insulin receptor auto-phosphorylation assay. Un-labelled original 
anti-phospho-tyrosine Western blot. 
 
8.2.4 Influence of CG3 05 A02 on the ABL1-mediated Rin1 phosphorylation 
 
 
 
Supporting figure 33: Coomassie gel of the ABL1-mediated Rin1 phosphorylation assay. The un-labelled 
original coomassie stained gel shows that equal amounts of Rin1-TS and ABL1 have been loaded. The two 
marker lanes on the right side have been cut in the results part.  
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Supporting figure 34: Western blot of the ABL1-mediated Rin1 phosphorylation assay. Un-labelled original 
anti-phospho-tyrosine Western blot. The two marker lanes on the right side have been cut in the results part. 
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8.3 Structures of the 26 secondary hits 
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Supporting figure 35: Structures of the 26 secondary hits. a – j: Compounds that were active when tested from 
library stock solutions. These compounds are described in the results part. k – z: Compounds that were inactive 
when tested from library stock solutions and excluded from further analysis. 
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8.4 Raw data of the IC50 measurements 
 
8.4.1 Secondary hits 
 
 
 
Supporting figure 36: Raw data of the IC50 measurements. The linear phases of the reactions (first 300 
seconds) were fitted and the corresponding slopes were calculated. Those slopes were used to generate the 
plots shown in the results part.  
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8.4.2 SAR compounds 
 
8.4.2.1 Linear fits 
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Supporting figure 37: Raw data of the SAR studies. No inhibition could be found for the compounds 010A (a), 
066A (b), 071A (d), 099A (e), 146A (h), 148A (i), 160A (j), 163A (l) and 179A (q). For the compounds 068A (c), 
103A (f), 137B (g), 162A (k), 165A (m), 166A (n), 167A (o) and 170A (p) the linear phases (the first 300 s) were 
fitted and the corresponding slopes were calculated. Those slopes were used to generate the plots shown in 
8.5.2.2. 
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8.4.2.2 IC50 calculations 
 
 
 
Supporting figure 38: IC50 calculations for the active SAR compounds. The slopes calculated from the linear fits 
shown in 8.4.2.1 were plotted against the logarithmic compound concentrations to calculate the IC50. 
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8.4.3 CG3 05 A02 in the Rin1C/Rab5a Bodipy-FL-GTP nucleotide exchange assay 
 
 
 
Supporting figure 39: Raw data of the IC50 measurement for CG3 05 A02 in the Bodipy-FL-GTP nucleotide 
exchange assay. The linear phase was fitted to calculate the slopes used for the IC50 calculation shown in the 
results part.  
 
8.4.4 CG3 05 A02 in the Rin1C/Rab5a Bodipy-FL-GDP release assay 
 
 
 
Supporting figure 40: Raw data of the IC50 measurement for CG3 05 A02 in the Bodipy-FL-GDP release assay. 
The linear phase was fitted to calculate the slopes used for the IC50 calculation shown in the results part.  
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8.5 Solubility of the CG3 05 A02 derivatives 
 
Table 25: Determination of the solubility of 068A. 
Concentration [µM] A350 before centrifugation A350 after centrifugation 
200 0.13 0.004 
100 0.097 0.003 
50 0.031 0.001 
25 0.012 0.004 
12.5 0.029 0.004 
6.25 0.010 0.005 
3.13 0.010 0.005 
1.6 0.004 0.004 
 
Table 26: Determination of the solubility of 137B. 
Concentration [µM] A350 before centrifugation A350 after centrifugation 
200 0.276 0.002 
100 0.171 0.003 
50 0.101 0.002 
25 0.042 0.001 
12.5 0.025 0.002 
6.25 0.016 0.003 
3.13 0.007 0.003 
1.6 0.007 0.001 
 
8.6 Bodipy-TR-GTP binding to Rab5a 
 
 
Supporting figure 41: Raw data showing the loading of Rab5a with Bodipy-TR-GTP. Rab5a was loaded with 
Bodipy-TR-GTP in presence of EDTA and different concentrations of CG3 05 A02 in absence of a GEF. A bi-
phasic increase in the fluorescence signal can be seen. First the signal increases very fast for about 100 
seconds. This linear phase has been used to calculate the slopes depicted in the results part. It is followed by a 
phase showing signs of saturation and then by another, slower, linear signal increase. This second linear phase 
has been fitted and is shown in shades of blue. It has not been used in the analysis shown in the results part, 
although the conclusions would have been the same, namely that there is no effect of CG3 05 A02 on the 
binding of Bodipy-TR-GTP to Rab5a. This bi-phasic signal increase could be explained with a phenomenon based 
on equilibration of the two isoforms of Bodipy-TR-GTP as has already been described by Guo et al.129 for mant-
GDP. 
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8.7 IC50 of CG3 05 A02 in the Rabex-5GEF/Rab5a Bodipy-TR-GTP nucleotide 
exchange assay 
 
 
 
Supporting figure 42: IC50 calculation of the compound CG3 05 A02 in the Rabex-5GEF/Rab5a Bodipy-TR-GTP 
nucleotide exchange assay. Different concentrations of CG3 05 A02 were tested. The data obtained in the first 
300 s (a) was fitted linearly to calculate the slopes depicted in b.  
 
8.8 MST binding studies 
 
In order to perform microscale thermophoresis (MST) experiments, the proteins Rin1C and 
Rab5a were labelled with Alexa-647 (NHS-ester) by addition of a 10-fold excess of Alexa-647 
(NHS-ester) over the proteins, respectively, in labelling buffer. The samples were incubated 
on ice for 1 h. Free dye was then removed using NAP-5 columns equilibrated with elution 
buffer. Elution buffer was also used to elute the labelled proteins. The degree of labelling 
was afterwards calculated using the following equation: 
 
𝐷𝑂𝐿 =
𝐴650 ∙ 𝜀𝑃𝑟𝑜𝑡𝑒𝑖𝑛
𝐴𝑃𝑟𝑜𝑡𝑒𝑖𝑛 ∙ 𝜀𝐴𝑙𝑒𝑥𝑎−647
 
 
239000 is the extinction coefficient ε of Alexa-647, εProtein is the extinction coefficient of the 
protein-to-be-labelled, A650 is the absorption of the sample at 650 nm and AProtein is the 
absorption of the protein without the dye. AProtein can be calculated as follows: 
 
𝐴𝑃𝑟𝑜𝑡𝑒𝑖𝑛 = 𝐴280 − 𝐴650 ∙ 𝐶𝐹 
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With A280 being the absorption of the sample at 280 nm and CF being 0.03, a correction 
factor for absorption readings, specific for Alexa-647.  
 
Table 27: Buffers for Alexa-647 (NHS-ester) labelling. 
Buffer Composition 
Labelling Buffer 50 mM HEPES, pH 8 
150 mM NaCl 
1 mM MgCl2 
5 % Glycerol 
Elution Buffer 50 mM HEPES, pH 7.5 
150 mM NaCl 
1 mM MgCl2 
5 % Glycerol 
 
In the MST experiments CG3 05 A02 concentrations from 0 – 200 µM were tested with a 
final DMSO concentration of 2 % in nucleotide exchange buffer (cp. section 7.2.3.1). 50 nM 
of labelled Rab5a and 100 nM of labelled Rin1C were used, respectively. When the 
GEF/GTPase complex was analysed, 1 µM of un-labelled Rab5a and 200 nM of labelled Rin1C 
were used. The compound was pre-diluted in DMSO before the protein samples were mixed 
with the compound dilutions. The samples were aspirated in standard coated glass 
capillaries (NanoTemper) and then measured using 40 % LED power (red) and 20 % MST 
power. Thermophoresis and temperature jump were included in the evaluation shown in the 
supporting figures 43 and 44.  
 
 
 
Supporting figure 43: MST binding studies for CG3 05 A02 on Rin1C and Rab5a. The compound was tested in 
concentrations between 0 and 200 µM on each labelled protein. Compound concentrations > 50 µM resulted in 
deformed thermophoresis curves (cp. a), probably due to compound aggregation, and were therefore excluded 
from the analysis. No concentration-dependent binding to any of the proteins could be detected in 
concentrations < 50 µM (b).  
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Supporting figure 44: MST binding studies for CG3 05 A02 on the complex between Rin1C and Rab5a. The 
compound was tested in concentrations between 0 and 200 µM on 1 µM un-labelled Rab5a and 200 nM 
labelled Rin1C. Compound concentrations > 50 µM resulted in deformed thermophoresis curves (cp. a), 
probably due to compound aggregation, and were therefore excluded from the analysis (grey dots, b). No 
concentration-dependent binding to the protein complex could be detected in concentrations < 50 µM (b).  
 
8.9 Expression, purification and nucleotide exchange activity of GAPVD1 
 
GAPVD1 was expressed in E. coli and the protein expression was monitored on an SDS-PAGE 
gel as described in sections 7.2.1.1. It was then purified by Ni-NTA affinity chromatography, 
reverse Ni-NTA binding and size exclusion chromatography. The expression and the 
purification were analysed at every step as shown on the gels depicted in the supporting 
figure 45.  
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Supporting figure 45: Expression and purification of GAPDV1. A pre-stained molecular weight marker has 
been loaded in lane 1 on each gel. a: The protein expression was monitored on this 15 % SDS-PAGE gel. The 
lanes 2 and 3 show 3 µL of an E. coli whole-cell lysate before (lane 2) and after (lane 3) induction of the 
expression with IPTG. In lanes 4 and 5 5 µL of the lysates have been loaded. 7.5 µL have been loaded in the 
lanes 6 and 7 and the lanes 8 and 9 contain 10 µL of the lysates before and after IPTG induction. After induction 
a strong band can be seen approx. at the height of the 25 kDa marker band. The expected molecular weight of 
GAPVD1 is supposed to be ∼ 31 kDa, it therefore runs a little low in the gel, what might be due to its 
hydrodynamic properties. b: 15 % SDS-PAGE gel showing step by step the GAPVD1 purification via NI-NTA 
affinity chromatography. The cleared lysate is shown in lane 2. Lane 3 shows the insoluble cell debris from the 
pellet after the lysate was cleared. The unbound material after Ni-NTA binding (flow-through) is shown in lane 
4. Lane 5 shows the washing fraction and lane 6 contains the eluate. Unfortunately a lot of the protein of 
interest appears to be insoluble and can be seen in the pellet sample. There is, however, some amount to be 
found in the eluate, although it is not very pure. c: 15 % SDS-PAGE gel analysing the reverse Ni-NTA binding and 
TEV digestion of GAPVD1. Lane 2 shows the eluate as it was already shown in lane 6 in b. The sample after TEV 
digestion is shown in lane 3. Lane 4 shows the unbound material after reverse Ni-NTA binding. The lanes 5 and 
6 contain two washing fractions and the eluate is shown in lane 7. There is no molecular weight shift in any of 
the bands visible when comparing lanes 2 and 3, which argues against a successful TEV digestion. This is 
supported by the absence of the protein of interest in the flow-through fraction. It appears to be found in the 
eluate again and seems to be rather impure. d: Size exclusion chromatography of the eluate after reverse Ni-
NTA binding analysed on a 15 % SDS-PAGE gel. Lane 2 shows the eluate after reverse Ni-NTA binding as already 
shown in lane 7 in c. The fractions were pooled by peaks. Lane 3 shows the fractions 1 – 4, the fractions 7 – 11 
are shown in lane 4. In lane 5 the fractions 14 – 19 have been loaded and lane 6 shows the fractions 20 – 27. 
The lanes 7, 8 and 9 show the fractions 28 – 31, 36 – 39 and 41 – 47, respectively. The protein of interest could 
be seen in lane 6 corresponding to the fractions 20 – 27. These fractions were concentrated afterwards. e: The 
concentrated final sample of GAPVD1 is shown in lane 2. If it is the correct protein it is rather impure. It was 
used for activity testing next. 
Appendix 
157 
 
The concentrated final sample from the GAPVD1 purification was used in different 
concentrations on 1 µM Rab5a. The results are shown in the supporting figure 46.  
 
 
 
Supporting figure 46: Activity testing of GAPVD1. Different concentrations of GAPVD1 have been tested on 1 
µM Rab5a using Bodipy-TR-GTP. No increase in the fluorescence signal could be seen for any of the tested 
conditions. The GEF GAPVD1 appears to be inactive. 
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